



Curriculum Vitae Europass

Informazioni personali

Cognome(i)/Nome(i) **Gronchi Alessandro**
Indirizzo(i) Istituto Nazionale Tumori, via G. Venezian 1, 20133, Milano
Telefono(i) +39 02 2390 3234
Fax +39 02 2390 2404
E-mail alessandro.gronchi@istitutotumori.mi.it

Cittadinanza italiana

Data di nascita

Sesso Maschile

Esperienza professionale

Date Dall'ottobre 2022 ad oggi
Lavoro o posizione ricoperti **Direttore Dipartimento di Chirurgia Oncologica**
Principali attività e responsabilità Coordinamento del dipartimento di Chirurgia Oncologica
Nome e indirizzo del datore di lavoro **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**
Tipo di attività o settore Chirurgia Oncologica

Date Dal maggio 2022 ad oggi
Lavoro o posizione ricoperti **Direttore Struttura Complessa Chirurgia dei Sarcomi**
Principali attività e responsabilità Coordinamento dell'attività chirurgica dei sarcomi delle parti molli e dei GIST
Nome e indirizzo del datore di lavoro **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**
Tipo di attività o settore Chirurgia Oncologica

Date Dal luglio 2011 a Maggio 2022
Lavoro o posizione ricoperti **Dirigente medico responsabile Struttura Semplice Chirurgia dei Sarcomi**
Principali attività e responsabilità Coordinamento dell'attività chirurgica dei sarcomi delle parti molli e dei GIST
Nome e indirizzo del datore di lavoro **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**
Tipo di attività o settore Chirurgia Oncologica

Date Dall'ottobre 2006 al giugno 2011
Lavoro o posizione ricoperti **Dirigente medico con incarico di alta professionalità per la Chirurgia dei Sarcomi**
Principali attività e responsabilità Coordinamento dell'attività chirurgica dei sarcomi delle parti molli e dei GIST
Nome e indirizzo del datore di lavoro **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**
Tipo di attività o settore Chirurgia Oncologica

Date Dall'aprile 2001 all'ottobre 2006
Lavoro o posizione ricoperti **Dirigente medico Chirurgia Generale presso la SC Melanoma/Sarcoma**
Principali attività e responsabilità Coordinamento dell'attività chirurgica dei sarcomi delle parti molli e dei GIST
Nome e indirizzo del datore di lavoro **Istituto Nazionale Tumori**, via G. Venezian 1, 20133 **Milano**
Tipo di attività o settore Chirurgia Oncologica

Date	Dal novembre 1999 ad aprile 2001
Lavoro o posizione ricoperti	Dirigente medico Chirurgia Generale presso la SC Chirurgia Muscolo-Scheletrica.
Principali attività e responsabilità	Posizione a tempo pieno di Chirurgo Oncologo
Nome e indirizzo del datore di lavoro	Istituto Nazionale Tumori, via G. Venezian 1, 20133 Milano
Tipo di attività o settore	Chirurgia Oncologica

Date	Dal luglio 1996 all'ottobre 1999
Lavoro o posizione ricoperti	Frequentatore / borsista / ricercatore associato / dirigente medico supplente
Principali attività e responsabilità	Chirurgo oncologo
Nome e indirizzo del datore di lavoro	Istituto Nazionale Tumori , via G. Venezian 1, 20133 Milano
Tipo di attività o settore	Chirurgia Oncologica

Date	Dal luglio 1994 al giugno 1996
Lavoro o posizione ricoperti	Assistente a tempo pieno
Principali attività e responsabilità	Chirurgo generale
Nome e indirizzo del datore di lavoro	St. Mary's Hospital Lacor – Gulu - Uganda
Tipo di attività o settore	Chirurgia generale e Ginecologia ed ostetricia

Istruzione e formazione

Date	Dal 1992 al 1997
Titolo della qualifica rilasciata	Specializzazione in Chirurgia generale ad indirizzo chirurgia d'urgenza
Principali tematiche/competenza professionali possedute	Chirurgia generale
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università di Milano
Livello nella classificazione nazionale o internazionale	ISCED 5A (Field of Education: 72)

Date	1993
Titolo della qualifica rilasciata	Abilitazione all'esercizio della professione di Medico chirurgo
Principali tematiche/competenza professionali possedute	Medicina e Chirurgia
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università di Milano

Date	Dal 1986 al 1992
Titolo della qualifica rilasciata	Laurea in Medicina e chirurgia (con lode)
Principali tematiche/competenza professionali possedute	Medicina e Chirurgia
Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione	Università di Milano
Livello nella classificazione nazionale o internazionale	ISCED 5A (Field of Education: 72)

Capacità e competenze personali

Madrelingua(e) **Italiano**

Altra(e) lingua(e) **Inglese**

Autovalutazione

Livello europeo ()*

Comprensione				Parlato				Scritto	
Ascolto		Lettura		Interazione orale		Produzione orale			
C1	Livello avanzato	C1	Livello avanzato	C1	Livello avanzato	C1	Livello avanzato	C1	Livello avanzato

(*) Quadro comune europeo di riferimento per le lingue

Ulteriori informazioni

- Abilitazione Scientifica Nazionale per professore di I fascia per il settore concorsuale 06/C1 (Chirurgia Generale), con validità fino al 30/03/2030
- Professore a contratto della Scuola di Specialità di Chirurgia Generale dell'Università di Milano, attività formativa di chirurgia epato-bilio-pancreatica, modulo di Chirurgia Oncologica 1
- Membro del consiglio direttivo dell'Italian Sarcoma Group (ISG) 2021-2027
- Membro della Sarcoma Task Force della European Society for Medical Oncology (ESMO) 2022-2025
- Membro del consiglio direttivo della Connective Tissue Oncology Society (CTOS) 2009-2012, tesoriere nel 2013, segretario nel 2014, vice presidente nel 2015, presidente nel 2016, past president 2017
- Presidente della Società Italiana di Chirurgia Oncologica (SICO) per il 2019-2021
- Chair del Soft Tissue and Bone Sarcoma Group dell'EORTC 2015-2017; Past Chair 2018-2019.
- Membro dell' International Committee della Society of Surgical Oncology (SSO) 2009-2011
- Rappresentante Internazionale del Nominating Committee, Society of Surgical Oncology (SSO) 2019-2020
- Membro del Sarcoma Disease Site Working Group Society of Surgical Oncology (SSO) 2018-2024
- Membro del Consiglio direttivo della Società Europea di Chirurgia Oncologica (ESSO) 2020-2024
- Membro del Consiglio direttivo della Società Americana di Chirurgia Oncologica (SSO) 2021-2024
- Associate Editor Annals of Surgical Oncology
- Associate editor of ESMO Rare Cancers
- Associate Editor Critical Reviews in Oncology/Hematology
- Associate Editor di Therapeutic Advances in Medical Oncology
- Associate Editor di Updates in Surgery
- Associate editor di Journal of Surgical Oncology
- Associate editor di Tumori Journal
- Membro Onorario della Società Polacca di Chirurgia Oncologica
- Membro delle seguenti società professionali/scientifiche:
 - European Society for Medical Oncology (ESMO)
 - European Muscolo-Skeletal Oncology Society (EMSOS)
 - Society of Surgical Oncology (SSO)
 - American Society of Clinical Oncology (ASCO)
 - Connective Tissue Oncology Society (CTOS)
 - Associazione Europea di Chirurgia (ESA)
 - Società Europea di Chirurgia Oncologica (ESSO)
 - Società Italiana di Chirurgia Oncologica (SICO)

Pubblicazioni: v. Allegati 1-2-3-4

Esperienza in trial clinici e finanziamenti competitivi: v. Allegato 5-6

- Allegati**
- Allegato 1: Elenco delle **Pubblicazioni censite da Meline, in inglese**
 - Allegato 2: Elenco delle **Pubblicazioni non censite da Meline, in inglese**
 - Allegato 3: Elenco dei **Capitoli di libri, in inglese**
 - Allegato 4: Elenco dei **Libri, in italiano**
 - Allegato 5: Elenco **Trial Clinici condotti**
 - Allegato 6: Elenco **Finanziamenti competitivi**

Il sottoscritto è a conoscenza che, ai sensi dell' art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi dell' ART. 13D. LGS. 30 giugno 2003 n° 196 –“codice in materia di protezione dei dati personali” e dell' ART. 13 GDPR 679/16 – “ Regolamento europeo sulla protezione dei dati personali”.

Luogo e data

Alessandro Gronchi

Milano, 9/7/2025



Allegato 1

Elenco delle pubblicazioni censite da Meline, in inglese, Scopus H-Index 106

1. Bozzetti F., Bertario L., Rossetti C., Gennari L., Andreola S., Baratti D., **Gronchi A.** Surgical treatment of locally recurrent rectal carcinoma. *Disease of the Colon Rectum* 1997; 40 (12): 1421-1424.
2. Bozzetti F., Baratti D., Andreola S., Zucali R., Schiavo M., Spinelli P., **Gronchi A.**, Valvo F., Mariani L., Gennari L. Preoperative Radiation Therapy for T2-T3 cancers of the middle-to-lower rectum. *Cancer* 1999; 86 (3): 398-404.
3. Azzarelli A., **Gronchi A.**, Bertulli R., Tesoro Tess J.D., Baratti D., Pennacchioli E., Dileo P., Rasponi A., Pilotti S., Casali P.G. Low-dose chemotherapy with Methotrexate and Vinblastine for advanced aggressive fibromatosis. *Cancer* 2001, 92 (5): 1259-1264.
4. Mezzelani A., Mariani L., Tamborini E., Agus V., Riva C., Lo Vullo S., Fabbri A., Stumbo M., Azzarelli A., Casali P.G., **Gronchi A.**, Sozzi G., Pierotti M.A., Pilotti S. SYT-SSX fusion genes and prognosis in synovial sarcoma. *Br J of Cancer* 2001, 85 (10): 1535-9.
5. Ferrari A., Casanova M., Bisogno G., Mattke A., Meazza C., **Gronchi A.**, Cecchetto G., Fidani P., Kunz D., Treuner J., Carli M. Hemangiopericytoma in pediatric age: a report from the italian and german soft tissue sarcoma cooperative group. *Cancer* 2001, 92 (10): 2692-2698.
6. Tamborini E., Agus V., Perrone F., Papini D., Romanò R., Pasini B., **Gronchi A.**, Colecchia M., Rosai J., Pierotti M.A., Pilotti S. Lack of SYT-SSX fusion transcripts in malignant peripheral nerve sheath tumors on RT-PCR analysis of 38 archival cases. *Lab Invest.* 2002, 82 (5): 609-618.
7. Deraco M, **Gronchi A.**, Mazzaferro V, Inglese MG, Pennacchioli E, Kusamura S, Rizzi M, Anselmi RA Jr, Vaglini M. Feasibility of peritonectomy associated with intraperitoneal hyperthermic perfusion in patients with Pseudomyxoma peritonei. *Tumori.* 2002, 88(5):370-5.
8. **Gronchi A.**, Casali PG, Mariani L, Lo Vullo S, Colecchia M, Lozza L, Bertulli R, Fiore M, Olmi P, Santinami M, Rosai J. Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution. *J Clin Oncol.* 2003; 21(7):1390-7.
9. Baratti D, **Gronchi A.**, Pennacchioli E, Lozza L, Colecchia M, Fiore M, Santinami M. Chordoma: natural history and results in 28 patients treated at a single institution. *Ann Surg Oncol.* 2003; 10(3):291-6.
10. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, Navarria P, Collini P, **Gronchi A.**, Olmi P, Fossati-Bellani F, Casali PG. Rhabdomyosarcoma in adults: a retrospective analysis of 171 patients treated at a single institution. *Cancer* 2003; 98 (3): 571-580.
11. Collini P, Mezzelani A, Modena P, Dagrada P, Tamborini E, Luksch R, **Gronchi A.**, Navarria P, Sozzi G, Pilotti S. Evidence of neural differentiation in a case of post-therapy primitive neuroectodermal tumor/Ewing sarcoma of bone. *Am J Surg Pathol* 2003 Aug;27(8):1161-1166.
12. Deraco M, Kusamura S, **Gronchi A.** [Cytoreductive surgery (peritonectomy) and intraperitoneal hyperthermic chemotherapy: an innovative and effective approach to the treatment of pseudomyxoma peritonei]. *Tumori.* 2003 89(4 Suppl): 54-5.
13. Perrone F, Tabano S, Colombo F, Dagrada G, Birindelli S, **Gronchi A.**, Colecchia M, Pierotti MA and Pilotti S. p15INK4b, p14ARF and p16INK4a inactivation in sporadic and NF1-related Malignant Peripheral Nerve Sheath Tumors. *Clin Cancer Res.* 2003 Sept.; 9(11): 4132-4138.
14. Tamborini E, Bonadiman L, Greco A, **Gronchi A.**, Riva C, Bertulli R, Casali PG, Pierotti MA and Pilotti S. Alternative expression of ligand-activated kit and PDGFRbeta tyrosine kinase receptors in synovial sarcoma. *Clin Cancer Res* 2004 Feb; 10(3): 938-943.
15. **Gronchi A.**, Diment J, Colecchia M, Fiore M and Santinami M. Atypical pleomorphic epithelioid angiomyolipoma localized to the pelvis: a case report and review of the literature. *Histopathology* 2004 Mar; 44(3): 292-295.
16. Rossi CR, Deraco M, De Simone M, Mocellin S, Pilati P, Foletto M, Cavaliere F, Kusamura S, **Gronchi A.**, Lise M. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis. *Cancer* 2004 May 1;100(9):1943-50.
17. **Gronchi A.**, Casali PG, Fiore M, Mariani L, Lo Vullo S, Bertulli R, Colecchia M, Lozza L, Olmi P, Santinami M and Rosai J. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. *Cancer* 2004, 100(11): 2448-2455.
18. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, **Gronchi A.**, Bertulli R, Colecchia M, Casali PG, Pierotti M and Pilotti S. A new mutation in the ATP pocket of Kit receptor is responsible for acquired resistance to Imatinib in a patient with gastrointestinal stromal tumor (GIST). *Gastroenterology* 2004, 127(1):294-9.
19. Ferrari A, **Gronchi A.**, Casanova M, Meazza C, Gandola L, Collini P, Lozza L, Bertulli R, Olmi P, Casali PG. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. *Cancer* 2004, 101(3): 627-634.
20. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, **Gronchi A.**, Orlandi R, Ripamonti C, Spreafico C, Alberti D, Bertieri R, Bertulli R, Coco P, Colecchia M, Fumagalli E, Greco A, Grosso F, Negri T, Olmi P, Pierotti MA, Pilotti S. Imatinib mesylate in chordoma. *Cancer* 2004, 101(9):2086-97.

21. Kusamura S, Raspagliesi F, Baratti D, **Gronchi A**, Casali P, Deraco M. Uterine sarcoma treated by cytoreductive surgery and intraperitoneal hyperthermic perfusion: a feasibility study. *J Chemother*. 2004, 16 Suppl 5:19-22.
22. Mariani L, Miceli R, Kattan MW, Brennan MF, Colechia M, Fiore M, Casali PG and **Gronchi A**. Validation and adaptation of a nomogram for predicting survival of extremity soft tissue sarcoma using a three grade system. *Cancer* 2005, 103(2):402-408.
23. **Gronchi A**, Casali PG, Mariani L, Miceli R, Fiore M, Lo Vullo S, Bertulli R, Collini P, Lozza L, Olmi P and Rosai J. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: A series of 911 consecutive patients treated at a single institution. *J Clin Oncol* 2005, 23(1):96-104.
24. Diment J, Tamborini E, Casali PG, **Gronchi A**, Carney JA and Colechia M. Carney Triad: case report and molecular analysis of gastric tumor. *Human Path* 2005, 36: 112-116.
25. Ferrari A, Casanova M, Collini P, Meazza C, Lukcsch R, Massimino M, Cefalo G, Terenziani M, Spreafico F, Catania S, Gandola L, **Gronchi A**, Mariani L and Fossati-Bellani F. Adult-type soft tissue sarcoma in pediatric age: experience at the Istituto Nazionale Tumori in Milan. *J Clin Oncol*. 2005, 23(18): 4021-4030.
26. Blay JY, Bonvalot S, Casali PG, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, **Gronchi A**, Hogendoorn PCW, Joensuu H, Le Cesne A, Joan Mac Clure, Joan Maurel, Nina Nupponen, Isabelle Ray-Coquard, Peter Reichardt, Raf Sciot, Sigrid Stroobants, Martine van Glabbeke, Allan van Oosterom, Georges D Dimetri. A consensus meeting for the management of gastro-intestinal stromal tumors. Report from the ESMO GIST consensus conference of March 20-21st, 2004. *Ann Oncol*. 2005 Apr;16(4):566-78.
27. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, Torre GD, **Gronchi A**, Pierotti MA, Pilotti S. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. *Cancer*. 2005, 104: 159-169.
28. Fiore M, Miceli R, Mussi C, Lo Vullo S, Mariani L, Lozza L, Collini P, Olmi P, Casali PG and **Gronchi A**. Dermatofibrosarcoma Protuberans treated at a single institution: a surgical disease with a high cure rate. *J Clin Oncol*. 2005; 23:7669-75.
29. Casanova M, Ferrari A, Collini P, Bisogno G, Aleggioro R, Cecchetto G, **Gronchi A**, Meazza C, Garaventa A, Di Cataldo A, Carli M. Epithelioid Sarcoma in children and adolescents: a report from the Italian soft tissue sarcoma committee. *Cancer*. 2006; 106(3):708-17.
30. Fiore M, Casali PG, Miceli R, Mariani L, Bertulli R, Lozza L, Collini P, Olmi P, Mussi C and **Gronchi A**. Prognostic effect of re-excision in adult soft tissue sarcoma of the extremities. *Ann Surg Oncol*. 2006; 13(1):110-7.
31. Anghileri M, Miceli R, Fiore M, Mariani L, Ferrari A, Mussi C, Lozza L, Collini P, Olmi P, Casali PG, Pilotti S and **Gronchi A**. Malignant peripheral nerve sheath tumours: prognostic factors and survival in a series of patients treated at a single institution. *Cancer*. 2006; 107(5):1065-1074.
32. Tamborini E, Priol S, Negri T, Lagonigro MS, Miselli F, Greco A, **Gronchi A**, Casali PG, Ferrone M, Fermeglia M, Carbone A, Pierotti MA, Pilotti S. Functional analyses and molecular modeling of two c-Kit mutations responsible for Imatinib secondary resistance in GIST patients. *Oncogene*. 2006, 25(45): 6140-6146.
33. Costa A, Daidone MG, Daprao L, Villa R, Cantù S, Pilotti S, Mariani L, **Gronchi A**, Henson JD, Reddel RR and Zaffaroni N. Telomere maintenance mechanisms in liposarcoma: association with histologic subtypes and disease progression. *Cancer Res*. 2006; 66(17):8918-24.
34. Tamborini E, Miselli F, Negri T, Lagonigro S, Staurengo S, Dagrada GP, Stacchiotti S, Pastore E, **Gronchi A**, Perrone F, Carbone A, Pierotti MA, Casali PG and Pilotti S. Molecular and biochemical analyses of PDGFRB, PDGFRA and KIT receptors in chordoma. *Clin Cancer Res*. 2006; 12(23):6920-8.
35. Pennacchioli E, Deraco M, Mariani L, Fiore M, Mussi C, Collini P, Olmi P, Casali PG, Santinami M and **Gronchi A**. Advanced extremity soft tissue sarcoma: prognostic effect of isolated limb perfusion in a series of 88 patients treated at a single institution. *Ann Surg Oncol* 2007; 14(2): 553-9.
36. **Gronchi A**, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S and Casali PG. Surgery of residual disease following molecular targeted therapy with Imatinib mesylate in advanced/metastatic GIST. *Ann Surg* 2007; 245: 341-346.
37. Miselli F, Casieri P, Negri T, Orsenigo M, Lagonigro MS, **Gronchi A**, Fiore M, Casali PG, Bertulli R, Carbone A, Pierotti MA, Tamborini E and Pilotti S. c-Kit/PDGFR gene status alterations possibly related to primary Imatinib resistance in Gastrointestinal Stromal Tumors. *Clin Cancer Res* 2007; 13(8): 2369-77.
38. Tamborini E, Casieri P, Miselli F, Orsenigo M, Negri T, Piacenza C, Stacchiotti S, **Gronchi A**, Pastorino U, Pierotti MA and Pilotti S. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas. *J Pathol* 2007; 212(2):227-235.
39. **Gronchi A**, Miceli R, Fiore M, Collini P, Lozza L, Grosso F, Mariani L and Casali PG. Extremity soft tissue sarcoma: adding to the prognostic meaning of local failure. *Ann Surg Oncol* 2007; 14(5):1583-90.
40. Fiore M, Grosso F, Lo Vullo S, Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L, Mariani L, Casali PG and **Gronchi A**. Myxoid/round cell and pleomorphic liposarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Cancer* 109: 2522-2531; 2007.
41. Casali PG, Stacchiotti S, Sangalli C, Olmi P, **Gronchi A**. Chordoma. *Curr Opin Oncol* 2007; 19(4): 367-370.

42. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, Sanfilippo R, Casieri P, Collini P, Dileo P, Spreafico C, Stacchiotti S, Tamborini E, Tercero TC, Jimeno J, D'Incalci M, **Gronchi A**, Fletcher JA, Pilotti S, Casali PG. Efficacy of trabectedin (ET-743) in advanced pre-treated myxoid liposarcomas. *Lancet Oncol* 2007; 8(7): 595-602.
43. Casanova M, Meazza C, **Gronchi A**, Fiore M, Zaffignani E, Podda M, Collini P, Gandola L, Ferrari A. Soft tissue sarcoma of the extremities in patients of pediatric age. *J Child Orthop* 2007; 1(3):195-203.
44. Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, Corless CL, Debiec-Rychter M, DeMatteo RP, Ettinger DS, Fisher GA, Fletcher CD, **Gronchi A**, Hohenberger P, Hughes M, Joensuu H, Judson I, Le Cesne A, Maki RG, Morse M, Pappo AS, Pisters PW, Raut CP, Reichardt P, Tyler DS, Van den Abbeele AD, von Mehren M, Wayne JD, Zalberg J; NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines. *J Natl Compr Canc Netw*. 2007; 5 Suppl 2:S1-29.
45. **Gronchi A**, Olmi P and Casali PG. Combined modalities approach for localized adult extremity soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2007; 7(8): 1135-1144.
46. Signoroni S, Frattini M, Negri T, Pastore E, Tamborini E, Casieri P, Orsenigo M, Da Riva L, Radice P, Sala P, **Gronchi A**, Bertario L, Pierotti MA and Pilotti S. Cyclooxygenase-2 and Platelet-Derived Growth Factor Receptors as potential targets in treating Aggressive Fibromatosis. *Clin Cancer Res* 2007; 13(17): 5034-5040.
47. Baratti D, Pennacchioli E, Casali PG, Bertulli R, Lozza L, Olmi P, Collini P, Redaelli S, Fiore M and **Gronchi A**. Epithelioid Sarcoma: Prognostic Factors and Survival in a series of Patients Treated at a Single Institution. *Ann Surg Oncol* 2007; 14(12):3542-51.
48. Ferrari A, Miceli R, Casanova M, **Gronchi A**, Collini P, Meazza C, Zaffignani E, Massimino M, Spreafico F, Mariani L. Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. *Eur J Cancer*. 2007 43(18): 2691-2697.
49. Venturini L, Erdas R, Costa A, **Gronchi A**, Pilotti S, Zaffaroni N and Daidone MG APB detection as a reproducible tool to assess alternative lengthening of telomere stability in liposarcoma. *J Pathol* 2008; 214(4): 410-414.
50. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY; ESMO Guidelines Working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii35-8.
51. Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY; ESMO Guidelines Working Group. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. *Ann Oncol*. 2008 May;19 Suppl 2:ii89-93.
52. Fiore M, Locati P, Mussi C, Guarino A, Piva L, Santinami M and **Gronchi A**. Banked venous homograft replacement of the inferior vena cava for primary leiomyosarcoma. *Eur J Surg Oncol* 2008; 34(6): 720-724.
53. Mussi C, Schildhaus HU, **Gronchi A**, Wardelmann E and Hohenberger P. Therapeutic Consequences From Molecular Biology For GIST Patients Affected By Neurofibromatosis Type 1. *Clin Cancer Res* 2008; 14(14): 4550-4555.
54. Mussi C, Collini P, Miceli R, Barisella M, Mariani L, Fiore M, Casali PG and **Gronchi A**. Prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of patients surgically treated at a single institution. *Cancer* 2008; 113: 1657-1665.
55. Miselli F, Negri T, **Gronchi A**, Losa M, Conca E, Brich S, Fumagalli E, Fiore M, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Is autophagy rather than apoptosis the regression driver in Imatinib-treated gastrointestinal stromal tumours ? *Transl Oncol* 2008; 1(4): 177-186.
56. Negri T, Bozzi F, Conca E, Brich S, **Gronchi A**, Bertulli R, Fumagalli E, Pierotti MA, Tamborini E, Pilotti S. Oncogenic and ligand-dependent activation of KIT/PDGFRα in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs). *J Pathol* 2009; 217:103-112
57. **Gronchi A**, Lo Vullo S, Fiore M, Mussi C, Stacchiotti S, Collini P, Lozza L, Pennacchioli E, Mariani L and Casali PG. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. *J Clin Oncol* 2009; 27(1): 24-30.
58. Ferrari A, Miceli R, Casanova M, Meazza C, Zaffignani E, **Gronchi A**, Piva L, Collini P, Podda M, Massimino M, Luksch R, Cefalo G, Terenziani M, Spreafico F, Polastri D, Mariani L. Soft Tissue Sarcoma of childhood and adolescence: the prognostic role of tumor size changes in relation to the patient's body size. *J Clin Oncol* 2009; 27(3): 371-376..
59. Stacchiotti S, Tamborini E, Marrari A, Brich S, Arisi Rota S, Orsenigo M, Crippa F, Morosi C, **Gronchi A**, Pierotti MA, Casali PG and Pilotti S. Response to sunitinib malate in advanced alveolar soft part sarcoma (ASPS). *Clin Cancer Res* 2009, 15(3): 1096-1104
60. Pennacchioli E, Fiore M and **Gronchi A**. Hyperthermia as a adjunctive treatment for soft tissue sarcoma. *Expert Rev. Anticancer Ther* 2009, 9(2): 199-210
61. Forni C, Minuzzo M, Virdis E, Tamborini E, Simone M, Tavecchio M, Erba E, Grosso F, **Gronchi A**, Aman P, Casali PG, D'Incalci M, Pilotti S and Mantovani R. Trabectedin (ET-743) promotes differentiation of myxoid liposarcoma tumors. *Mol Cancer Ther* 2009, 8(2): 449-457
62. **Gronchi A**, Bonvalot S, Le Cesne A and Casali PG. Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma. *J Clin Oncol* 2009, 27(12):2106-2107
63. **Gronchi A**, Judson I, Nishida T, Poveda A, Martin J, Reichardt P, Casali PG, Le Cesne A, Hohenberger P, Blay JY. Adjuvant treatment with Imatinib for GIST: solid ground or still quicksand ? A comment on behalf of the EORTC soft tissue and bone sarcoma group, the Italian

sarcoma Group, the NCRI Sarcoma Clinical Studies Group (UK), the Japanese Study Group on GIST, the French Sarcoma Group, the Spanish Sarcoma Group (GEIS). *Eur J Cancer* 2009, 45(7):1103-1106.

64. Stacchiotti S, Collini P, Messina A, Morosi C, Barisella M, Bertulli R, Piovesan C, Dileo P, Torri V, **Gronchi A** and Casali PG Tumor response assessment in high grade soft tissue sarcomas (STS): a pilot study to assess the correlation between radiological and pathological response using both RECIST and Choi's criteria. *Radiology* 2009, 251(2): 447-456
65. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S, Pennacchioli E, Casali PG and **Gronchi A**. Preoperative Imatinib mesylate for unresectable or locally advanced primary Gastrointestinal Stromal Tumors (GIST). *Eur J Surg Oncol* 2009, 35: 739-745.
66. Thomas DM, O'Sullivan B and **Gronchi A**. Current concepts and future perspectives in Retroperitoneal Soft Tissue Sarcoma management. *Expert Rev Anticancer Ther* 2009, 9(8):1145-57
67. Reichardt P, Hogendoorn PC, Tamborini E, Loda M, **Gronchi A**, Poveda A, Schöffski P. Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues. *Semin Oncol*. 2009, 36(4):290-301.
68. Fiore M, Rimareix F, Mariani L, Domont J, Collini P, Le Péchoux C, Casali PG, Le Cesne A, **Gronchi A** and Bonvalot S. Desmoid-Type Fibromatosis: a front-line conservative approach to select patients for surgical treatment. *Ann Surg Oncol* 2009, 16(9): 2587-2593.
69. Grosso F, Sanfilippo R, Virdis E, Piovesan C, Collini P, Dileo P, Morosi C, Tercero JC, Jimeno J, D'Incalci M, **Gronchi A**, Pilotti S and Casali PG. Trabectedin in Myxoid Liposarcomas (MLS): a long-term analysis of a single institution series. *Ann Oncol* 2009, 20(8):1439-44
70. Colombo C and **Gronchi A**. Desmoid-type fibromatosis: what works best? *Eur J Cancer* 2009, 45 suppl1: 466-467.
71. Conca E, Negri T, **Gronchi A**, Fumagalli E, Tamborini E, Pavan GM, Fermeleglia M, Pierotti MA, Priol S and Pilotti S. Activate and Resist: L576P in GIST. *Mol Cancer Ther* 2009, 8(9):2491-2495
72. Stacchiotti S, Marrari A, Tamborini E, Palassini E, Virdis E, Messina A, Crippa F, Morosi C, **Gronchi A**, Pilotti S and Casali PG. Response to imatinib plus sirolimus in advanced chordoma. *Ann Oncol* 2009; 20(11):1886-1894.
73. Perrone F, Da Riva L, Orsenigo M, Losa M, Jocolle G, Millefanti C, Pastore E, **Gronchi A**, Pierotti MA, and Pilotti S. PDGFRA, PDGFRB, EGFR and downstream signalling activation in malignant peripheral nerve sheath tumour. *Neuro Oncology* 2009; 11(6): 725-736
74. Stacchiotti S, Casali PG, Lo Vullo S, Mariani L, Palassini E, Mercuri M, Alberghini M, Pilotti S, Zanella L, **Gronchi A** and Picci P. Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centres. *Ann Surg Oncol* 2010; 17: 211-219
75. Meazza C, Bisogno G, **Gronchi A**, Fiore M, Cecchetto G, Alaggio R, Milano GM, Casanova M, Carli M, Ferrari A. Aggressive fibromatosis in children and adolescents: the italian experience. *Cancer* 2010; 116(1):233-240
76. Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, Fiore M, Hohenberger P and **Gronchi A**. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients ? *Ann Oncol* 2010; 21(2):403-408
77. **Gronchi A**, Lo Vullo S, Colombo C, Collini P, Stacchiotti S, Mariani L, Fiore M and Casali PG. Extremity soft tissue sarcoma in a series of patients treated at a single institution: the local control directly impacts survival. *Ann Surg* 2010; 251: 512-517
78. Germano G, Frapolli R, Simone M, Tavecchio M, Erba E, Pesce S, Pasqualini F, Grosso F, Sanfilippo R, Casali PG, **Gronchi A**, Virdis E, Tarantino E, Pilotti S, Greco A, Nebuloni M, Galmarini CM, Tercero JC, Mantovani A, D'Incalci M and Allavena P. Anti-tumor and anti-inflammatory effects of Trabectedin on human myxoid liposarcoma cells. *Cancer Res* 2010; 70(6): 2235-2244
79. **Gronchi A**, Blay JY and Trent JC. The Role of High-Dose Imatinib in the Management of Patients with Gastrointestinal Stromal Tumor (GIST). *Cancer* 2010; 116(8):1847-1858
80. Stacchiotti S, Grosso F, Negri T, Palassini E, Morosi C, Pilotti S, **Gronchi A** and Casali PG. Tumor response to Sunitinib Malate observed in Clear Cell Sarcoma. *Ann Oncol* 2010; 21(5):1130-1131
81. Ardoino I., Miceli R, Berselli M, Mariani L, Biganzoli E, Fiore M, Collini P, Stacchiotti S, Casali PG and **Gronchi A**. Histology-Specific Nomogram for Primary Retroperitoneal Sarcoma. *Cancer* 2010; 116: 2429-2436
82. Stacchiotti S, Negri T, Palassini E, Conca E, **Gronchi A**, Morosi C, Messina A, Pastorino U, Pierotti MA, Casali PG and Pilotti S. Sunitinib malate and Figitumumab in solitary fibrous tumor (SFT): patterns and molecular bases of tumor response. *Mol Cancer Ther* 2010; 9(5): 1286-1297
83. Bonvalot S, Miceli R, Berselli M, Causeret S, Colombo C, Mariani L, Bouzaïene H, Le Pechoux C, Casali PG, Le Cesne A, Fiore M and **Gronchi A**. Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma carried out at high volume centers is safe and associated to an improved local control. *Ann Surg Oncol* 2010; 17: 1507-1514
84. Venturini L, Motta R, **Gronchi A**, Daidone MG and Zaffaroni N. Prognostic relevance of ALT-associated markers in liposarcoma: a comparative analysis. *BMC Cancer* 2010; 10: 254
85. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET. Consensus Panel of experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010; 21 Suppl 5:v198-203

86. Casali PG, Blay JY; ESMO/CONTICANET/EUROBONET. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010; 21 Suppl 5:v98-102.
87. Hogendoorn PC; ESMO/EUROBONET Working Group, Athanasou N, Bielack S, De Alava E, Tos AP, Ferrari S, Gelderblom H, Grimer R, Hall KS, Hassan B, Hogendoorn PC, Jurgens H, Paulussen M, Rozeman L, Taminiau AH, Whelan J, Vanel D. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2010; 21 Suppl 5:v204-13.
88. Tamborini E, Virdis E, Negri T, Orsenigo M, Brich S, Conca E, **Gronchi A**, Stacchiotti S, Manenti G, Casali PG, Pierotti MA and Pilotti S. Analysis of Receptor Tyrosine Kinases (RTK) and Downstream Pathways in Chordomas. *Neuro Oncol* 2010; 12(8): 776-789
89. Frapolli R, Tamborini E, Virdis E, Bello E, Tarantino E, Marchini S, Grosso F, Sanfilippo R, **Gronchi A**, Tercero J, Peloso G, Casali PG, Pilotti S, D'Incalci M. Novel models of Myxoid Liposarcoma Xenografts mimicking the biological and pharmacological features of human tumors. *Clin Cancer Res* 2010;16(20):4958-4967
90. Pennacchioli E, Fiore M, Collini P, Radaelli S, Dileo P, Stacchiotti S, Casali PG and **Gronchi A**. Alveolar Soft Part Sarcoma: clinical presentation, treatment and outcome in a series of 33 patients at a single institution. *Ann Surg Oncol* 2010; 17: 3229-3233
91. Gatta G, Capocaccia R, Trama A, Martinez-Garcia C; RARECARE Working Group. The burden of rare cancers in Europe. *Adv Exp Med Biol* 2010; 686: 285-303
92. Baratti D, Pennacchioli E, Kusamura S, Fiore M, Balestra MR, Colombo C, Mingrone E, **Gronchi A** and Deraco M. Peritoneal Sarcomatosis: is there a subset of patients who may benefit of a cytoreductive surgery and hyperthermic intraperitoneal chemotherapy? *Ann Surg Oncol* 2010; 17(12): 3220-3228
93. Orsenigo M, Brich S, Riva C, Conca E, Bertulli R, Dileo P, **Gronchi A**, Casali PG, Pierotti MA, Tamborini E, Pilotti S. Fluorescence in situ hybridization analysis and immunophenotyping of c-kit/PDGFRα and Bcl-2 expression in gastrointestinal stromal tumors. *Anal Quant Cytol Histol* 2010; 32(4): 225-233
94. Gennaro M, Valeri B, Casalini P, Carcangiu ML, **Gronchi A**, Conti AR, Agresti R, Greco M. Angiosarcoma of the breast and vascular endothelial growth factor receptor. *Tumori*. 2010; 96(6):930-935.
95. Dileo P, Priol S, Tamborini E, Negri T, Stacchiotti S, **Gronchi A**, Posocco P, Laurini E, Coco P, Fumagalli E, Casali PG, Pilotti S. Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRα mutations: an imaging, biochemical and molecular modeling study. *Int J Cancer* 2011; 128(4): 983-990
96. Gasparini P, Facchinetti F, Boeri M, Lorenzetto E, Livio A, **Gronchi A**, Ferrari A, Massimino M, Spreafico F, Giangaspero F, Forni M, Maestro R, Alaggio R, Pilotti S, Collini P, Modena P and Sozzi G. Prognostic determinants in Epithelioid Sarcoma. *Eur J Cancer* 2011; 47: 287-295
97. Bonvalot S and **Gronchi A**. ILP and RT: the study that will never be. *Ann Surg Oncol* 2011; 18: 303-305
98. Sanfilippo R, Miceli R, Grosso F, Fiore M, Pennacchioli E, Puma E, Barisella M, Sangalli C, Mariani L, Casali PG and **Gronchi A**. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. *Ann Surg Oncol* 2011; 18: 720-725
99. Berselli M, Coppola S, Colombo C, Pennacchioli E, Fiore M and **Gronchi A**. Morbidity of Left Pancreatectomy when associated with multivisceral resection for Abdominal Mesenchymal Neoplasm. *JOP* 2011; 12(2): 138-144
100. **Gronchi A**, Miceli R, Colombo C, Collini P, Stacchiotti S, Olmi P, Mariani L, Bertulli R, Fiore M and Casali PG. Primary Extremity Soft Tissue Sarcoma: outcome improvement over time at a single institution. *Ann Oncol* 2011; 22(7): 1675-1681
101. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, **Gronchi A**, Casali PG and Pilotti S. Sunitinib in advanced alveolar soft part sarcoma: evidence of direct antitumor effect. *Ann Oncol* 2011; 22(7): 1682-1690
102. Bozzi F, Conca E, Manenti G, Negri T, Brich S, **Gronchi A**, Pierotti MA, Tamborini E, Pilotti S. High CD133 expression levels in gastrointestinal stromal tumors. *Cytometry B Clin Cytom* 2011; 80(B): 238-247
103. **Gronchi A** and Pollock RE. Surgery in retroperitoneal soft tissue sarcoma: a call for a consensus between Europe and North America. *Ann Surg Oncol* 2011; 18: 2107-2110
104. Stacchiotti S, Pedeutour F, Negri T, Conca E, Marrari A, Palassini E, Collini P, Keslair F, Morosi C, **Gronchi A**, Pilotti S and Casali PG. Dermatofibrosarcoma protuberans-derived fibrosarcoma: clinical history, biological profile and sensitivity to imatinib. *Int J Cancer* 2011; 129(7): 1761-1772
105. Rossi S, Miceli R, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogni A, Sidoni A, Toffolatti L, Laurino L, Mariani L, Vinaccia V, Gnocchi C, **Gronchi A**, Casali PG and Dei Tos AP. Natural history of Imatinib-naïve GISTs: a retrospective analysis of 929 cases with long-term follow-up and development of a survival nomogram based on mitotic index and size as continuous variables. *Am J Surg Pathol* 2011; 35(11):1646-1656
106. Da Riva L, Bozzi F, Mondellini P, Micciché F, Fumagalli E, Vaghi E, Tarantino E, Huber V, **Gronchi A**, Tamborini E, Pierotti MA, Pilotti S and Bongarzone I. Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy. *J Transl Med* 2011; 9:158

107. Gatta G, van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Kunkler I, Otter R, Licitra L, Mallone S, Tavilla A, Trama A, Capocaccia R; RARECARE working group. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer*. 2011; 47(17): 2493-2511
108. Visser O, Adolfsson J, Rossi S, et al. Incidence and survival of rare urogenital cancers in Europe. *Eur J Cancer*. 2012; 48(4):456-464
109. Van Dijk BA, Gatta G, Capocaccia R, et al. Rare cancers of the head and neck area in Europe. *Eur J Cancer*. 2012; 48(6):783-796.
110. Mallone S, De Vries E, Guzzo M, et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. *Eur J Cancer*. 2012; 48(8):1167-1175
111. Negri T, Brich S, Conca E, Bozzi F, Orsenigo M, Stacchiotti S, Alberghini M, Mauro V, **Gronchi A**, Dusio GF, Pelosi G, Picci P, Casali PG, Pierotti MA, Pilotti S. Receptor Tyrosine Kinase Pathway Analysis Sheds Light on Similarities between Clear Cell Sarcoma and Metastatic Melanoma. *Gene Chromosomes Cancer* 2012; 51(2): 111-126
112. Fiore M, Colombo C; Locati P, Berselli M, Radaelli S, Morosi C, Casali PG and **Gronchi A**. Surgical technique, morbidity and outcome of primary retroperitoneal sarcoma involving inferior vena cava. *Ann Surg Oncol* 2012; 19(2): 511-518.
113. Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E, Berrino F; RARECARE Working Group. Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe. *Eur J Cancer*. 2012; 48(2):159-169
114. Faivre J, Trama A, De Angelis R, Elferink M, Siesling S, Audisio R, Bosset JF, Cervantes A, Lepage C; RARECARE Working Group. Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. *Eur J Cancer*. 2012; 48(10):1417-24
115. Crocetti E, Trama A, Stiller C, Caldarella A, Soffietti R, Jaal J, Weber DC, Ricardi U, Slowinski J, Brandes A; RARECARE working group. Epidemiology of glial and non-glial brain tumours in Europe. *Eur J Cancer*. 2012; 48(10):1532-42
116. Gatta G, Ferrari A, Stiller CA, Pastore G, Bisogno G, Trama A, Capocaccia R; RARECARE Working Group. Embryonal cancers in Europe. *Eur J Cancer*. 2012; 48(10):1425-33
117. van der Zwan JM, Mallone S, van Dijk B, Bielska-Lasota M, Otter R, Foschi R, Baudin E, Links TP; RARECARE WG. Carcinoma of endocrine organs: results of the RARECARE project. *Eur J Cancer*. 2012;48(13):1923-31
118. **Gronchi A**, Bui BN, Bonvalot S, Pilotti S, Ferrari S, Hohenberger P, Hohl RJ, Demetri GD, Le Cesne A, Lardelli P, Perez I, Nieto A, Tercero JC, Alfaro V, Tamborini E and Blay JY. Phase II Clinical Trial of Neoadjuvant Trabectedine in patients with advanced localized myxoid liposarcoma. *Ann Oncol* 2012; 23(3): 771-776
119. **Gronchi A**, Frustaci S, Mercuri M, Martin J, Lopez-Pousa A, Verderio P, Mariani L, Valagussa P, Miceli R, Stacchiotti S, Dei Tos AP, De Paoli A, Longhi A, Poveda A, Quagliuolo V, Comandone A, Casali PG and Picci P. Short, Full-Dose Adjuvant Chemotherapy in High-Risk Adult Soft Tissue Sarcomas (STS): a Randomized Clinical Trial from the Italian Sarcoma Group (ISG) and the Spanish Sarcoma Group (GEIS). *J Clin Oncol* 2012; 30(8): 350-356
120. Stacchiotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, Bertuzzi A, Tamborini E, Pilotti S, Messina A, Spreafico C, **Gronchi A**, Amore P, Vinaccia V and Casali PG. A Phase II study on imatinib in advanced chordoma. *J Clin Oncol* 2012; 30(9): 914-920
121. **Gronchi A** and Raut CP. The combination of Surgery and Imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones. *Ann Surg Oncol* 2012; 19: 1051-1055
122. **Gronchi A**, Miceli R, Colombo C, Stacchiotti S, Collini P, Mariani L, Sangalli C, Radaelli S, Sanfilippo R, Fiore M and Casali PG. Frontline extended surgery is associated with improved survival in retroperitoneal low-intermediate grade soft tissue sarcomas. *Ann Oncol* 2012; 23(4):1067-1073
123. Siesling S, van der Zwan JM, Izarzugaza I, et al. Rare thoracic cancers, including peritoneum mesothelioma. *Eur J Cancer*. 2012; 48(7):949-960
124. Visser O, Trama A, Maynadié M, Stiller C, Marcos-Gragera R, De Angelis R, Mallone S, Tereanu C, Allemani C, Ricardi U, Schouten HC; RARECARE Working Group. Incidence, survival and prevalence of myeloid malignancies in Europe. *Eur J Cancer*. 2012; 48(17):3257-66
125. Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, **Gronchi A**, Corless CL, Goldstein D, Rubin B, Maki RB, Lazar AJ, Lev D, Trent JC and von Mehren M. Non-random association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): Case series of 28 patients. *Ann Oncol* 2012; 23(5): 1335-1340
126. Venturini L, Daidone MG, Motta R, Hoare SF, **Gronchi A**, Folini M, Keith WN, Zaffaroni N. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance. *Neuro-oncology* 2012;14(6):736-744.
127. Collini P, Negri T, Barisella M, Stacchiotti S, Palassini E, Tarantino E, Pastorino U, **Gronchi A**, Casali PG and Pilotti S. High-Grade sarcomatous overgrowth in Solitary Fibrous Tumors: a clinical-pathological study of 10 cases. *Am J Surg Pathol* 2012; 36(8):1202-1215
128. Casali PG, Fumagalli E and **Gronchi A**. Adjuvant Therapy of Gastrointestinal Stromal Tumors (GIST). *Curr Treat Opt in Oncol* 2012; 13(3):277-284
129. Bonvalot S, Raut CP, Pollock RE, Rutkowski P, Strauss DC, Hayes AJ, Van Coevorden F, Fiore M, Stoeckle E, Hohenberger P and **Gronchi A**. Technical Considerations in Surgery For Retroperitoneal Sarcomas. Position paper from e-SURGE, a masterclass in sarcoma surgery, and EORTC - STBSG. *Ann Surg Oncol* 2012; 19(9):2981-2991

130. Colombo C, Ronellenfisch U, Yuxin Z, Rutkowski P, Miceli R, Bylina E, Hohenberger P, Raut CP and **Gronchi A**. Clinical, pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival: a multi-center study. *Ann Surg Oncol* 2012; 19(11):3361-3367
131. Reichardt P, Morosi C, Wardelmann E and **Gronchi A**. Gastrointestinal stromal tumors: Evolving role of the multidisciplinary team approach in management. *Expert Rev Anticancer Ther* 2012; 12(8):1053-1068
132. Colombo C, R Randall L, Andtbacka RHI and **Gronchi A**. A new surgical perspective in soft tissue sarcoma (STS) management: more conservative in ESTS (Extremity Soft Tissue Sarcoma), more extended in RSTS (Retroperitoneal Soft Tissue Sarcoma). *Expert Rev Anticancer Ther* 2012; 12(8):1079-1087
133. Colombo C, Miceli R, Collini P, Radaelli S, Palassini E, Stacchiotti S, Fiore M, Mariani L, Casali PG and **Gronchi A**. Leiomyosarcoma and sarcoma with myogenic differentiation: two different entities or two faces of the same disease? *Cancer* 2012; 118(21): 5349-5357
134. Stacchiotti S, Dagrada P, Morosi C, Negri T, Romanini A, Pilotti S, **Gronchi A** and Casali PG. Extraskeletal Myxoid Chondrosarcoma: tumor response to Sunitinib. *Clin Sarcoma Res* 2012; 2(1): 22
135. Stacchiotti S, Verderio P, Messina A, Morosi C, Collini P, Llombart-Bosch A, Martin J, Comandone A, Cruz J, Ferraro A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Casali PG and **Gronchi A**. Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy: an exploratory analysis on a Phase III trial. *Cancer* 2012; 118(23):5857-5866
136. Stacchiotti S, Negri T, Libertini M, Palassini E, Marrari A, De Troia B, **Gronchi A**, Dei Tos AP, Morosi C, Messina A, Pilotti S, Casali PG. Sunitinib malate in solitary fibrous tumor (SFT). *Ann Oncol* 2012; 23(12):3171-3179
137. **Gronchi A** and Raut CP. Optimal approach to sporadic desmoid tumor: from radical surgery to observation. Time for a consensus ? *Ann Surg Oncol* 2012; 19:3995-3997
138. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii92-99
139. ESMO / European Sarcoma Network Working Group. Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii49-55
140. ESMO / European Sarcoma Network Working Group. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2012;23 Suppl 7: vii100-109
141. Jakob J, Mussi C, Ronellenfisch U, Wardelmann E, Negri T, **Gronchi A** and Hohenberger P. Gastrointestinal Stromal Tumor (GIST) of the rectum: results of surgical and multimodality therapy in the era of Imatinib. *Ann Surg Oncol* 2013; 20(2):586-592.
142. **Gronchi A**. Risk stratification models and mutational analysis: keys to optimising adjuvant therapy in patients with GIST. *Eur J Cancer* 2013; 49: 884-892
143. **Gronchi A**, Verderio P, De Paoli A, Ferraro A, Tendero O, Majò J, Martin J, Comandone A, Grignani G, Pizzamiglio S, Quagliuolo V, Picci P, Frustaci S, Dei Tos AP, Palassini E, Stacchiotti S, Ferrari S, Fiore M and Casali PG. Quality of surgery and neoadjuvant combined therapy in the ISG-GEIS trial on soft tissue sarcomas of limbs and trunk wall. *Ann Oncol* 2013; 24(3):817-23
144. **Gronchi A**, Miceli R, Shurell E, Eilber FC, Eilber FR, Anaya DA, Kattan MW, Honoré C, Lev DC, Colombo C, Bonvalot S, Mariani L and Pollock RE. Outcome prediction in primary resected retroperitoneal soft tissue sarcoma: histology-specific overall survival and disease-free survival nomograms built on major sarcoma center datasets. *J Clin Oncol* 2013; 31:1649-1655
145. Stacchiotti S, Libertini M, Negri T, Palassini E, **Gronchi A**, Fatigoni S, Poletti P, Vincenzi B, Dei Tos AP, Mariani L, Pilotti S and Casali PG. Response to chemotherapy of Solitary Fibrous Tumor: a retrospective study. *Eur J Cancer* 2013; 49(10): 2376-2383
146. **Gronchi A** and Pollock RE. Quality of local treatment or biology of the tumor: which are the trump cards for loco-regional control of retroperitoneal sarcoma? *Ann Surg Oncol* 2013; 20: 2111-2113.
147. Stacchiotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, Casale A, Crippa F, Conca E, Negri T, Palassini E, Marrari A, Palmerini E, Mariani L, **Gronchi A**, Pilotti S, Casali PG. Phase II Study on Lapatinib in advanced EGFR positive Chordoma. *Ann Oncol* 2013; 24: 1931-1936
148. Rutkowski P and **Gronchi A**. Efficacy and economic value of adjuvant Imatinib in GIST. *The Oncologist* 2013; 18: 689-696.
149. Duranti L, **Gronchi A**, Stacchiotti S, Fiore M, Casali PG, Collini P, Pelosi G, Galeone C and Pastorino U. Localized thoracic sarcomas: outcome improvement over time at a single institution. *Eur J Cancer* 2013; 49: 2689-2697
150. Baldi G, Stacchiotti S, Mauro V, Dei Tos AP, **Gronchi A**, Pastorino U, Duranti L, Provenzano S, Marrari A, Libertini M, Pilotti S and Casali PG. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. *Clin Sarcoma Res* 2013; 3(1): 4
151. Stacchiotti S, Crippa F, Messina A, Pilotti S, **Gronchi A**, Blay JY and Casali PG. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. *Clin Sarcoma Res* 2013; 3(1): 8

152. Mattavelli D, Miceli R, Radaelli S, Mattavelli F, Cantù G, Barisella M, Quattrone P, Stacchiotti S, Sangalli C, Casali PG, **Gronchi A** and Fiore M. Head and neck soft tissue sarcomas: prognostic factors and outcome in a series of patients treated at a single institution. *Ann Oncol* 2013; 24(8): 2181-2189
153. Rutkowski P, **Gronchi A**, Hohenberger P, Bonvalot S, Schöffski P, Bauer S, Fumagalli E, Nyckowski P, Nguyen BP, Kerst JM, Fiore M, Bylina I, Hoiczky M, Cats A, Casali PG, Le Cesne A, Treckmann J, Stoeckle E, van de Wilt JH, Sleijfer S, Tielen R, van der Graaf W, Verhoef C and van Coevorden F. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST), the EORTC STBSG experience. *Ann Surg Oncol* 2013; 20(9): 2937-2943
154. **Gronchi A** and Casali PG. Adjuvant Therapy for High-Risk Soft Tissue Sarcoma in the Adult. *Curr Treat Opt in Oncol* 2013; 14(3):415-24
155. Stacchiotti S, Tortoreto M, Bozzi F, Tamborini E, Morosi C, Messina A, Libertini M, Palassini E, Cominetti D, Negri T, **Gronchi A**, Pilotti S, Zaffaroni N and Casali PG. Dacarbazine in solitary fibrous tumor: a case series analysis and preclinical evidence vis-à-vis temozolomide and antiangiogenics. *Clin Cancer Res* 2013; 19(18):5192-201
156. **Gronchi A**. Extended surgery for retroperitoneal sarcoma: the key to maximizing the potential for cure and survival. *Pro. Oncology (Williston Park)*. 2013; 27(7):640, 642
157. **Gronchi A** and Raut CP. Treatment of localized sarcomas. *Hematol Oncol Clin N Am* 2013; 27:921-938
158. Colombo C, Miceli R, Lazar AJ, Perrone F, Pollock RE, Le Cesne A, Hartgrink HH, Cleton-Jansen AM, Domont J, Bovée JVMG, Bonvalot S, Lev D, and **Gronchi A**. CTNNB1 45F mutation is a molecular prognosticator of increased postoperative primary desmoid tumor recurrence: an independent multicenter validation study. *Cancer* 2013; 119:3696-3702.
159. Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollé J, Sanfilippo R, **Gronchi A**, Perrone F, Tamborini E, Pelosi G, Pierotti M, Maestro R, Priol S and Pilotti S. In vitro and in silico studies of MDM2/MDMX isoforms predict NUTLIN-3A sensitivity in well/differentiated liposarcomas. *Lab Invest* 2013; 93(11): 1232-1240
160. Bonvalot S, Ternès N, Fiore M, Bitsakou G, Colombo C, Honoré C, Marrari A, Le Cesne A, Perrone F, Dunant A and **Gronchi A**. Spontaneous regression of primary abdominal wall desmoids: more common than previously thought. *Ann Surg Oncol* 2013; 20(13): 4096-4102
161. Raut CP and **Gronchi A**. Cytoreductive Surgery in Advanced GIST: timing is everything. *Ann Surg Oncol* 2013; 20(13): 4059-4060
162. Stacchiotti S, Dagrada G, Sanfilippo R, Negri T, Vittimberga I, Ferrari S, Grosso F, Apice G, Tricomi M, Colombo C, **Gronchi A**, Dei Tos AP, Pilotti S and Casali PG. Anthracycline-based CT in extraskeletal myxoid chondrosarcoma: a retrospective study. *Clinical Sarcoma Research* 2013; 3: 16.
163. Mallone S, De Angelis R, van der Zwan JM, Trama A, Siesling S, Gatta G, Capocaccia; RARE CARE WG. Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. *Cancer Epidemiol* 2013; 37(6): 850-856
164. Martin-Broto J, Gutierrez AM, Ramos RF, Lopez-Guerrero JA, Ferrari S, Stacchiotti S, Picci P, Calabuig S, Collini P, Gambarotti M, Bague S, Dei Tos AP, Palassini E, Luna P, Cruz J, Cubedo R, Martinez-Trufero J, Poveda A, Casali PG, Fernandez A, Lopez-Pousa A and **Gronchi A**. MRP1 overexpression determines poor prognosis in prospectively treated localized high risk soft tissue sarcoma patients of limbs and trunk wall. An ISG/GEIS study. *Mol Cancer Ther* 2014, 13(1):249-59
165. Bozzi F, Manenti G, Conca E, Stacchiotti S, Messina A, Dagrada G, **Gronchi A**, Panizza P, Pierotti M, Tamborini E and Pilotti S. Development of transplantable human chordoma xenograft for preclinical assessment of novel therapeutic strategies. *Neuro-Oncol* 2014; 16(1):72-80
166. **Gronchi A**, De Paoli A, Dani C, Merlo DF, Quagliuolo V, Grignani G, Bertola G, Navarra P, Sangalli C, Buonadonna A, De Sanctis R, Sanfilippo R, Dei Tos AP, Stacchiotti S, Giorrello L, Fiore M, Bruzzi P and Casali PG. Preoperative chemo-radiation therapy for localized retroperitoneal sarcoma: a phase I-II study from the Italian Sarcoma Group. *Eur J Cancer* 2014; 50:784-792
167. **Gronchi A**, Colombo C, Le Péchoux C, Dei Tos AP, Le Cesne A, Marrari A, Penel N, Grignani G, Blay JY, Casali PG, Stoeckle E, Gherlinzoni F, Meeus P, Mussi C, Gouin F, Duffaud F, Fiore M and Bonvalot S on behalf of ISG and FSG. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm. A position paper from the Italian and the French Sarcoma Group. *Ann Oncol* 2014; 25(3): 578-583
168. Meazza C, Luksch R, Daolio P, Podda M, Luzzati A, **Gronchi A**, Parafioriti A, Gandola L, Collini P, Ferrari A, Casanova M, Terenziani M, Spreafico F, Polastri D, Biassoni V, Schiavello E, Pecori E, Massimino M. Axial Skeletal Osteosarcoma: a 25 year monoinstitutional experience in children and adolescence. *Med Onc* 2014; 31(4): 875
169. Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, Nguyen BP, Kerst M, Fiore M, Nyckowski P, Hoiczky M, Cats A, Casali PG, Treckmann J, van Coevorden F, **Gronchi A**. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study). *Eur J Surg Oncol* 2014; 40(4):412-419
170. Pastorino U, Duranti L, Scannagatta P, Leo F, Piccioni F, Collini P and **Gronchi A**. Thoracopleuropneumectomy with rib-like reconstruction for recurrent thoracic sarcomas. *Ann Surg Oncol* 2014; 21(5):1610-1615

171. Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, Casali PG, Swallow CJ, **Gronchi A**, Bonvalot S and Raut RP. Desmoid-type Fibromatosis and pregnancy. A multi-institutional analysis of recurrence and obstetric risk. *Ann Surg* 2014; 259(5):973-978.
172. Radaelli S, Stacchiotti S, Casali PG and **Gronchi A**. Emerging Therapies for Adult Soft Tissue Sarcomas. *Exp Rev Anticancer Ther* 2014; 14(6):689-704
173. Stacchiotti S, Pantaleo MA, Astolfi A, Dagrada GP, Negri T, Dei Tos AP, Indio V, Morosi C, **Gronchi A**, Colombo C, Conca E, Toffolatti L, Tazzari M, Crippa F, Maestri R, Pilotti S and Casali PG. Activity of Sunitinib in Extraskelatal Myxoid Chondrosarcoma. *Eur J Cancer* 2014; 50(9): 1657-1664
174. **Gronchi A**, Colombo C and Raut CP. Surgical Management of Localized Soft Tissue Tumors. *Cancer* 2014; 120(17):2638-2648
175. De Cecco L, Negri T, Brich S, Mauro V, Bozzi F, Dagrada GP, Disciglio V, Sanfilippo R, **Gronchi A**, D'Incalci M, Casali PG, Canevari S, Pierotti MA, Pilotti S. Identification of a gene expression driven progression pathway in Myxoid Liposarcoma. *Oncotarget* 2014; 5(15):5965-5977
176. Radaelli S, Desai A, Hodson J, Colombo C, Roberts K, Gourevitch D and **Gronchi A**. Prognostic factors and outcome of Spermatic Cord Sarcoma. *Ann Surg Oncol* 2014; 21:3557-3563
177. ESMO / European Sarcoma Network Working Group. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25 (Supplement 3): iii102–iii112.
178. ESMO / European Sarcoma Network Working Group. Gastrointestinal Stromal Tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25 (Supplement 3): iii21–iii26.
179. ESMO / European Sarcoma Network Working Group. Bone Sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2014; 25 (Supplement 3): iii113–iii123.
180. Di Giandomenico S, Frapolli R, Bello E, Uboldi S, Licandro SA, Marchini S, Beltrame L, Brich S, Mauro V, Tamborini E, Pilotti S, Casali PG, Grosso F, Sanfilippo R, **Gronchi A**, Mantovani R, Gatta R, Galmarini CM, Sousa-Faro JMF and D'Incalci M. Mode of action of trabectedin in myxoid liposarcoma. *Oncogene* 2014; 33(44):5201-5210
181. Tazzari M, Negri T, Rini F, Vergani B, Huber V, Villa A, Dagrada P, Colombo C, Fiore M, **Gronchi A**, Stacchiotti S, Casali PG, Pilotti S, Rivoltini L and Castelli C. Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy. *Br J Cancer* 2014; 11(7):1350-1362
182. van Broekhoven DLM, Deroose JP, Bonvalot S, **Gronchi A**, Grünhagen DJ, Eggermont AMM and Verhoef C. Isolated limb perfusion by tumor necrosis factor alpha and melphalan in patients with advanced aggressive fibromatosis. *Br J Surg* 2014; 101(13):1674-80.
183. Le Cesne A, Ouali M, Leahy MG, Santoro, Hoekstra HJ, Hohenberger P, Van Coevorden F, Rutkowski P, Van Hoesel R, Verweij J, Bonvalot S, Steward WP, **Gronchi A**, Hogendoorn PCW, Litiere S, Marreaud S, Blay JY and Van Der Graaf WTA. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. *Ann Oncol* 2014; 25(12):2425-2432
184. Sanfilippo R, Bertulli R, Marrari A, Fumagalli E, Pilotti S, Morosi C, Messina A, Dei Tos AP, **Gronchi A** and Casali PG. High-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcoma. *Clin Sarcoma Res* 2014; 4:16
185. Stacchiotti S, Tortoreto M, Baldi GG, Grignani G, Toss A, Badalamenti G, Cominetti D, Morosi C, Dei Tos AP, Festinese F, Fumagalli E, Provenzano S, **Gronchi A**, Pennacchioli E, Negri T, Dagrada GP, Spagnuolo RD, Pilotti S, Casali PG and Zaffaroni N. Preclinical and clinical evidence of activity of Pazopanib in Solitary Fibrous Tumor. *Eur J Cancer* 2014; 50(17):3021-8
186. Morosi C, Stacchiotti S, Marchianò A, Bianchi A, Radaelli S, Sanfilippo R, Colombo C, Richardson C, Collini P, Barisella M, Casali PG, **Gronchi A**, Fiore M. Correlation between Radiological Assessment and Histopathological Diagnosis in Retroperitoneal Tumors: analysis of 291 consecutive patients at a tertiary referral Sarcoma Center. *Eur J Surg Oncol* 2014; 40(12):1662-1670
187. Stiller CA, Trama A, Brwster DH, Verne J, Bouchardy C, Navarro C, Chirlaque MD, Marcos-Gragera R, Visser O, Serraino D, Weiderpass E, Dei Tos AP, Ascoli V; Rarecare Working Group. Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. *Cancer Epidemiol* 2014; 38(6):670-678
188. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group* *Ann Surg Oncol* 2015; 22(1): 256-263
189. Kasper B, Baumgarten C, Bonvalot S, Haas R, Haller F, Hohenberger P, Moreau G, Van der Graaf W and **Gronchi A**. Management of Sporadic Desmoid-Type Fibromatosis: A European consensus approach based on patients' and professionals' expertise - A Sarcoma Patients EURONET (SPAEN) and European Organization for Research and Treatment of Cancer (EORTC) / Soft Tissue and Bone Sarcoma Group (STBSG) initiative. *Eur J Cancer* 2015; 51(2):127-136
190. Casali PG, Bruzzi P, Bogaerts J and Blay JY on behalf of the Rare Cancers Europe (RCE) Consensus Panel. Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. *Ann Oncol* 2015; 26(2):300-306
191. Colombo C, Miceli R, Le Pécoux C, Palassini E., Honoré C, Stacchiotti S, Mir O , Casali PG, Dômont J, Fiore M, Le Cesne A, **Gronchi A** and Bonvalot S. Sporadic Extra abdominal wall desmoid-type fibromatosis: surgical resection can be safely limited to a minority of patients. *Eur J Cancer* 2015; 51(2):186-192

192. Palmerini E, Staals EL, Maki RG, Pengo S, Cioffi A, Gambarotti A, Picci P, Daolio PA, Paraforiti A, Morris C, Antonescu CR, **Gronchi A**, Casali PG, Donati DM, Ferrari S, Stacchiotti S. Tenosynovial giant cell tumor/pigmented villonodular synovitis: Outcome of 294 patients before the era of kinase inhibitors. *Eur J Cancer* 2015; 51(2):210-217
193. **Gronchi A**. Individualizing the use/non-use of radiation therapy (RT) in soft tissue sarcoma (STS): when abstention is better than care. *J Surg Oncol* 2015; 111(2):133-134
194. **Gronchi A**, Collini P, Miceli R, Renne SL, Dagrada G, Fiore M, Sanfilippo R, Barisella M, Colombo C, Morosi C, Stacchiotti S, Casali PG, Dei Tos AP and Pilotti S. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. *Am J Surg Pathol* 2015; 39(3):383-93
195. Stacchiotti S, Sommer J, Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. *Lancet Oncol* 2015; 16(2): e71-83
196. Colombo C, Baratti D, Kusamura S, Deraco M and **Gronchi A**. The role of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Isolated Perfusion (ILP) Interventions in Sarcoma. *J Surg Oncol* 2015; 111(5):570-579
197. Frezza AM, Cesari M, Baumhoer D, Biau D, Bielack S, Campanacci DA, Casanova J, Esler C, Ferrari S, Funovics PT, Gerrand C, Grimer R, **Gronchi A**, Haffner N, Hecker-Nolting S, Höller S, Jeys L, Jutte P, Leithner A, San-Julian M, Thorkildsen J, Vincenzi B, Windhager R, Whelan J. Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. *Eur J Cancer* 2015; 51(3):374-81.
198. **Gronchi A**, Miceli R, Allard MA, Callegaro D, Le Pécoux C, Fiore M, Honoré C, Sanfilippo R, Coppola S, Stacchiotti S, Terrier P, Casali PG, Le Cesne A, Mariani L, Colombo C and Bonvalot S. Personalizing the approach to Retroperitoneal Soft Tissue Sarcoma: histology specific patterns of failure and post-relapse outcome after primary extended resection. *Ann Surg Oncol* 2015; 22(5):1447-54
199. Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litiere S, Bonnetain F, Dabakuyo TS, Benjamin R, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grossclaude P, **Gronchi A**, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Karup-Hansen A, Le Pécoux C, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut CP, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van Glabbeke M, Woll P, Gorgou-Bourgade S, Mathoulin-Pelissier S. Guidelines for time-to-event endpoint definitions in sarcoma and gastrointestinal stromal tumor (GIST) trials. Results of the DATECAN initiative (Definition for the Assessment of Time-to event Endpoints in CANcer trials). *Ann Oncol* 2015; 26:865-872
200. Callegaro D, Fiore M and **Gronchi A**. Personalizing surgical margins in retroperitoneal sarcoma. *Exp Rev Anticancer Ther* 2015; 15(5):553-67
201. Rossi S, Gasparotto D, Miceli R, Toffolatti L, Gallina G, Scaramel E, Marzotto A, Boscato E, Messerini L, Bearzi I, Mazzoleni G, Capella C, Arrigoni G, Sonzogno A, Sidoni A, Mariani L, Amore P, **Gronchi A**, Casali PG, Maestro R, and Dei Tos AP. KIT, PDGFRA and BRAF mutational spectrum impacts on the natural history of Imatinib-naïve localized GIST: a population-based study. *Am J Surg Pathol* 2015; 39(7):922-930
202. Callegaro D, Miceli R, Brunelli C, Colombo C, Sanfilippo R, Radaelli S, Casali PG, Caraceni A, **Gronchi A**, Fiore M. Long-term morbidity after multivisceral resection for retroperitoneal sarcoma. *Br J Surg* 2015; 102:1079-1087
203. Dagrada GP, Spagnuolo RD, Mauro V, Tamborini E, Cesana L, **Gronchi A**, Stacchiotti S, Pierotti MA, Negri T and Pilotti S. Solitary Fibrous Tumor: loss of chimeric protein expression and genomic instability mark dedifferentiation. *Mod Pathol* 2015; 28(8):1074-1083
204. Hohenberger P, Gorlick R, **Gronchi A**. Collaborations Between SSO and the Connective Tissue Oncology Society (CTOS) Series. *Ann Surg Oncol* 2015; 22(9): 2815-2816
205. Palassini E, Ferrari S, Verderio P, De Paoli A, Martin Broto J, Quagliuolo V, Comandone A, Sangalli C, Palmerini E, Lopez-Pousa A, De Sanctis R, Bottelli S, Libertini M, Picci P, Casali PG and **Gronchi A**. Feasibility of pre-operative chemotherapy + radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk within the ISG/GEIS randomized clinical trial on 3 vs 5 cycles of full-dose epirubicin + ifosfamide. *J Clin Oncol* 2015; 33(31):3628-3634
206. Hindi N, Casali PG, Morosi C, Messina A, Palassini E, Pilotti S, Tamborini E, Radaelli S, **Gronchi A**, Stacchiotti S. Imatinib in advanced chordoma: a retrospective case series analysis. *Eur J Cancer* 2015; 51:2609-14
207. Fiore M, Colombo C, Radaelli S, Callegaro D, Palassini E, Barisella M, Morosi C, Baldi GG, Stacchiotti S, Casali PG, **Gronchi A**. Hormonal manipulation with Toremifene in Sporadic Desmoid-type Fibromatosis. *Eur J Cancer* 2015; 51:2800-2807
208. Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann J, Goldstein D, Martin Broto J, **Gronchi A**, Dei Tos AP, Matreud S, van der Graaf W, Zalcberg JR, Litiere S and Blay JY. Time to definitive failure to the first tyrosine kinase inhibitor in localized gastrointestinal stromal tumors (GIST) treated with Imatinib as an adjuvant: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS). *J Clin Oncol* 2015; 33:4276-4283
209. Wardelmann E, Haas RL, Bovée JVMG, Terrier Ph, Lazar A, Messiou C, LePécoux C, Hartmann W, Collin F, Fisher C, Mechttersheimer G, Dei Tos AP, Stacchiotti S, Jones R, **Gronchi A**, Bonvalot S. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the

210. Messiou C, Bonvalot S, **Gronchi A**, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, LePechoux C, Wardelman E, Winfield JM, Boulet B, Haas RL. Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer – Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on Magnetic Resonance Imaging. Eur J Cancer 2016; 56: 37-44
211. Stacchiotti S, Pantaleo MA, Negri T, Astolfi A, Tazzari M, Dagrada GP, Urbini M, Indio V, Maestro R, **Gronchi A**, Fiore M, Dei Tos AP, Conca E, Palassini E, Vincenzi B, Grosso F, Pilotti S, Castelli C, Casali PG. Efficacy and biological activity of imatinib in metastatic dermatofibrosarcoma protuberans (DFSP). Clin Cancer Res 2016; 22(4):837-46
212. Vlietier M, Litière S, Rizzo E, Marréaud S, Judson I, Gelderblom I, Le Cesne A, Wardelmann E, Messiou C, **Gronchi A**, van der Graaf WTA. Outcome of chemotherapy in advanced synovial sarcoma patients: review of 15 clinical trials from European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG); Setting a new landmark for studies in this subtype. Eur J Cancer 2016; 58: 62-72
213. **Gronchi A**, Strauss DC, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE and Raut CP. Variability in patterns of recurrence after resection of Primary Retroperitoneal Sarcoma (RPS): a report on 1007 patients from the multi-institutional collaborative Transatlantic RPS Working Group. Ann Surg 2016; 263(5):1002-1009
214. Raut CP, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Fiore M, Callegaro D, Casali PG, Haas RL, Hayes AJ, Honoré C, Cannell AJ, Jakob J, Szacht M, Fairweather M, Pollock RE, Bonvalot S, **Gronchi A**. External Validation of a Multi-Institutional Retroperitoneal Sarcoma Nomogram. Cancer 2016; 122(9):1417-24
215. Bogani G, Ditto A, Martinelli F, Signorelli M, Chiappa V, Lorusso D, Sabatucci I, Carcangiu ML, Fiore M, **Gronchi A**, Raspagliesi F. Morcellator's port-site metastasis of a uterine smooth muscle tumor of uncertain potential after minimally invasive myomectomy. J Minim Invasive Gynecol. 2016; 23(4):647-9.
216. Saponara M, Stacchiotti S and **Gronchi A**. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. Exp Rev Anticancer Ther 2016; 16(5):473-484
217. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pechoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Mariani L, Wunder JS, Pollock RE, Casali PG and **Gronchi A**. Development and external validation of two nomograms to predict overall survival and distant metastases after surgical resection of localised soft tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol 2016; 17:671-680
218. Radaelli S, Fiore M, Colombo C, Ford S, Palassini E, Sanfilippo R, Stacchiotti S, Sangalli C, Morosi C, Casali PG and **Gronchi A**. Vascular resection en-bloc with tumor removal and graft reconstruction is safe and effective in soft tissue sarcoma (STS) of the extremities and retroperitoneum. Surg Oncol 2016; 25(3): 125-131
219. **Gronchi A**, Guadagnolo BA, Erinjeri JP. Local Ablative Therapies to Metastatic Soft Tissue Sarcoma. Am Soc Clin Oncol Educ Book. 2016;35:e566-e575
220. Radaelli S, Stacchiotti S, Ruggieri P, Donati D, Casali PG, Palmerini E, Collini P, Gambarotti M, Porcu L, Boriani S, **Gronchi A**, Picci P. Sacral Chordoma: Long-Term Outcome of a Large Series of Patients Surgically Treated at Two Reference Centers. Spine 2016; 41(12):1049-1057.
221. Ford S and **Gronchi A**. Indications for Surgery in Advanced/Metastatic GIST. Eur J Cancer 2016; 63: 154-167
222. Grünwald V, Young R, Messiou C, Lia M, Wardelmann E, van der Graaf W, **Gronchi A**, Judson I for the EORTC STBSG. Absence of progression, not extent of remission tumour shrinkage defines prognosis in soft tissue sarcoma – an analysis of the EORTC 62012 study of the EORTC STBSG. Eur J Cancer 2016; 64:44-51.
223. Ray-Coquard I, Litière S, Rizzo E, Blay JY, Casali PG, Judson I, Krarup Hansen A, Lindner LH, Dei Tos AP, Gelderblom H, Marreaud S, Rutkowski P, Hohenberger P, **Gronchi A**, Van der Graaf WT. Impact of chemotherapy in Uterine Sarcoma (UtS): review of 13 clinical trials from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) involving advanced/metastatic UtS compared to other Soft Tissue Sarcoma (STS) patients treated with first line chemotherapy. Gynecol Oncol 2016;142(1):95-101
224. **Gronchi A**, Haas RL and Bonvalot S. Cancer Registries and randomized clinical trials in rare tumors: at the 2 extremes of daily clinical practice. Eur J Cancer 2016; 64:113-115
225. Meazza C, Perrone F, Belfiore A, Busico A, Settanni G, Paielli N, Cesana L, Ferrari A, Chiaravalli S, **Gronchi A**, Colombo C, Pilotti S, Massimino A. AKT1 and BRAF mutations in pediatric aggressive fibromatosis. Cancer Med 2016; 5(6):1204-13
226. Pasquali S, **Gronchi A**, Strauss D, Bonvalot S, Jeys L, Stacchiotti S, Hayes A, Honoré C, Collini P, Renne SL, Alexander N, Grimer RJ, Callegaro D, Sumathi VP, Gourevitch D, Desai A. Resectable extrapleural and extrameningeal Solitary Fibrous Tumor: a multi centre prognostic study. Eur J Surg Oncol 2016; 42:1064-1070
227. Eastley N, McCulloch T, Esler C, Hennig I, Fairbairn J, **Gronchi A** and Ashford R. Extra-abdominal Desmoids Fibromatosis: a review of management, current guidance and unanswered questions. Eur J Surg Oncol 2016; 42:1071-1083

228. Stacchiotti A, Provenzano S, Dagrada GP, Negri T, Brich S, Basso U, Brunelio A, Grosso F, Galli L, Palassini E, Libertini M, Colia V, **Gronchi A**, Dei Tos AP, Crippa F, Morosi C, Pilotti S and Casali PG. Sirolimus in advanced hemangioendothelioma: a retrospective case series analysis from the Italian Rare Cancer Network database. *Ann Surg Oncol* 2016; 23(9):2735-44
229. van Broekhoven DL, Grünhagen DJ, van Dalen T, van Coevorden F, Bonenkamp HJ, Been LB, Bemelmans MH, Dijkstra SD, Colombo C, **Gronchi A**, Verhoef C. Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoid tumor patients without therapeutic intervention. *BMC Cancer*. 2016;16(1):686
230. Fiore M, MacNeill A, **Gronchi A**, Colombo C. Desmoid-type Fibromatosis: evolving treatment standards. *Surg Oncol Clin N Am* 2016; 25:803-826
231. Management of Recurrent Retroperitoneal Sarcoma (RPS) in the Adult. A Consensus Approach from the Trans-Atlantic RPS Working group*. *Ann Surg Oncol* 2016; 23:3531-3540
232. Stacchiotti S, Astolfi A, **Gronchi A**, Fontana A, Pantaleo MA, Negri T, Brenca M, Tazzari M, Urbini M, Indio V, Colombo C, Radaelli S, Brich S, Dei Tos AP, Casali PG, Castelli C, Dagrada GP, Pilotti S, Maestro R. Evolution of Dermatofibrosarcoma protuberans (DFSP) to DFSP-derived fibrosarcoma (FS-DFSP): an event marked by epithelial mesenchymal transition-like process and 22q loss. *Mol Cancer Res* 2016; 14(9):820-9
233. Tseng WW, Pollock RE and **Gronchi A**. The Trans-Atlantic Retroperitoneal Sarcoma Working Group (TARPSWG): "Red wine or white"? *Ann Surg Oncol* 2016; 23(13):4418-4420
234. **Gronchi A**, Delrio P, Quagliuolo V, Sandrucci S. The Italian Society of Surgical Oncology (SICO) survey on the minimum requirements of rare cancers referral centers. *Updates Surg* 2016; 68(4):321-323
235. Belli F, **Gronchi A**, Corbellini C, Milione M and Leo E. Abdominosacral resection for locally recurring rectal cancer. *World J Gastrointest Surg* 2016; 8(12): 770-778.
236. **Gronchi A**, Stacchiotti S, Verderio P, Ferrari S, Martin Broto J, Lopez-Pousa A, Llombart-Bosch S, Dei Tos AP, Collini P, Cruz Jurado J, De Paoli A, Donati DM, Poveda A, Quagliuolo A, Comandone A, Grignani G, Morosi C, Messina A, De Sanctis R, Bottelli S, Palassini E, Casali PG and Picci P. Short, Full-Dose Adjuvant Chemotherapy (CT) in High-Risk Adult Soft Tissue Sarcomas (STS): Long term Follow-Up of a Randomized Clinical Trial From the Italian Sarcoma Group and the Spanish Sarcoma Group. *Ann Oncol* 2016; 27(12):2283-2288
237. Saponara M, Stacchiotti S, Casali PG and **Gronchi A**. (Neo)adjuvant treatment in localized soft tissue sarcoma (STS): the unsolved affair. *Eur J Cancer* 2017; 70:1-11
238. **Gronchi A**, Maki RG, Jones RL. Treatment of soft tissue sarcoma: a focus on earlier stages. *Future Oncol*. 2017; 13(1s):13-21
239. Kollár A, Jones RL, Stacchiotti S, Gelderblom H, Guida M, Boccone P, Steeghs N, Safwat A, Katz D, Duffaud F, Sleijfer S, van der Graaf W, Touati N, Litière S, Marreud S, **Gronchi A**, Kasper B. Pazopanib in advanced vascular sarcomas: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. *Acta Oncol* 2017; 56(1): 88-92
240. Gasparotto D, Rossi S, Polano M, Tamborini E, Lorenzetto E, Sbaraglia M, Mondello A, Massani M, Lamon S, Bracci R, Mandolesi A, Frate E, Stanzial F, Agaj J, Mazzoleni G, **Gronchi A**, Dei Tos AP and Maestro R. Quadruple-negative GIST is a sentinel for unrecognized Neurofibromatosis Type 1 syndrome. *Clin Cancer Res* 2017; 23(1):273-282.
241. Tazzari M, Indio V, Vergani B, De Cecco L, Rini F, Negri T, Camisaschi C, Fiore M, Stacchiotti S, Dagrada GP, Casali PG, **Gronchi A**, Astolfi A, Villa A, Lombardo C, Arienti F, Pilotti S, Rivoltini L, Castelli C. Adaptive immunity in fibrosarcomatous dermatofibrosarcoma protuberans and response to imatinib treatment. *J Invest Dermatol* 2017; 137:484-493
242. Longhi A, Bielack SS, Grimer R, Whelan J, Windhager R, Leithner A, **Gronchi A**, Biau D, Jutte P, Krieg AH, Klenke FM, Grignani G, Donati DM, Capanna R, Casanova J, Gerrand C, Bisogno G, Hecker-Nolting S, De Lisa M, D'Ambrosio L, Willegger M, Scoccianti G and Ferrari S. Extraskelatal osteosarcoma: a European Musculoskeletal Oncology Society (EMSOS) study on 266 patients. *Eur J Cancer* 2017; 74:9-16
243. Janssen ML, van Broekhoven DLM, Cates JMM, Bramer WM, Nuytens JJME, **Gronchi A**, Baumert BG, Salas S, Bonvalot S, Ihalainen HR, Grünhagen DJ, Verhoef C. The Influence of Adjuvant Radiotherapy and Surgical Margin on Local Control After Resection of Sporadic Desmoid-type Fibromatosis: A Systematic Review and Meta-Analysis. *Br J Surg* 2017;104(4):347-357
244. Saponara M, Stacchiotti S and **Gronchi A**. Pharmacological therapies for Liposarcoma. *Exp Rev Clin Pharmacol* 2017;10(4):361-377
245. Stacchiotti S, M. Saponara, Frapolli R, Tortoreto M, Cominetti D, Provenzano S, Negri T, Dagrada GP, **Gronchi A**, Colombo C, Vincenzi B, Badalamenti G, Zuco V, Renne SL, Collini P, Morosi C, Dei Tos AP, Bello E, Pilotti S, Casali PG, D'Incalci M, Zaffaroni N. Patient-derived solitary fibrous tumor xenografts predict high sensitivity to Doxorubicin/Dacarbazine combination confirmed in the clinic and highlight the potential effectiveness of trabectedin or eribulin against this tumor. *Eur J Cancer* 2017; 76:84-92.
246. Sandrucci S, Trama A, Quagliuolo V, **Gronchi A**. Accreditation for centers of sarcoma surgery. *Updates Surg* 2017;69(1):1-7
247. Fiore M, Raut CP and **Gronchi A**. Are We Allowed to Limit Surgical Aggressiveness With Small Rectal Gastrointestinal Stromal Tumors? *Ann Surg Oncol* 2017; 24:1153-1156
248. Delhorme JB, Fontana A, Levy A, Terrier P, Fiore M, Tzanis D, Callegaro D, Dratwa C, **Gronchi A**, Bonvalot S. Renal Angiomyolipomas: at Least Two Diseases. A Series of Patients Treated at Two European Institutions. *Eur J Surg Oncol* 2017; 43:831-836

249. Palassini E, Frezza AM, Mariani L, Lalli L, Colombo C, Fiore M, Messina A, Casale A, Morosi C, Collini P, Stacchiotti S, Casali PG, **Gronchi A**. Long-term efficacy of methotrexate plus vinblastine/vinorelbine in large series of patients affected by desmoid-type fibromatosis. *Cancer J* 2017; 23: 86–91
250. Pantaleo MA, Urbini M, Indio V, Ravegnini G, Nannini M, De Luca M, Tarantino G, Angelini S, **Gronchi A**, Vincenzi B, Grignani G, Colombo C, Fumagalli E, Gatto L, Saponara M, Ianni M, Paterini P, Santini D, Pirini MG, Ceccarelli C, Altamari A, Gruppioni E, Renne SL, Collini P, Stacchiotti S, Brandi G, Casali PG, Pinna AD, Astolfi A, Biasco G. Genome-wide Analyses Identifies MEN1 and MAX Mutations and a Neuroendocrine-like Molecular Heterogeneity in Quadruple WT GIST. *Mol Cancer Res* 2017; 15(5):553-562
251. Pasquali S and **Gronchi A**. Retroperitoneal Liposarcoma: an aggressive strategy to maximize disease control. *Int J Radiat Oncol Biol Phys* 2017; 98:273-274
252. Urbini M, Astolfi A, Pantaleo MA, Serravalle S, Dei Tos AP, Picci P, Indio V, Sbaraglia M, Benini S, Righi A, Gambarotti M, **Gronchi A**, Colombo C, Dagrada GP, Pilotti S, Maestro R, Polano M, Saponara M, Tarantino G, Pession G, Biasco G, Casali PG, Stacchiotti S. HSPA8 as a novel fusion partner of NR4A3 in extraskeletal myxoid chondrosarcoma. *Gene Chrom Cancer* 2017; 56(7):582-586
253. **Gronchi A**; Ferrari S Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Basso U; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Donati DM; Palassini E; Palmerini E; De Sanctis R; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P and Casali PG. Neoadjuvant Chemotherapy in High-risk Soft Tissue Sarcomas: A Randomized Clinical Trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG) and the Polish Sarcoma Group (PSG). *Lancet Oncol* 2017;18:812-822
254. Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner L, Judson I, Schöffski P, Bauer J, Italiano A, Grünwald V, Lopez Pousa A, Kotasek D, Sleijfer S, Kerst JM, Rutkowski P, Fumagalli E, Hogendoorn PCW, Litière S, Marreud S, Van der Graaf W, **Gronchi A**, Verweij J, on behalf of EORTC STBSG, ISG, AGITG. Ten-year progression-free and overall survival in patients with unresectable or metastatic gastrointestinal stromal tumours (GIST). Long-term analysis of the EORTC, ISG, AGITG intergroup Phase III randomized trial on imatinib at two dose levels. *J Clin Oncol* 2017; 35:1713-1720
255. Callegaro D, Miceli R and **Gronchi A**. Sarcoma nomograms: a light over the darkness. *Oncoscience* 2017; 4(3-4):15-16
256. Young R, Litiere S, Lia M, Hogendoorn PCW, Fisher C, Mechttersheimer G, Daugaard S, Sciort R, Collin F, Messiou C, Grünwald V, **Gronchi A**, van der Graaf W, Wardelmann E, Judson I. Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study. *Acta Oncol* 2017; 56(7):1013-1020
257. MacNeill AJ, Miceli R, Strauss DC, Bonvalot S, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE, Raut CP, **Gronchi A** and Swallow CJ. Post-relapse outcomes after primary extended resection of retroperitoneal sarcoma: a report from the Trans-Atlantic RPS Working Group (TARPSWG). *Cancer* 2017; 123(11):1971-1978
258. Stacchiotti S, **Gronchi A**, Fossati P, Akiyama T, Alapetite C, Baumann M, Blay JY, Bolle S, Boriani S, Bruzzi P, Capanna R, Caraceni A, Casadei R, Colia V, Debus J, Delaney T, Desai A, Dileo P, Dijkstra S, Doglietto F, Flanagan A, Froelich S, P. Gardner A, Gelderblom H, Gokaslan ZL, Haas R, Heery C, Hindi N, Hohenberger P, Hornicek F, Imai R, Jeys L, Jones RL, Kasper B, Kawai A, Krengli M, Leithner A, Logowska I, Martin Broto J, Mazzatenta D, Morosi C, Nicolai P, Norum OJ, Patel S, Penel N, Picci P, Pilotti S, Radaelli S, Ricchini F, Rutkowski P, Scheipl S, Sen C, Tamborini E, Thornton KA, Timmermann B, Torri V, Tunn PU, Uhl M, Yamada Y, Weber DC, Vanel D, Varga PP, LA Vleggeert-Lankamp C, Casali PG, and Sommer J. Best practices for the Management of Local-regional Recurrent Chordoma. A Position Paper by the Chordoma Global Consensus Group. *Ann Oncol* 2017; 28:1230-1242
259. Frezza AM, Stacchiotti S and **Gronchi A**. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new. *BMC Medicine* 2017; 15:109
260. Pasquali S, Palassini E, Stacchiotti S, Casali PG and **Gronchi A**. Neoadjuvant treatment: a novel standard? *Curr Opin Oncol* 2017; 29:253-259
261. Pasquali S and **Gronchi A**. Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications. *Ther Adv Med Oncol* 2017; 9(6):415-429
262. Ford SJ, Almond LM and **Gronchi A**. An update on non-extremity soft tissue sarcomas. *Clin Oncol* 2017; 29:516-527
263. Callegaro D, Miceli R, Mariani L, Raut CP and **Gronchi A**. Soft Tissue Sarcoma Nomograms and their Incorporation into Practice. *Cancer* 2017;123:2802-2820
264. Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Onetti Muda A, **Gronchi A**, Casali PG, Dei Tos AP and Tonini G. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma. *Br J Cancer* 2017; 117:340-346
265. Tseng WW and **Gronchi A**. Surgery for Recurrence in Retroperitoneal Leiomyosarcoma: Is it All About Selection? *J Surg Oncol* 2017; 16(3):267-268.
266. Frezza AM, Stacchiotti S and **Gronchi A**. Highlights in soft tissue sarcomas and gastrointestinal stromal tumours (GIST) trials reported at ASCO 2017 Annual Meeting. *BMC Med* 2017; 15(1):160

267. Colia V, Fiore M, Provenzano S, Fumagalli E, Bertulli R, Morosi C, Dei Tos AP, Barisella M, **Gronchi A**, Casali PG and Sanfilippo R. Activity of anthracycline and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma. *Clin Sarcoma Res* 2017; 7:16
268. Urbini M, Astolfi A, Indio V, Tarantino G, Serravalle S, Saponara M, Nannini M, **Gronchi A**, Fiore M, Maestro R, Brenca M, Dei Tos AP, Dagrada GP, Negri T, Pilotti S, Casali PG, Biasco G, Pession A, Stacchiotti S, Pantaleo MA. Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. *Oncotarget* 2017; 8(36):60036-60045
269. Kasper B, Baumgarten C, Garcia J, Bonvalot S, Haas R, Haller F, Hohenberger P, Penel N, Messiou C, van der Graaf WT, **Gronchi A** on behalf of the Desmoid Working Group. An update on the management of sporadic Desmoid-Type Fibromatosis: a European consensus initiative between Sarcoma Patients Euronet (SPAEN) and European Organisation for Research and Treatment of Cancer (EORTC) / Soft Tissue and Bone Sarcoma Group (STBSG). *Ann Oncol* 2017; 28:2399-2408
270. Colia V, Fumagalli E, Provenzano S, Bertulli R, Stacchiotti S, Morosi C, Collini P, **Gronchi A**, Casali PG and Sanfilippo R. High-dose Ifosfamide chemotherapy in a series of patients affected by myxoid liposarcoma. *Sarcoma* 2017; 2017:3739159
271. De Sanctis R, Giordano L, Colombo C, De Paoli A, Navarria P, Sangalli C, Buonadonna A, Sanfilippo R, Bertola G, Fiore M, Marrari A, Navarria F, Bertuzzi A, Casali PG, Basso S, Santoro A, Quagliuolo V, **Gronchi A**. Long-term follow-up and post-relapse outcome of patients with localized retroperitoneal sarcoma treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STTS) Protocol 0303. *Ann Surg Oncol* 2017; 24:3872-3879
272. Colombo C, Belfiore A, Paielli N, De Cecco L, Canevari S, Laurini E, Fermeiglia M, Priol S, Verderio P, Bottelli S, Fiore M, Stacchiotti S, Palassini E, **Gronchi A**, Pilotti S, Perrone F. β -catenin in Desmoid-Type Fibromatosis: deep insights on the role of T41A and S45F mutations on protein structure and gene expression. *Mol Oncol* 2017; 11(11):1495-1507
273. Pastorino U, Scannagatta P, Girotti P, Rolli L, **Gronchi A**. Long-term results of thoraco-pleuro-pneumectomy (TPP) for recurrent thoracic sarcomas. *Ann Surg Oncol* 2017; 24(Suppl 3):551-554
274. Strauss DC, Renne SL and **Gronchi A**. Adjacent, Adherent, Invaded: a spectrum of biological aggressiveness rather than a rationale for selecting organ resection in surgery of primary retroperitoneal sarcomas. *Ann Surg Oncol* 2018;25(1):13-16
275. Rossi S, Gasparotto D, Cacciatore M, Sbaraglia M, Mondello A, Polano M, Mandolesi A, **Gronchi A**, Reuss DE, von Deimling A, Maestro R and Dei Tos AP. Neurofibromin C terminus-specific antibody (clone NFC) is a valuable tool for the identification of NF1-inactivated GISTs. *Mod Pathol* 2018;31(1):160-168
276. Haas RL, **Gronchi A**, van de Sande MAJ, Baldini EH, Gelderblom H, Messiou C, Wardelmann E, Le Cesne A. Perioperative management of extremity soft tissue sarcomas. *J Clin Oncol* 2018;36(2):118-124
277. Albertsmeier M, Rauch A, Roeder F, Hasenhüttl S, Pratschke S, Kirschneck M, **Gronchi A**, Jebens NL, Cassier PA, Sargos P, Belka C, Lindner LH, Werner J, Angele MK. External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma – a Systematic Review and Meta-Analysis. *Ann Surg Oncol* 2018; 25(3):754-767
278. Corino VDA, Montin E, Messina A, Casali PG, **Gronchi A**, Marchiano A, Mainardi LT. Radiomic analysis of soft tissues sarcomas can distinguish intermediate from high-grade lesions. *J Magn Reson Imaging* 2018;47:829–840.
279. Pasquali S, Colombo C, Pizzamiglio S, Verderio P, Callegaro D, Stacchiotti S, Martin Broto J, Lopez-Pousa A, Ferrari S, Poveda A, De Paoli A, Quagliuolo V, Cruz Jurado J, Comandone A, Grignani G, De Sanctis R, Palassini E, Llompart-Bosch A, Dei Tos AP, Casali PG, Picci P, and **Gronchi A**. High-risk soft tissue sarcomas treated with perioperative chemotherapy: improving prognostic classification in a randomised clinical trial. *Eur J Cancer* 2018; 93:28-36
280. Tseng WW, Pollock RE. **Gronchi A**. Retroperitoneal Sarcomas: Big tumors that Involve More than Just “Getting It Out”. *J Surg Oncol* 2018; 117:5-6
281. Tseng WW, Pollock RE. **Gronchi A**. Historical Perspectives and Future Directions in the Surgical Management of Retroperitoneal Sarcoma. *J Surg Oncol* 2018; 117:7-11
282. Paderno A, **Gronchi A** and Piazza C. Synovial Sarcoma of the upper aero-digestive tract: is there a role for conservative surgery. *Curr Opin Otolaryngol Head Neck Surg* 2018; 26(2):94-101
283. Zanotti S, Kapetis D, Gibertini S, Salerno F, Ciusani E, Colombo C, **Gronchi A**, Morandi L, Mantegazza R, Molteni F, Mora M. Botulinum toxin type A affects the transcriptome of cell cultures derived from muscle biopsies of controls and spastic patients. *Toxicol in Vitro* 2018; 50:124-136
284. Verschoor AJ, Litiere S, Marreaud S, Judson I, Toulmonde M, Wardelmann E, van der Graaf WT, Le Cesne A, **Gronchi A**, Gelderblom H. Prognostic relevance of distant metastases versus locally advanced disease in soft tissue sarcomas: An EORTC-STBSG database study. *Eur J Cancer* 2018; 94:187-198
285. MacNeill AJ, **Gronchi A**, Miceli R, Bonvalot S, Swallow CJ, Hohenberger P, Van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Cannell A, Jakob J, Haas RL, Szacht M, Fiore M, Casali PG, Pollock RE, Barretta F, Raut CP and Strauss DC. Title: Post-operative morbidity after radical resection of primary retroperitoneal sarcoma: a report from the Transatlantic RPS Working Group (TARPSWG). *Ann Surg* 2018; 267(5):959-964

286. Almond LM, **Gronchi A**, Strauss DC, Jafri M, Ford S, Desai A. Neoadjuvant and Adjuvant Strategies in Retroperitoneal Sarcoma. *Eur J Surg Oncol* 2018; 44:571-579
287. Kasper B, Lecoite-Artznerb E, Waitc S, Boldond S, Wilson R, **Gronchi A**, Valverde C, Eriksson M, Dumont S, Drove N, Kanli A, Wartenberg M. Working to improve the management of sarcoma patients across Europe: a policy checklist. *BMC Cancer* 2018; 18(1):424
288. Management of metastatic retroperitoneal sarcoma: a consensus approach from the Transatlantic Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Oncol* 2018; 29(4):857-871
289. Fiore M, Ford S, Callegaro D, Sangalli C, Colombo C, Radaelli S, Frezza AM, Renne SL, Casali PG, **Gronchi A**. Adequate local control in high risk soft tissue sarcoma of the extremity treated with surgery alone at a reference center: should radiotherapy still be a standard? *Ann Surg Oncol* 2018; 25(6):1536-1543
290. Lindner LH, Litière S, Sleijfer S, Benson C, Italiano A, Kasper B, Messiou C, Gelderblom H, Wardelmann E, Le Cesne A, Blay JY, Marreaud S, Hindi N, Desai IME, **Gronchi A**, van der Graaf WTA. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy. An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer - Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). *Int J Cancer* 2018; 42(12):2610-2620
291. Benna C, Simioni A, Pasquali S, De Boni D, Rajendran S, Spiro G, Colombo C, Virgone C, Dubois S, **Gronchi A**, Rossi CR, Mocellin S. Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis. *Oncotarget* 2018;9(26):18607-18626
292. Italiano A, Touati N, Litière S, Collin F, Pourquier P, **Gronchi A**. Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial. *Cancer Med* 2018; 7(5):1575-1577
293. Jung E, Fiore M, **Gronchi A**, Grignol V, Pollock RE, Chopra, S, Chong SS, Hamilton AS, Tseng WW. Second Primary Malignancies in Patients with Well differentiated / Dedifferentiated Liposarcoma. *Anticancer Res* 2018; 38(6):3535-3542
294. Issels RD, Lindner LH, Verweij J, Wessalowski R, Reichardt P, Wust P, Ghadjar P, Hohenberger P, Angele M, Salat C., Vujaskovic Z, Daugaard S, Mella O, Mansmann U., Dürr HR, Knösel T, Abdel-Rahman S., Schmidt M, Hiddemann W, Jauch KW, Belka K, and **Gronchi A**, for the European Organization for the Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group and the European Society for Hyperthermic Oncology. Neoadjuvant Chemotherapy Plus Regional Hyperthermia and Long-term Outcomes among Patients with Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial. *Jama Oncol* 2018;4(4):483-492
295. Tseng WW, Tsao-Wei DD, Callegaro D, Grignani G, D'Ambrosio L, Bonvalot S, Ethun CG, Cardona K, Mullen JT, Canter RJ, Mullinax JE, Gonzalez RJ, van Coevorden F, Albertsmeier M, Dhanireddy KK, Renne SL, **Gronchi A**. Pancreaticoduodenectomy in the surgical management of primary retroperitoneal sarcoma. *Eur J Surg Oncol* 2018 Jun;44(6):810-815
296. Touati N, Schöffski P, Litière S, Judson I, Sleijfer S, van der Graaf WT, Italiano A, Isambert N, Gil T, Blay JY, Stark D, Brodowicz T, Marréaud S, **Gronchi A**. EORTC Soft Tissue and Bone Sarcoma Group (STBSG) experience with advanced/metastatic epithelioid sarcoma patients treated in prospective trials: clinical profile and response to systemic therapy. *Clin Oncol* 2018; 30:448-454
297. **Gronchi A** Crago A and Raut CP. Minimally Invasive Surgery for Retroperitoneal Sarcoma: Just Because We Can Does Not Mean We Should. *Ann Surg Oncol* 2018; 25:2129-2131
298. Tattersall HL and **Gronchi A**. Surgical Resection as an Adjuvant to Tyrosine Kinase Inhibitors in Metastatic GIST: Association or Causation? / Are we any closer to an answer? *Eur J Surg Oncol* 2018; 44:1287-1288
299. Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali PG, **Gronchi A**, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R. Denosumab treatment of inoperable or locally advanced Giant Cell Tumor of Bone - multicenter analysis outside clinical trial. *Eur J Surg Oncol* 2018; 44:1384-1390
300. **Gronchi A**. Towards the standard use of (Neo)adjuvant chemotherapy in selected localized soft tissue sarcoma at high risk of relapse: are we finally getting there? *Eur J Cancer* 2018; 101:251-253
301. Urbini M, Indio V, Astolfi A, Tarantino G, Renne SL, Pilotti S, Dei Tos AP, Maestro R, Collini P, Nannini M, Saponara M, Murrone L, Dagrada P, Colombo C, **Gronchi A**. Pession A, Casali PG, Stacchiotti S, Pantaleo M. Identification of an actionable mutation of Kit in a case of extraskeletal myxoid chondrosarcoma. *Int J Mol Science* 2018 Jun 23;19(7). pii: E1855
302. Levy A, Bonvalot S, Callegaro D, Botticella A, Le Cesne A, **Gronchi A** and Le Pechoux C. Consistent margin status reporting in soft tissue sarcoma essential to establish risk adapted strategies integrating biology and histotype in perioperative treatments. *J Clin Oncol* 2018; 36(22):2357-2358
303. Colombo C, Urbini M, Astolfi A, Collini P, Belfiore A, Paielli N, Perrone F, Indio V, Tarantino G, Palassini E, Fiore M, Stacchiotti S, Pantaleo MA, **Gronchi A**. Novel intra-genic large deletions of CTNNB1 gene identified in WT desmoid-type fibromatosis. *Gene Chrom Cancer* 2018; 57(10):495-503
304. Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, **Gronchi A**. Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-Soft Tissue and Bone Sarcoma Group database. *Acta Oncol* 2018; 57(8):1117-1126
305. Frezza AM, Lee ATJ, Nizri E, Sbaraglia M, Jones RL, **Gronchi A**, Dei Tos AP, Casali PG. 2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma. *ESMO Open* 2018; 3(4):e000390

306. Tattersall HL, Callegaro D, Ford SJ, **Gronchi A**. Staging, Nomograms and Other Predictive Tools in Retroperitoneal Soft Tissue Sarcoma. *Chin Clin Oncol* 2018; 7(4):36
307. Wang J, Grignol VP, **Gronchi A**, Luo CH, Pollock RE, Tseng WW. Surgical Management of Retroperitoneal Sarcoma and Opportunities for Global Collaboration. *Chin Clin Oncol* 2018; 7(4):39
308. Dumitra S and **Gronchi A**. The diagnosis and management of retroperitoneal sarcoma. *Oncology* 2018; 32(9):464-469
309. Frezza AM; Jones RL, Lo Vullo S, Asano N, Lucibello F, Ben-Ami E, Ratan R, Teterycz P, Boye K, Brahmi M, Palmerini E, Fedenko A, Vincenzi B, Brunello A, Desai IME, Benjamin RSE, Blay JY, Martin Broto J, Casali PG, Gelderblom H, Grignani G, **Gronchi A**, Sundby Hall K, Mir O, Rutkowski P, Wagner AJ, Anurova O, Collini P, Dei Tos AP, Flucke U, Hornick JL, Lobmaier I, Terrier P, Picci P, Ranchere D, Renne SL, Sbaraglia M, Thway K, Wagrodski M, Wang WL, Yoshida A, Mariani L, Kawai A, Stacchiotti S. Anthracycline, gemcitabine and pazopanib in epithelioid sarcoma: results of a retrospective multi-institutional case series. *Jama Oncol* 2018; 4(9):e180219
310. **Gronchi A** and Jones RL. The value of neoadjuvant chemotherapy in localized high risk soft tissue sarcoma of the extremities and trunk. *JAMA Oncol* 2018; 4(9):1167-1168
311. Casali PG, Bielack S, Abecassis N, Haro HT, Bauer S, Biagini R, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Brennan B, Broto JM, Brugier L, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Dhooge C, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gaspar N, Gasperoni S, Gelderblom H, Gil T, Grignani G, **Gronchi A**, Haas RL, Hassan B, Hecker-Nolting S, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kager L, Kasper B, Kopeckova K, Krákorová DA, Ladenstein R, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Morland B, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Strauss SJ, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY, on behalf of the ESMO Guidelines Committee, PaedCan and ERN EURACAN. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29 (Supplement 4): iv79–iv95
312. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, **Gronchi A**, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29 (Supplement 4): iv68–iv78
313. Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T, Broto JM, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dileo P, Eriksson M, Fedenko A, Ferraresi V, Ferrari A, Ferrari S, Frezza AM, Gasperoni S, Gelderblom H, Gil T, Grignani G, **Gronchi A**, Hannu A, Hassan B, Hohenberger P, Issels R, Joensuu H, Jones RL, Judson I, Jutte P, Kaal S, Kasper B, Kopeckova K, Krákorová DA, Le Cesne A, Lugowska I, Merimsky O, Montemurro M, Pantaleo MA, Piana R, Picci P, Piperno-Neumann S, Pousa AL, Reichardt P, Robinson MH, Rutkowski P, Safwat AA, Schöffski P, Sleijfer S, Stacchiotti S, Sundby Hall K, Unk M, Van Coevorden F, Van der Graaf W, Whelan J, Wardelmann E, Zaikova O, Blay JY; ESMO Guidelines Committee and EURACAN. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29 (Supplement 4): iv51–iv67
314. Younger E, Litière S, Le Cesne A, Mir O, Gelderblom H, Italiano A, Marreaud S, Jones RL, **Gronchi A**, van der Graaf WT. Outcomes of elderly advanced soft tissue sarcoma patients treated with first-line chemotherapy: a pooled analysis of twelve EORTC Soft Tissue and Bone Sarcoma Group trials. *The Oncologist* 2018; 23(10):1250-1259
315. Savina M, Litière S, Italiano A, Burzykowski T, Bonnetain F, Gourgou S, Rondeau V, Blay JY, Cousin S, Duffaud F, Gelderblom H, **Gronchi A**, Judson I, Le Cesne A, Lorigan P, Maurel J, van der Graaf W, Verweij J, Mathoulin-Pelissier S, Bellera C. Surrogate endpoints in advanced sarcoma trials: a meta-analysis. *Oncotarget* 2018; 9(77):34617-34627
316. Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss DC, Levy A, Griffin A, Hayes AJ, Stacchiotti S, Le Pèchoux C, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Catton C, Casali PG, 10, Wunder JS, **Gronchi A**. Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: retrospective analysis across major histological subtypes and major reference centers. *Eur J Cancer* 2018; 105:19-27
317. Stacchiotti S, Morosi C, Lo Vullo S, Casale A, Palassini E, Frezza AM, Dinoi G, Messina A, **Gronchi A**, Morelli D, Cavalleri A, Venturelli E, Pilotti S, Collini P, Blich S, Tamborini E, Mariani L, Casali PG. Imatinib in combination with everolimus in patients with progressing advanced chordoma: a Phase 2 clinical study. *Cancer* 2018; 124(20):4056-4063
318. Raut CP, Bonvalot S and **Gronchi A**. A Call to Action: Why Sarcoma Surgery Needs to be Centralized. *Cancer* 2018; 124(23):4452-4454
319. Giannini L, Incandela F, Fiore M, **Gronchi A**, Stacchiotti S, Sangalli C and Piazza C. Radiation Induced Sarcoma of the Head and Neck: a review of the literature. *Front Oncol* 2018 Oct 17;8:449
320. Fiore M and **Gronchi A**. ASO Author Reflections: Evolving Concepts for Radiation Therapy in Extremity and Trunk Soft Tissue Sarcoma. *Ann Surg Oncol* 2018; 25(Suppl 3):942-943

321. Stacchiotti S, Simeone N, Lo Vullo S, Morosi C, Greco FG, **Gronchi A**, Barisella M, Collini P, Zaffaroni N, Dagrada GP, Frezza AM, Mariani L, Casali PG. Activity of axitinib in progressive advanced solitary fibrous tumor: results from an exploratory, investigator-driven Phase 2 clinical study. *Eur J Cancer* 2019; 106:225-233
322. Gonzato O and **Gronchi A**. The evolving role of patient advocates in rare cancers: opportunities and challenges. *Expert Rev Pharmacoecon Outcomes Res* 2019; 19(1):1-3
323. Pasquali S; Bonvalot S; Tzanis D; Casali PG; Trama A; **Gronchi A**. Treatment challenges in and outside a network setting: soft tissue sarcomas. *Eur J Surg Oncol* 2019; 45:31-39
324. Pasquali S, Pizzamiglio S, Touati N, Litiere S, Marreud S, Kasper B, Gelderblom H, Stacchiotti S, Judson I, Dei Tos AP, Verderio P, Casali PG, Woll PJ and **Gronchi A**, on behalf of the EORTC – Soft Tissue and Bone Sarcoma Group. The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomized trial. *Eur J Cancer* 2019; 109:51-60
325. Nizri E, Fiore M, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Morosi C, Stacchiotti S, Casali PG, **Gronchi A**. Completion surgery of residual disease after primary inadequate surgery of retroperitoneal sarcomas achieves comparable oncological outcomes- a propensity score analysis. *J Surg Oncol* 2019; 119:318-323
326. Pastorino U, Morelli D, Leuzzi G, Rolli aL, Suatoni P, Taverna F, Bertocchi E, Boeri M, Sozzi G, Cantarutti A, Corrao G, **Gronchi A**. Baseline and postoperative C-reactive protein levels predict long-term survival after lung metastasectomy. *Ann Surg Oncol* 2019; 26(3):869-875
327. Almond LM, Tirota F, Tattersall H, Hodson J, Cascella T, Barisella M, Marchianò A, Greco G, Desai A, Ford SJ, **Gronchi A**, Fiore M, Morosi C. Diagnostic Accuracy of Percutaneous Biopsy in Retroperitoneal Sarcoma. *Br J Surg* 2019; 106(4):395-403
328. Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, Blay JY, Leahy M, Young R, Mathijssen R, Van Erp NP, Gelderblom AJ, Van der Graaf WT, **Gronchi A**. Impact of concomitant administration of gastric acid suppressive agents and pazopanib on outcomes in soft tissue sarcoma patients treated within EORTC 62043/62072 trials. *Clin Cancer Res* 2019; 25(5):1479-1485
329. Haas RL, Bonvalot S, Miceli R, Strauss DC, Swallow CJ, Hohenberger P, van Coevorden F, Rutkowski P, Callegaro D, Hayes AJ, Honoré C, Fairweather M, Gladly R, Jakob J, Szacht M, Fiore M, Chung PW, van Houdt WJ, Raut CP, **Gronchi A**. Radiation Therapy for Retroperitoneal Liposarcoma – a report from TARPSWG. *Cancer* 2019;125:1290-1300
330. **Gronchi A** and Jones RL. Treatment of Desmoid Tumor in 2019. *JAMA Oncol* 2019;5(4):567-568
331. Raut CP, Callegaro D, Miceli R, Barretta F, Rutkowski P, Blay JY, Lahat G, Strauss DC, Gonzalez R, Ahuja N, Grignani G, Quagliuolo V, Stoeckle E, De Paoli A, Pillarisetty VG, Nessim C, Swallow CJ, Bagaria S, Canter R, Mullen J, Gelderblom HJ, Pennacchioli E, van Coevorden F, Cardona K, Fiore M, Fairweather M, **Gronchi A**. Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWG. *Clin Cancer Res* 2019; 25(8):2664-2671
332. **Gronchi A**, Hindi N, Cruz J, Blay JY, Lopez-Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Sanfilippo R, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin-Broto J. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): results of a phase I study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. *EClinicalMedicine* 2019; 9:35-43
333. Ferraris M, Callegaro D, Barretta F, Fiore M, Radaelli S, Stacchiotti S, Miceli R, Socrate AM, Locati P, **Gronchi A**. Outcome of ilio caval resection and reconstruction for retroperitoneal sarcoma. *J Vasc Surg Venous Lymphat Disord* 2019; 7:547-556.
334. Van Houdt W, Raut CP, Bonvalot S, Swallow CJ, Haas RL and **Gronchi A**. New research strategies in retroperitoneal sarcoma: the case of TARPSWG, STRASS and RESAR – making progress through collaboration. *Curr Opin Oncol* 2019; 31(4):310-316
335. Mastboom MJL, Palmerini E, Verspoor FGM, Rueten-Budde AJ, Stacchiotti S, Staals EL, Schaap GR, Jutte PC, Aston W, Gelderblom H, Leithner A, Dammerer D, Takeuchi A, Thio Q, Niu X, Wunder JS; TGCT Study Group, van de Sande MAJ. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study. *Lancet Oncol* 2019; 20(6):877-886
336. Tirota F, Fumagalli E, Colombo C, Morosi C, Barisella M, Radaelli S, Frezza AM, Casali PG, **Gronchi A**, Fiore M. Management of complicated tumor response to tyrosine kinase inhibitors in gastrointestinal stromal tumors (GIST), *J Surg Oncol* 2019;120:256-261
337. Fucà G, Hindi N, Ray-Coquard I, Colia V, Dei Tos AP, Martin-Broto J, Brahmi M, Collini P, Lorusso D, Raspagliesi F, Pantaleo MA, Vincenzi B, Fumagalli E, **Gronchi A**, Casali PG, Sanfilippo R. Treatment Outcomes and Sensitivity to Hormone Therapy of Aggressive Angiomyxoma: A Multicenter, International, Retrospective Study. *The Oncologist* 2019;24:e536–e541
338. Brenca M, Stacchiotti S, Fassetta K, Sbaraglia M, Janjusevic M, Racanelli D, Polano M, Rossi S, Brich S, Dagrada GP, Collini P, Colombo C, **Gronchi A**, Astolfi A, Indio V, Pantaleo MA, Picci P, Casali PG, Dei Tos AP, Pilotti S, Maestro R. NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas. *J Pathol* 2019; 249:90-101
339. Suarez-Kelly LP, Baldi GG and **Gronchi A**. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments. *Exp Opin Pharmacother* 2019; 20(12):1503-1515
340. Dingley B, Fiore M and **Gronchi A**. Personalizing surgical margins in retroperitoneal sarcomas: an update. *Exp Rev Anticancer Ther* 2019; 19(7):613-631

341. Mastboom MJL, Staals EL, Verspoor FGM, Rueten-Budde AJ, Stacchiotti S, Palmerini E, Schaap GR, Jutte PC, Aston W, Leithner A, Dammerer D, Takeuchi A, Thio Q, Niu X, Wunder JS, and van de Sande MAJ, on behalf of the Tenosynovial Giant Cell Tumors (TGCT) Study Group. Surgical Treatment of Localized-Type Tenosynovial Giant Cell Tumors of Large Joints. *J Bone and Joint Surg* 2019; 101(14):1309-1318
342. Stacchiotti S, Zuco V, Tortoreto M, Cominetti D, Frezza AM, Percio S, Indio V, Barisella M, Monti V, Brich S, Astolfi A, Colombo C, Pasquali S, Folini M, Gounder M, Pantaleo MA, Collini P, Dei Tos AP, Casali PG, **Gronchi A**, Zaffaroni N. Comparative assessment of antitumor effect and autophagy induction as resistance mechanism by cytotoxics and EZH2 inhibition in INI1-negative epithelioid sarcoma patient-derived xenograft. *Cancers* 2019; 11(7). pii: E1015
343. Bonvalot S, Rutkowski PL, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong A, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco B, Herraes AC, **Gronchi A**, Mangel L, Sy-Ortin T, Hohenberger P, de Baère T, Le Cesne A, Helfre S, Saada-Bouazid E, Borkowska A, Anghel R, Co A, Gebhart M, Kantor G, Montero A, Loong HH, Vergés R, Lapeire L, Dema S, Kacso G, Austen L, Moureau-Zabotto L, Servois V, Wardelmann E, Terrier P, Lazar AJ, Bovée JVMG, Le Péchoux C, Papai Z. NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (Act.In.Sarc): a multicentre, phase 2-3, randomised, controlled trial. *Lancet Oncol* 2019; 20(8):1148-1159
344. Hohenberger P, Bonvalot S, van Coevorden F, Rutkowski P, Stoeckle E, Olungu C, Litiere S, Wardelmann E, **Gronchi A**, Casali PG. Quality of surgery and surgical reporting for patients with primary gastrointestinal stromal tumours participating in the EORTC STBSG 62024 adjuvant imatinib study. *Eur J Cancer* 2019; 120:47-53
345. Sanfilippo R; Jones R; Blay JY; LeCesne A; Provenzano S; Antoniou G; Mir O; Fucà G; Fumagalli E; Bertulli R; Stacchiotti S; Brahmi M; Grosso F; Dufresne A; Hindi N; **Gronchi A**; Collini P; Dei Tos AP; Casali PG. Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas). *Clin Cancer Res* 2019; 25(17):5295-5300
346. Nizri E, Fiore M, Barretta F, Colombo C, Radaelli S, Callegaro D, Sanfilippo R, Sangalli C, Collini P, Stacchiotti S, Casali PG, Miceli R, **Gronchi A**. Intraperitoneal invasion of retroperitoneal sarcomas- a risk factor for dismal prognosis. *Ann Surg Oncol* 2019; 26:3535-3541
347. Bello E, Brich S, Craparotta I, Mannarino L, Ballabio S, Gatta R, Marchini S, Carrassa L, Matteo C, Sanfilippo R, **Gronchi A**, Casali PG, Pilotti S, D'Incalci M, and Frapolli R. Establishment and characterization of a new patient-derived model of myxoid liposarcoma with acquired resistance to trabectedin. *Br J Cancer* 2019; 121:464-473
348. Tseng WW, Pasquali S, Hu JS, Menendez LR, **Gronchi A**. Staging Systems and Nomograms in Soft Tissue Sarcoma: Outcome Prediction by Categorization or Personalization? *Chin Clin Oncol* 2019;8(S1):S12
349. Frapolli R, Bello E, Ponzo M, Craparotta I, Mannarino L, Ballabio S, Marchini S, Carrassa L, Ubezio P, Porcu L, Brich S, Sanfilippo R, Casali PG, **Gronchi A**, Pilotti S, and D'Incalci M. Combination of PPARγ agonist pioglitazone and trabectedin overcomes resistance against trabectedin in myxoid liposarcomas by induction of adipocytic differentiation. *Clin Cancer Res* 2019;25(24):7565-7575
350. Nizri E, **Gronchi A**. ASO Author Reflections: A Breach in the Border—Retroperitoneal Sarcoma with an Intraperitoneal Component. *Ann Surg Oncol* 2019;26(Suppl 3):838-839
351. Callegaro D, Miceli R, Bonvalot S, Ferguson PC, Strauss DC, van Praag VVM, Levy A, Griffin AM, Hayes AJ, Stacchiotti S, Pèchoux CL, Smith MJ, Fiore M, Dei Tos AP, Smith HG, Catton C, Szkandera J, Leithner A, van de Sande MAJ, Casali PG, Wunder JS, **Gronchi A**. Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors. *EClinicalMedicine* 2019; 17:100215
352. Frezza AM, Assi T, Lo Vullo S, Ben-Amy E, Dufresne A, Yonemori K, Noguchi E, Siontis B Ferraro R, Tetery P, Duffaud F, Ravi V, Vincenzi B, Gelderblom H, Pantaleo MA, Baldi GG, Desai I, Fedenko A, Maki RG, Jones R, Benjamin RS, Blay JY, Kawai A, Gounder M, **Gronchi A**, Le Cesne A, Mir O, Czarnecka AM, Schuetze S, Wagner AJ, Adam J, Barisella M, Sbaraglia M, Hornick JL, Meurgey A, Mariani L, Casali PG, Thornton K, Stacchiotti S. Systemic treatments in MDM2 positive intimal sarcoma: a multicentre experience with anthracycline, gemcitabine and pazopanib within the World Sarcoma Network (WSN) *Cancer* 2020;126(1):98-104
353. The Management of Desmoid Tumors: a joint global consensus-based guideline approach for adult and pediatric patients. Desmoid Working Group. *Eur J Cancer* 2020; 127:96-107
354. Smolle MA, van de Sande M, Callegaro D, Wunder J, Hayes A, Leitner L, Bergovec M, Tunn PU, van Praag V, Fiocco M, Panotopoulos J, Willegger M, Windhager R, Dijkstra S, van Houdt W, Riedl J, Stotz M, Gerger A, Pichler M, Stöger H, Liegl-Atzwanger B, Smolle J, Andreou D, Leithner A, **Gronchi A**, Haas R, Szkandera J. Individualising follow-up strategies in high-grade soft tissue sarcoma with flexible parametric competing risk regression models. *Cancers* 2020;12(47) 1-13.
355. Mcaddy N, Hallin M, Strauss D, Smith M, Hayes A, Yusuf S, Moskovic E, Van Houdt W, Jones RL, **Gronchi A**, Thway K, Messiou C. CT imaging improves histopathological grading of retroperitoneal leiomyosarcomas. *Eur J Surg Oncol* 2020; 46:288-292
356. Intercontinental collaborative experience with abdominal, retroperitoneal, and pelvic schwannomas. Transatlantic Australasian Retroperitoneal Sarcoma Working Group. *Br. J Cancer* 2020; 107:452–463
357. **Gronchi A**, Bonvalot S, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom HJ, van Coevorden F, Penel N, Kopp HG, Duffaud F, Goldstein D, Martin Broto J, Wardelmann E, Marréaud S, Smithers M, Le Cesne A, Zaffaroni F, Litière S, Blay JY and Casali PG. Quality of Surgery and Outcome in Localized GIST treated within an International Intergroup Randomized Trial on Adjuvant Imatinib. *JAMA Surg.* 2020;155(6):e200397

358. Tseng WW, **Gronchi A**, Bonvalot S, Pollock RE. A Sommelier to Guide Wine Selection and a Specialist to Manage the Sarcoma Patient: Barriers to Referral and Definition of a Sarcoma Specialist. *J Surg Oncol* 2020; 121(6):925-926
359. Martin Broto J, Hindi N; Lopez-Pousa A; Peinado-Serrano J; Alvarez R; Alvarez-Gonzalez A; Italiano A; Sargos P; Cruz-Jurado J; Isern-Verdum J; Dolado MC; Rincon-Pérez I; Sanchez-Bustos P; Gutierrez A; Romagosa C; Morosi C; Grignani G; Gatti M; Luna P; Alastuey I; Redondo A; Belinchon B; Martinez-Serra J; Sunyach MP; Coindre JM, PhD; Dei Tos AP; Romero J; **Gronchi A**; Blay JY; Moura DS. Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas. A Nonrandomized Phase 1/2 Clinical Trial. *JAMA Oncol* 2020; 6(4):535-541
360. Napolitano A, Provenzano S, Colombo C, Vitellaro M, Brunello A, Badalamenti G, Nannini M, Ibrahim T, Hohenberger P, Gasperoni G, Gennatasi S, Jones RL, Hindi N, Martin Broto J, Spalato Ceruso M, Silletta M, Dei Tos AP, **Gronchi A**, Stacchiotti S, Santini D, Tonini G, Palassini E and Vincenzi B. FAP-related desmoid tumors treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis. *ESMO Open* 2020;5(1):e000604
361. D'Ambrosio L, Touati N; Blay JY; Grignani G; Flippot R; Czarnecka AM; Piperno-Neumann S; Martin-Broto J; Sanfilippo R; Katz F; Duffaud F; Vincenzi B; Stark DP; Mazzeo F; Tuchscherer A; Chevreau C; Sherriff J; Estival A; Litière S; Sents W; Ray-Coquard I; Tolomeo F; Le Cesne A; Rutkowski P; Stacchiotti S; Kasper B; Gelderblom H; **Gronchi A** on behalf of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as first-line treatment for advanced leiomyosarcoma: a propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. *Cancer* 2020; 126:2637-2647.
362. Previtali P, Fiore M, Colombo J, Arendar I, Fumagalli L, Pizzocri M, Colombo C, Rampello NN, Mariani L, **Gronchi A**, Codazzi D. Malnutrition and perioperative nutritional support in retroperitoneal sarcoma patients. Results from a prospective study. *Ann Surg Oncol* 2020; 27(6):2025-2032.
363. Restivo A, De Luca R, Spolverato G, Delrio P, Lorenzon L, D'Ugo D, **Gronchi A**. The need of COVID19 free hospitals to maintain cancer care. *Eur J Surg Oncol* 2020; 46:1186-1187
364. Haas RL, Walraven I, Lecointe-Artzner E, van Houdt WJ, Strauss DC, Schrage Y, Hayes AJ, Raut CP, Fairweather M, Baldini EH, **Gronchi A**, De Rosa L, Griffin AM, Ferguson PC, Wunder J, van de Sande MAJ, Krol ADG, Skoczylas J, Sangalli C, Stacchiotti S. Extrameningeal Solitary Fibrous Tumors; surgery alone or surgery plus perioperative radiotherapy, a retrospective study from the Global SFT Initiative in collaboration with the Sarcoma Patients EuroNet. *Cancer* 2020; 126:3002-3012
365. Kirienko M, Padovano B, Serafini G, Marchianò A, **Gronchi A**, Seregini E, Alessi A. CT, [18F]FDG-PET/CT and clinical findings before and during early Covid-19 onset in a patient affected by vascular tumour. *Eur J Nucl Med Mol Imaging* 2020; 47:1769-1770.
366. Gamboa AC, **Gronchi A**, Kardona K. Soft Tissue Sarcoma in Adults: An Update on the Current State of Histotype-Specific Management in an Era of Personalized Medicine. *Ca Cancer J* 2020; 70:200-229
367. Frezza AM; Sbaraglia M; Lo Vullo S; Baldi GG; Simeone N; Frenos F; Campanacci D; Stacchiotti S; Pasquali S; Callegaro D; Gambarotti M; Barisella M; Palomba A; Mariani L; Casali PG; Dei Tos AP; **Gronchi A**. The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group. *Eur J Surg Oncol* 2020; 46:1320-1326
368. Spolverato G, Capelli G, Restivo A, Bao Quoc R, Pucciarelli S, Pawlik TM, **Gronchi A**. The management of surgical patients during the COVID-19 pandemic. *Surgery* 2020; 168:4-10
369. **Gronchi A**; Palmerini E; Quagliuolo V; Martin Broto J; Lopez Pousa A; Grignani G; Brunello A; Blay JY; Tendero O; Diaz Beveridge R; Ferraresi V; Lugowska I; Merlo DF; Fontana V; Marchesi E; Braglia L; Donati DM; Palassini E; Bianchi G; Marrari A; Morosi C; Stacchiotti S; Bagué S; Coindre JM; Dei Tos AP; Picci P; Bruzzi P and Casali PG. Neoadjuvant chemotherapy in high risk soft tissue sarcoma: final results of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG), Polish (PSG) sarcoma groups. *J Clin Oncol* 2020; 38(19):2178-2186
370. Belli F, Sorrentino L, Gallino G, **Gronchi A**, Scaramuzza D, Valvo F, Cattaneo L, and Cosimelli M. A proposal of an updated classification for pelvic relapses of rectal cancer to guide surgical decision-making. *J Surg Oncol* 2020; 122:350-359
371. Radaelli S, Fossati P, Stacchiotti S, Akiyama T, Asencio J.M., Bandiera S, Benlloch AM, Boglione A, Boland P, Bolle S, Bruland Ø, Brunello A, Bruzzi P, Campanacci D, Cananzi F, Capanna R, Casadei R, Cordoba A, Court C, Dei Tos A.P, DeLaney T.F, De Paoli A, De Pas TM, Desai A, Di Brina L, Donati D.M, Fabbri N, Fiore M.R, Frezza A.M, Gambarotti M, Gasbarrini A, Georg P, Grignani G, Hindi N, Hug E.B, Jones R, Kawai A., MD, Krol A.D, Le Grange F, Luzzati A, Marquina G, Mazzocco K, Navarria F, Patel S, Pennacchioli E, Petrongari M.G, Picci P., MD40, Pollock R., MD41, Porcu L., PhD42, Quagliuolo V., MD15 Sangalli C., MD43, Scheipl S., MD44, Scotto G.M., MD34, Spalek M, Steinmeier T, Timmermann B, Trama A, Uhl M, Valverde C, Varga P.P, Verges R, Zoccali C, Casali P.G, Sommer J, **Gronchi A**. The sacral chordoma margin. *Eur J Surg Oncol* 2020;46:1415-1422
372. Are C, Bartlett DL, Nissan A, Dov Z, Gupta A, Savant D, Bargallo-Rocha JE, Martinez Said H, Oliveira AF, de Castro Ribeiro HS, Leon A, Kitagawa Y, Yang HK, Park DJ, Zaghloul A, Gawad WA, McKay A, Helyer LK, Majid HJ, Cheema MA, Chen G, **Gronchi A**, Kovacs T, D'Ugo D. Global Forum of Cancer Surgeons: position statement. *Ann Surg Oncol* 2020; 27:2573-2576
373. Spolverato G, Callegaro D and **Gronchi A**. Defining which patients are at high risk for Recurrence of Soft Tissue Sarcoma. *Curr Treat Opt Oncol* 2020; 21:56
374. Sorrentino L, Belli F, Valvo F, Villa S, Guaglio M, Scaramuzza D, **Gronchi A**, Di Bartolomeo M, Cosimelli M. Neoadjuvant (re)chemo-radiation for recurrent rectal cancer: impact of anatomical site of pelvic recurrence on long term results. *Surg Oncol* 2020; 35:89-96

375. Al-Sukhni E, van Houdt WJ, Burtenshaw SM, Babichev Y, Raut CP, Fiore M, Demicco EG, **Gronchi A** and Gladdy RA. Virtual biobanking for Retroperitoneal Sarcoma – A Transatlantic Australasian RetroPeritoneal Sarcoma Working Group (TARPSWG) initiative. *Ann Surg Oncol* 2020; 27:3573-3576
376. Roland CL, van Houdt WJ, **Gronchi A**. The Landmark Series: Multimodality Treatment of Extremity Sarcoma. *Ann Surg Oncol* 2020; 27:3672-3682
377. Casali PG, Dei Tos AP, **Gronchi A**. When does a new sarcoma exist? *Clin Sarcoma Res* 2020; 10:19
378. Tirotta F, Hodson J, Parente A, Pasquali S, Sutcliffe R, Desai A, Muesan P, Ford SJ, Fiore M, **Gronchi A**, Almond LM. Liver resection for sarcoma metastases. *Eur J Surg Oncol* 2020; 46:1807-1813
379. Bonvalot S, **Gronchi A**, Le Péchoux C, Swallow CJ, Strauss DC, Meeus P, van Coevorden F, Stoldt S, Stoeckle E, Rutkowski P, Rastrelli M, Raut CP, Hompes D, De Paoli A, Sangalli C, Honoré C, Chung P, Miah A, Blay JY, Fiore M, Stelmes JJ, Dei Tos AP, Baldini EH, Litière S, Marreaud S, Gelderblom H, Haas RL. Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC 62092: STRASS) : a multicenter, randomised, phase 3 trial. *Lancet Oncol* 2020; 21:1366-1377
380. Martin-Broto J, Hindi N, Aguiar S, Badilla-González R, Castro-Olden V, Chacón M, Correa-Generoso R, de Álava E, Donati DM, Eriksson M, Falla-Jimenez M, German G, Gobo Silva ML, Gouin F, **Gronchi A**, Haro-Varas JC, Jiménez-Brenes N, Kasper B, Lopes de Mello CA, Maki R, Martínez-Delgado P, Martínez-Said H, Martínez-Tlahuel JL, Morales-Pérez JM, Muñoz-Casares FC, Nakagawa SA, Ortiz-Cruz EJ, Palmerini E, Patel S, Moura DS, Stacchiotti S, Sunyach MP, Valverde CM, Waisberg F, Blay JY. Sarcoma European & Latin American Network (SELNET) recommendations on prioritization in Sarcoma care during COVID-19 pandemic. *The Oncologist* 2020; 25:1562-1573
381. Sanfilippo R, Fabbroni C, Fucà G, Fumagalli E, Morosi C, Sbaraglia M, **Gronchi A**, Collini P, Dei Tos AP, Casali PG. Addition of anti-estrogen treatment in patients with malignant PEComa progressing to mTOR inhibitors. *Clin Cancer Res* 2020; 26(20):5534-5538
382. Baldi GG, **Gronchi A**, Stacchiotti S. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumours. *Expert Rev Clin Pharmacol* 2020; 13(6):571-576
383. Tirotta F, Morosi C, Hodson J, Desai A, Barisella M, Ford SJ, **Gronchi A**, Almond MJ, Fiore M. Improved biopsy accuracy in dedifferentiated liposarcoma. *Ann Surg Oncol* 2020; 27(11):4574-4581
384. van Houdt WJ, Fiore M, Barretta F, Rutkowski P, Blay JY, Lahat G, Strauss DC, Gonzalez RJ, Ahuja N, Grignani G, Quagliuolo V, Stoeckle E, De Paoli A, Schrage Y, Cardona K, Pennacchioli E, Pillarisetty VG, Nessim C, Swallow CJ, Bagaria SP, Canter R, Mullen JT, Callegaro D, Fairweather M, Miceli R, Raut CP, **Gronchi A**, Gladdy RA. Patterns of recurrence and survival probability following second relapse of retroperitoneal sarcoma: a study from TARPSWG. *Cancer* 2020;126:4917-4925
385. Ferrandina G, Aristei C, Biondetti PR, Cananzi FCM, Casali P, Ciccarone F, Colombo N, Comandone A, Corvo' R, De Iaco P, Dei Tos AP, Donato V, Fiore M, Franchi, Gadducci A, **Gronchi A**, Guerriero S, Infante A, Odicino F, Pirroni T, Quagliuolo V, Sanfilippo R, Testa AC, Zannoni GF, Scambia G, Lorusso D. Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Società italiana di Ginecologia E Ostetricia). *Eur J Cancer* 2020; 139:149-168
386. Haas RL and **Gronchi A**. In response to: "Intraoperative radiation therapy (IORT) for soft tissue sarcoma – ESTRO IORT Task Force / ACROP recommendations. *Rad Oncol* 2021; 154:170-171
387. Baldi GG, Brahmi M, Lo Vullo S, Cojocar E, Mir O, Casanova M, Vincenzi B, De Pas T, Grignani G, Pantaleo MA, Blay JY, Jones RL, Le Cesne A, Frezza AM, **Gronchi A**, Collini P, Dei Tos AP, Morosi C, Mariani L, Casali PG and Stacchiotti S. The activity of chemotherapy in inflammatory myofibroblastic tumour (IMT): a multicentre, European retrospective case series analysis. *The Oncologist* 2020; 25:1777-1784
388. D'Ambrosio L, Litiere S, Stacchiotti S and **Gronchi A**. Response to "Ifosfamide deleterious effect in leiomyosarcoma: convergence of weak signals". *Cancer* 2020; 126(20):4615-4616
389. Roland CL, van Houdt W, **Gronchi A**. ASO Author reflections: moving the needle in extremity and trunk soft tissue sarcoma. *Ann Surg Oncol* 2020; 27(Suppl 3):899-900
390. Paioli A, Stacchiotti S and **Gronchi A**. Extraskeletal myxoid chondrosarcoma: a rare sarcoma associated with prolonged survival. *Ann Surg Oncol* 2020; 27(Suppl 3):797-798
391. Demetri GD, Antonescu CR, Bjerkheggen B, Bovée JVMG, Boye K, Chacón M, Tos APD, Desai J, Fletcher JA, Gelderblom H, George S, **Gronchi A**, Haas RL, Hindi N, Hohenberger P, Joensuu H, Jones RL, Judson I, Kang YK, Kawai A, Lazar AJ, Le Cesne A, Maestro R, Maki RG, Martin J, Patel S, Penault-Llorca F, Raut CP, Rutkowski P, Safwat A, Sbaraglia M, Schaefer IM, Shen L, Serrano C, Schöffski P, Stacchiotti S, Hall KS, Tap WD, Thomas DM, Trent J, Valverde C, van der Graaf WTA, von Mehren M, Wagner A, Wardelmann E, Naito Y, Zalcberg J, Blay JY. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. *Ann Oncol* 2020; 27(Suppl 3):899-900
392. Kasper B, Raut CP and **Gronchi A**. Desmoid tumor: to treat or not to treat that is the question. *Cancer* 2020; 126(24):5213-5221
393. Delaying surgery for patients with a previous SARS-CoV-2 infection.COVIDSurg Collaborative. *Br J Surg.* 2020;107(12):e601-e602
394. Improta L, Valeri S, Alloni R, Pagnoni C, Mallozzi Santa Maria F, Brunetti B, Greco C, Aprile I, Maselli M, Vincenzi B, **Gronchi A**. Locally recurrent extraskeletal myxoid chondrosarcoma of the shoulder: a case of complete neoadjuvant radiotherapy response. *Clin Sarcoma Res* 2020; 10(1):27

395. Stacchiotti S, Baldi GG, Morosi C, **Gronchi A**, Maestro R. Extraskeletal Myxoid Chondrosarcoma: State of the art and current research on biology and clinical management. *Cancers* 2020; 12(9):2703
396. Bonvalot S, **Gronchi A**, Le Pechoux C, Baldini EH, Haas RL. STRASS: Positive Results in a Negative Trial. *Lancet Oncol* 2021; 22(1):e4
397. Paioli A, Stacchiotti S, Campanacci D, Palmerini E, Frezza AM, Longhi A, Radaelli S, Donati DM, Beltrami G, Bianchi G, Barisella M, Righi A, Benini S, Fiore M, Picci P and **Gronchi A**. Extraskeletal myxoid chondrosarcoma with molecularly confirmed diagnosis: a multicenter retrospective study within the Italian Sarcoma Group. *Ann Surg Oncol* 2021; 28:1142-1150
398. Perhavec A, Provenzano S, Baia M, Sangalli C, Morosi C, Barisella M, Colombo C, Radaelli S, Pasquali S, Callegaro D, **Gronchi A**, Fiore M. Inoperable Primary Retroperitoneal Sarcomas: clinical characteristics and reasons against resection at a single referral institution. *Ann Surg Oncol* 2021; 28:1151-1157
399. Callegaro D; Raut CP; Zeung EK; Kim T; Le Pechoux C; Martin-Broto J; **Gronchi A**; Swallow CJ; Gladdy R. Strategies for care of patients with gastrointestinal stromal tumor or soft tissue sarcoma during COVID-19 pandemic: a guide for surgical oncologists. *J Surg Oncol* 2021;123:12–23
400. Haas RL, Walraven I, Lecointe-Artzner E, van Houdt WJ, Scholten AN, Strauss D, Schrage Y, Hayes AJ, Raut CP, Fairweather M, Baldini EH, **Gronchi A**, De Rosa L, Griffin AM, Ferguson PC, Wunder J, van de Sande MAJ, Krol ADG, Skoczylas J, Sangalli C, Stacchiotti S. Management of Meningeal Solitary Fibrous Tumors / Hemangiopericytoma; surgery alone or surgery plus postoperative radiotherapy? *Acta Oncol* 2021; 60(1):35-41
401. Cavaliere D, Parini D, Marano L, Cipriani F, Di Marzo F, Macrì A, D'Ugo D, Roviello F, **Gronchi A**; SICO (Italian Society of Surgical Oncology). Surgical management of oncologic patient during and after the COVID-19 outbreak: practical recommendations from the Italian society of Surgical Oncology. *Updates Surg* 2021; 73(1):321-329
402. Callegaro D; Raut CP; Ng D; Strauss DC; Honoré C; Stoeckle E; Bonvalot S; Haas RL; Vassos N; Conti L; Gladdy RA; Fairweather M; van Houdt V; Schrage Y; van Coevorden F; Rutkowski P; Miceli R; **Gronchi A**; Swallow CJ. Has the outcome of patients who undergo resection of primary retroperitoneal sarcoma changed over time? A time-trends study over the past 15 years. *Ann Surg Oncol* 2021; 28(3):1700-1709
403. Tseng WW, Barretta F, Conti L, Grignani G, Tolomeo F, Albertsmeier M, Angele MK, Rutkowski P, Skoczylas J, De Paoli A, Navarria F, Raut CP, Fairweather M, Farma JM, Nessim C, Goel N, Grignol VP, Ford SJ, Cardona K, Subhawong T, Tattersall HL, Lee RM, Hu J, von Mehren M, Sanfilippo R, **Gronchi A**. Defining the Role of Neoadjuvant Systemic Therapy in High Risk Retroperitoneal Sarcoma: A Multi-Institutional Study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). *Cancer* 2021; 127:729-738
404. Tattersall HL, Hodson J, Cardona K, Lee RM, Nessim C, Gladdy R, Van Der Hage J, Schrage Y, Tseng W, van Houdt W, Novak M, Grignani G, Tolomeo F, Goel N, Ryon E, Gyorki D, Bagaria SP, Gonzalez JA, Martin Arnau AB, Sayyed R, Tirota F, Evenden C, Desai A, Almond M, Glasbey J, Fiore M, **Gronchi A**, Ford SJ. Primary Mesenteric Sarcomas: Collaborative experience from the TransAtlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). *J Surg Oncol* 2021; 123:1057–1066.
405. Frezza AM, Napolitano A, Miceli R, Badalamenti G, Brunello A, Buonomenna C, Casali PG, Caraceni A, Grignani G, **Gronchi A**, Infante G, Morosi C, Saita L, Simeone N, Zaffaroni N, Vincenzi B, Stacchiotti S. Clinical prognostic factors in advanced epithelioid haemangioendothelioma: a retrospective case series analysis within the Italian Rare Cancers Network. *ESMO Open* 2021; 6(2):100083
406. Fabbri C, Fucà G, Ligorio F, Fumagalli E, Barisella M, Collini P, Morosi C, **Gronchi A**, Dei Tos AP, Casali PG, Sanfilippo R. Impact of pathological stratification on the clinical outcomes of advanced well differentiated/dedifferentiated liposarcoma treated with trabectedin. *Cancers* 2021, 13(6):1453
407. Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Penel N, Kopp HG, Duffaud F, Goldstein D, Martin Broto J, **Gronchi A**, Wardelmann E, Marréaud S, Zalberg JR, Litière S, Blay JY. Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma Group (STBSG), the Australasian Gastro-Intestinal Trials Group (AGITG), UNICANCER, French Sarcoma Group (FSG), Italian Sarcoma Group (ISG), Spanish Group for Research on Sarcomas (GEIS). *Ann Oncol* 2021; 32(4):533-541
408. Zuco V, Pasquali S, Tortoreto M, Bric S, Percio S, Dagrada P, Colombo C, Sanfilippo R, Lauricella C, Gounder M, El Bezawy R, Barisella M, Dei Tos AP, Casali PG, **Gronchi A**, Stacchiotti S, Zaffaroni N. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation. *J Exp Clin Cancer Res* 2021; 40(1):83
409. Spolverato G, Restivo A, Capelli G, De Luca R, Roviello F, D'Ugo D, Delrio P, Garofalo A, Lorenzon L, Boggi U, Folli S, Torzilli G, **Gronchi A**. Cancer Networks as a response to COVID pandemic: A framework from the Italian Society of Surgical Oncology. *J Surg Oncol* 2021; 123(5):1201-1203
410. Oliveira AF, Quadros CA, de Castro Ribeiro HS, Wainstein AJA, de Queiroz Sarmiento BJ, Lyra J, Neto GB, Ribeiro R, Pinheiro RN, da Silva Barreto EJS, Park J, McKay A, Gupta A, Savant D, Nissan A, Zippel D, Leon A, Bargallo-Rocha JE, Martinez Said H, Kitagawa Y, Yoshida K, Lee WY, Park DJ, Zaghloul A, Gawad WA, Chen G, Majid HJ, Cheema MA, **Gronchi A**, Kovacs T, D'Ugo D, Bartlett DL, Howe JR, Are C. Global Forum of Cancer Surgeons: Support for the Brazilian Society of Surgical Oncology Journey towards Implementation of Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy in Brazil. *Ann Surg Oncol* 2021; 28(4):1892-1895.

411. Timbergen MJM, Colombo C, Renckens M, Sung Kim H, van Rosmalen J, Salas, S, Mullen JT, Colombo P, Nishida Y, Wiemer EAC, Verhoef C, Sleijfer S, **Gronchi A**, Grünhagen DJ. The prognostic role of β -catenin mutations in desmoid-type fibromatosis undergoing resection only: a meta-analysis of individual patient data. *Ann Surg* 2021;273:1094–1101.
412. Nessim C, Raut CP, Callegaro D, Barretta F, Miceli R, Fairweather M, Rutkowski P, Blay JY, Strauss D, Gonzalez R, Ahuja N, Grignani G, Quagliuolo V, Stoeckle E, De Paoli A, Pillarisetty VG, Swallow CJ, Bagaria SP, Canter RJ, Mullen JT, Schrage Y, Pennacchioli E, van Houdt W, Cardona K, Fiore M, **Gronchi A**, Lahat G. Postoperative Morbidity after Resection of Recurrent Retroperitoneal Sarcoma: A Report from the Transatlantic Australasian RPS Working Group (TARPSWG). *Ann Surg Oncol* 2021; 28(5):2705-2714.
413. Fiore M, Brunelli C, Miceli R, Manara M, Lenna S, Rampello NN, Callegaro D, Colombo C, Radaelli S, Pasquali S, Caraceni AT, **Gronchi A**. A Prospective Observational Study on Multivisceral Resection for Retroperitoneal Sarcoma: Clinical and Patient-reported Outcomes One Year after Surgery. *Ann Surg Oncol* 2021; 28:3904-3916
414. Fiore M, Caraceni AT and **Gronchi A**. ASO Author Reflections: Understanding the impact on well-being after resection of primary RPS: one step forward to learn how caring patients is as important as curing their cancers. *Ann Surg Oncol* 2021; 28:3917-3918
415. Stacchiotti S, Miah AB, Frezza AM, Messiou C, Morosi C, Caraceni A, Abecasis N, Razak AR, Antonescu C, Bajpai J, Baldini E, Bauer S, Biagini R, Bielack S, Blay JY, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Callegaro D, De Alava E, Deoras-Sutcliffe M, Duffresne A, Eriksson M, Errani C, Fedenko A, Ferraresi V, Ferrari A, Fletcher C, Garcia del Muro X, Gelderblom H, Gladdy RA, Gouin F, Grignani G, Gutkovich J, Haas R, Hindi N, Hohenberger P, Huang P, Joensuu H, Jones RL, Jungels C, Kasper B, Kawai A, LeCesne A, Le Grange F, Leithner A, Leonard H, Lopez Pousa A, Martin Broto J, Merimsky O, Merriam P, Miceli R, Mir O, Molinari M, Montemurro M, Oldani G, Palmerini E, Pantaleo M, Patel S, Piperno-Neumann S, Raut CP, Ravi V, Reichardt P, Rubin B, Rutkowski P, Safwat AA, Sangalli C, Sapisochin G, Sbaraglia M, Scheipl S, Schöffski P, Strauss D, Strauss SJ, Sundby Hall K, Tap WD, Trama A, Tweddle A, van der Graaf WTA, Van De Sande MAJ, Van Houdt W, van Oortmerssen G, Wagner AJ, Wartenberg M, Wood J, Zaffaroni N, Zimmermann C, Casali PG, Dei Tos AP, **Gronchi A**. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts. *ESMO Open* 2021; 6(3):100170
416. Callegaro D, Raut CP, Swallow CJ and **Gronchi A**. Retroperitoneal Sarcoma: the TARPSWG Program. *Cur Opin Oncol* 2021; 33(4):301-308
417. **Gronchi A**. Surgery in soft tissue sarcoma: the thin line between a surgical or more conservative approach. *Future Oncol* 2021; 17(21s):3-6
418. Danieli M, Barretta F, Fiore M, Radaelli S, Sangalli C, Barisella M, Stacchiotti S, Palassini E, Miceli R, Callegaro D, Casali PG and **Gronchi A**. Unplanned excision of extremity and trunk wall soft tissue sarcoma: to re-resect or not to re-resect? *Ann Surg Oncol* 2021; 28(8):4706-4717
419. Danieli M and **Gronchi A**. ASO Author Reflections: Re-excision after macroscopically complete unplanned excision in Extremity and Trunk Wall Soft Tissue Sarcoma: is less more? *Ann Surg Oncol* 2021; 28(8):4718-4719.
420. Zanchetta E, Ciniselli CM, Bardelli A, Colombo C, Stacchiotti S, Baldi GG, Provenzano S, Bertulli R, Bini F, Casale A, Greco FG, Ferrari A, Verderio P, Fiore M, **Gronchi A**, Casali PG, Morosi C, Palassini E. Magnetic Resonance Imaging pattern of tumor response to chemotherapy in desmoid-type fibromatosis. *Cancer Med* 2021;10:4356–4365
421. Stacchiotti S, Frezza AM, Blay JY; Baldini EH; Bonvalot S; Bovée JVMG; Callegaro D; Casali PG; Chiang RC; Demetri GD; Demicco EG; Desai J; Eriksson M, Gelderblom H; George S; Gounder M; **Gronchi A**; Gupta A; Haas R; Hayes A; Hohenberger P, Jones KB; Jones RL; Kasper B; Kawai A; Kirsch DG; Kleiner ES; Le Cesne A; Lim J; Chirlaque López MD; Maestro R; Marcos-Gragera R; Martin Broto J; Matsuda T; Mir O; Patel SR; Raut CP; Razak A; Reed DR; Rutkowski P; Sanfilippo RG; Sbaraglia M; Schaefer IM; Strauss D; Sundby Hall K; Tap W; Thomas DM; Van der Graaf W; van Houdt WJ; Visser O; von Mehren M, Wagner AJ; Wilky BA; Won YJ; Fletcher C; Dei Tos AP, Trama A. Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities. *Cancer* 2021; 127(16):2934-2942.
422. Giannini L, Bresciani L, Paderno A, Incandela F, Fiore M, **Gronchi A**, Piazza C. Head and neck adult-type soft tissues sarcomas: survival analysis and comparison between the last two editions of the TNM staging system. *Eur Arch Otorhinolaryngol* 2021; 278(8):3003-3010
423. Bonvalot, S, Wunder J, **Gronchi A**, Martin Borto J, Turcotte R, Rastrelli M, Papai S, Radaelli S, MD, Lindner LH, Shumelinsky F, Cubillo A, Rutkowski P, Demaire C, Strens D, Nalbantov G. Complete pathological response to neoadjuvant treatment is associated with better survival outcomes in patients with Soft Tissue Sarcoma: Results of a retrospective multicenter study. *Eur J Surg Oncol* 2021; 47(8):2166-2172
424. Mohammadi M IJzerman NS, Hohenberger P, Rutkowski P, Jones RL, Martin-Broto J, **Gronchi A**, Schöffski P Vassos N, Farag S, Baia M, Oosten AW, Steeghs N, Desar,IME, Reyners AKL, van Sandick JW, Bastiaannet E, Gelderblom H, Schrage Y. Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): a large, retrospective multicenter European study. *Eur J Surg Oncol* 2021; 47(8):2173-2181
425. Cananzi FCM, Ruspi L, Fiore M, Sicoli F, Quagliuolo V and **Gronchi A**. Major vascular resection in retroperitoneal sarcoma surgery. *Surgery* 2021; 170:848-856
426. Tseng WW, Barretta F, Baia M, Barisella M, Radaelli S, Callegaro D, Yoon DH, Fiore M, **Gronchi A**. Dedifferentiation within well differentiated liposarcoma of the extremity or trunk: implications for clinical management. *J Surg Oncol* 2021; 124:838–845
427. Callegaro D; Barretta F; Swallow CJ; Strauss DC; Bonvalot S; Honoré C; Stoeckle E; van Coevorden F, Haas R; Rutkowski P; Schrage Y; Fairweather M; Conti L; Vassos N; Gladdy RA; Ng D; van Houdt VJ; Miceli R, Raut CP; **Gronchi A**. Longitudinal prognostication in retroperitoneal sarcoma survivors: development and external validation of two dynamic nomograms. *Eur J Cancer* 2021; 157:291-300

428. Pagnoni C, Improta L, Alloni R, Mallozzi S, Maria F, Aprile I, Brunett B, Greco C, Vincenzi B, **Gronchi A**, Valeri S. Recurrent Neck myxofibrosarcoma: a case of complete radiotherapy response. *J Med Case Rep* 2021;15(1):484
429. Bagaria SP, Swallow CJ, Suraweera H, Raut CP, Fairweather M, Cananzi F, Quagliuolo V, Grignani G, Hompes D, Ford SJ, Nessim C, Apte S, Skoczylas J, Rutkowski P, Bonvalot S, Tzanis D, Gabriel E, Pennacchioli E, Albertsmeier M, Canter RJ, Pollock RE, Grignol V, Cardona K, Gamboa AC, Novak M, Stoeckle E, Almquist M, Ahuja N, Klemen N, Van Houdt W, Gyorki D, Gangi A, Rastrelli M, van der Hage J, Schrage Y, Valeri S, Conti L, Spiegel M, Li Z, Fiore M, **Gronchi A**. Morbidity and outcomes following distal pancreatectomy for primary retroperitoneal sarcoma: an analysis by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group. *Ann Surg Oncol* 2021;28:6882-6889
430. Bagaria SP and **Gronchi A**. Distal Pancreatectomy for primary retroperitoneal sarcoma – clinical implications and future directions. *Ann Surg Oncol* 2021; 28:6990-6991
431. Nessim C, Raut CP, Callegaro D, Barretta F, Miceli R, Fairweather M, Blay JY, Strauss DC, Rutkowski P, Ahuja N, Gonzalez R, Grignani G, Quagliuolo V, Stoeckle E, Lahat G, De Paoli A, Pillarisetty VG, Canter RJ, Mullen JT, Pennacchioli E, van Houdt W, Swallow CJ, Schrage Y, Cardona K, Fiore M, **Gronchi A**, Bagaria SP. An Analysis on Differentiation Changes and Outcomes at the Time of First Recurrence of Retroperitoneal Liposarcoma by the Trans-Atlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Surg Oncol* 2021; 28:7854-7863
432. Swallow CJ, Strauss DC, Bonvalot S, Rutkowski P, Desai A, Gladdy RA, Gonzalez R, Gyorki DE, Fairweather M, van Houdt WJ, Stoeckle E, Berm Park J, Albertsmeier M, Nessim C, Cardona K, Fiore M, Hayes A, Tzanis D, Skoczylas J, Ford SJ, Ng D, Mullinax JE, Snow H, Haas RL, Callegaro D, Smith MJ, Bouhadiba T, Stacchiotti S, Jones RL, DeLaney T, Roland CL, Raut CP, **Gronchi A**, on behalf of the Transatlantic Australasian RPS Working Group (TARPSWG). Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: An Updated Consensus Approach from the Transatlantic Australasian RPS Working Group. *Ann Surg Oncol* 2021; 28:7873-7888
433. **Gronchi A**, Miah AB, Dei Tos AP, Abecassis N, Bajpai J, Bauer S, R. Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee J, JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, De Álava E, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Gouin F, Grignani G, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss DC, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Casali PG & Stacchiotti S on behalf of the ESMO Guidelines Committee, EURACAN and GENTURIS. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2021; 32(11):1348-1365
434. Strauss S, Frezza AM, Abecassis N, Bajpai J, Bauer S, R. Biagini R, Bielack S, Blay JY, Bolle S, Bonvalot S, Boukovinas I, Bovee J, JVMG, Boye K, Brennan B, Brodowicz T, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Gaspar N, Gasperoni S, Gelderblom H, Gouin F, Grignani G, **Gronchi A**, Haas R, Hassan AB, Hecker-Nolting S, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kager L, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morland B, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss DC, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, Ladenstein R, Casali PG & Stacchiotti S on behalf of the ESMO Guidelines Committee, EURACAN, GENTURIS and ERNPaedCan. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERNPaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2021; 32(12):1520-1536
435. Martin-Broto J, Lopez-Alvarez M, Moura DS, Ramos R, Collini P, Romagosa C, Bagué S, Renne RL, Barisella M, Velasco V, Coindre JM, Lopez-Lopez D, Dopazo J, Gambarotti M, Braglia L, Merlo D, Palmerini E, Stacchiotti S, Quagliuolo V, Lopez-Pousa A, Grignani G, Blay JY, Brunello A, Gutierrez A, Valverde C, Hindi N, Dei Tos AP, Picci P, Casali PG and **Gronchi A**. Predictive or prognostic value of MRP-1 in localized high-risk soft tissue sarcomas: a translational research associated to ISG-STS 1001 randomized phase III trial. *Mol Cancer Ther* 2021; 20(12):2539-2552
436. Spolverato G, Chiminazzo V, Lorenzoni G, Fiore M, Radaelli S, Sanfilippo R, Sangalli C, Barisella M, Callegaro D, **Gronchi A**. Oncological Outcomes after Major Vascular Resections for Primary Retroperitoneal Liposarcoma. *Eur J Surg Oncol* 2021; 47:3004-3010
437. Lahat G, **Gronchi A**, Raut CP and Nessim C. ASO Author Reflections: Selecting patients for recurrent Retroperitoneal Sarcoma surgery—The challenging trade-off between oncologic outcome and morbidity. *Ann Surg Oncol* 2021; 28(Suppl 3):852-853
438. Bini F, Fiore M, Provenzano S, Bertulli R, Ottini A, Colombo C, Vitellaro M, Greco G, Morosi C, **Gronchi A**, Casali PG, Palassini E. Management of serious complications in intra-abdominal Desmoid-type Fibromatosis. *Cancer Report* 2021;4(6):e1411
439. Gervais MK, Callegaro D and **Gronchi A**. The Evolution of Adjuvant/neoadjuvant trials for resectable localized sarcoma. *J Surg Oncol* 2022; 125 :17–27
440. Pasquali S, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Infante G, Braglia L, Merlo FD, Fontana V, Marchesi E, Donati DM, Palassini E, Bianchi G, Marrari A, Morosi C, Stacchiotti S, Bagué S, Coindre JM, Dei Tos AP, Picci P, Bruzzi P, Miceli R, Casali PG and **Gronchi A**. Neoadjuvant chemotherapy in high risk soft tissue sarcomas: a sarculator-based risk stratification analysis of the randomized trial ISG-STS 1001. *Cancer* 2022; 128(1):85-93.

441. Voss RK, Callegaro D, Chiang YJ, Fiore M, Miceli R, Keung EZ, Feig BW, Torres KE, Scally CP, Hunt KK, **Gronchi A**, Roland CL. Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in U.S. Patients. *Ann Surg Oncol* 2022; 29:4376-4385
442. Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, R. Biagini R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Boye K, Brodowicz T, Buonadonna A, De Álava E, Dei Tos AP, Del Muro XG, Dufresne A, Eriksson M, Fagioli F, Fedenko A, Ferraresi V, Ferrari A, Frezza AM, Gasperoni S, Gelderblom H, Guin F, Grignani G, Haas R, Hassan AB, Hindi N, Hohenberger P, Joensuu H, Jones RL, Jungels C, Jutte P, Kasper B, Kawai A, Kopeckova K, Krákorová DA, Le Cesne A, Le Grange F, Legius E, Leithner A, Lopez-Pousa A, Martin-Broto J, Merimsky O, Messiou C, Miah AB, Mir O, Montemurro M, Morosi C, Palmerini E, Pantaleo MA, Piana R, Piperno-Neumann S, Reichardt P, Rutkowski P, Safwat AA, Sangalli C, Sbaraglia M, Scheipl S, Schöffski P, Sleijfer S, Strauss DC, Strauss SJ, Sundby Hall K, Trama A, Unk M, van de Sande MAJ, van der Graaf WTA, van Houdt WJ, Frebourg T, **Gronchi A** & Stacchiotti S on behalf of the ESMO Guidelines Committee, EURACAN, GENTURIS and ERNPaedCan. Gastrointestinal Stromal Tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2022; 33(1):20-33
443. Fairweather M, Lyu H, Conti L, Callegaro D, Radaelli S, Fiore M, Ng D, Swallow CJ, **Gronchi A**, Raut CP. Post-nephrectomy Outcomes Following en bloc Resection of Primary Retroperitoneal Sarcoma (RPS): A Multicenter Analysis. *Br J Surg* 2022; 109:165-8
444. Ng D, Cyr DP, Burtenshaw SM, Callegaro D, **Gronchi A**, Shultz D, Brar S, Chung P, Gladly RA, Catton C, Swallow CJ. The effect of preoperative treatment on the performance of predictive nomograms in primary retroperitoneal sarcoma (RPS). *Ann Surg Oncol* 2022; 29:2304-2314.
445. **Gronchi A** and Raut CP. So Now What? Unanswered Questions Regarding Retroperitoneal Sarcomas, Hospital Volume, Multidisciplinary Expertise, and Outcomes. *Ann Surg Oncol* 2022; 29:2138-2140.
446. Moulin B, Messiou C, Crombe A, Kind M, Hohenberger P, Rutkowski P, van Houdt WJ, Strauss DC, **Gronchi A** and Bonvalot S. Diagnosis strategy of adipocytic soft-tissue tumors in adults. A consensus from European Experts. *Eur J Surg Oncol* 2022; 48(3):518-525.
447. Danieli M, Barretta F, Fiore M, Radaelli S, Sangalli C, Barisella M, Stacchiotti S, Palassini E, Miceli R, Frezza AM, Callegaro D, Casali PG and **Gronchi A**. Refining the approach to patients with primary soft tissue sarcoma of the extremities and trunk wall: outcome improvement over time at a single institution. *Ann Surg Oncol* 2022; 29(5):3274-3286.
448. Danieli and **Gronchi A**. ASO Author Reflections: Outcome improvement over time in extremity and trunk wall soft tissue sarcomas--to whom the merit? *Ann Surg Oncol* 2022; 29(5):3287-3288
449. Baia M, Conti L, Pasquali S, Sarre-Lazcano C, Abatini C, Cioffi SPB, Della Valle S, Greco G, Vigorito R, Casirati A, Proto P, Gavazzi C, **Gronchi A**, Fiore M. Delayed gastric emptying after multivisceral resection for retroperitoneal sarcoma. *Ann Surg Oncol* 2022; 29(5):3264-3270.
450. Vincenzi B, Napolitano A, Fiocco M, Mir O, Rutkowski P, Blay JY, Reichardt P, Joensuu H, Fumagalli E, Gennatas S, Hindi N, Nannini M, Spalato Ceruso M, Italiano A, Grignani G, Brunello A, Gasperoni S, De Pas TM, Badalamenti G, Pantaleo MA, van Houdt WJ, IJzerman NS, Steeghs N, Gelderblom H, Desai IME, Falkenhof J, Silletta M, Sbaraglia M, Tonini G, Martin-Broto J, Hohenberger P, Le Cesne A, Jones RL, Dei Tos AP, **Gronchi A**, Bauer S and Casali PG. Adjuvant imatinib in GIST patients harboring exon 9 KIT mutations: results from a multi-institutional European retrospective study. *Clin Cancer Res* 2022; 28(8):1672-1679.
451. Istl AC and **Gronchi A**. Neoadjuvant therapy for primary resectable retroperitoneal sarcomas – looking forward. *Cancers* 2022; 14(7):1831
452. Are C, Tyler D, Howe J, Olivares A, Nissan A, Zippel D, Gupta A, Savant D, D'Ugo D, Rubio, Bargallo-Rocha JE, Martinez-Said H, Takeuchi H, Taketomi A, Oliveira AF, Castro Ribeiro HS, Cheema MA, Majid HJ, Chen H, Roviello F, **Gronchi A**, Leon A, Lee WY, Park DJ, Park J, Auer R, Gawad WA and Zaghloul A. Global Forum of Cancer Surgeons: Cancer Surgery During the COVID-19 Pandemic: Impact and Lessons Learned. *Ann Surg Oncol* 2022; 29(5):2773-2783
453. Fiore M, Baia M, Conti L, Piccioni F, Mariani L, Pasquali S, Seregini E, Maltese G, Galizia M, Radaelli S, Villa AM, Lo Vullo S, Valenza F, **Gronchi A**. Post-operative residual adrenal function after major surgery including adrenalectomy within multivisceral resection. *JAMA Surg* 2022; 157(5):415-423
454. Casirati A, Baia M, Vandoni G, Della Valle S, Greco G, Morosi C, Fiore M, **Gronchi A**, Gavazzi C. Risk of misclassification during diagnosis of malnutrition in retroperitoneal sarcoma patients. *Clin Nutr ESPEN* 2022; 49:459-465
455. Baldi GG, **Gronchi A**, Tazzari M, Stacchiotti S. Immunotherapy in soft tissue sarcomas: current evidence and future perspective in a variegated family of different tumours. *Exp Rev Anticancer Ther* 2022; 22:491-503
456. Conforti F, **Gronchi A**, Penel N, Jones RL, Martin Broto J, Sala I, Bagnardi V, Napolitano A, Pala L, Pennacchioli E, Queirolo P, Grigani G, Merlini A, Stacchiotti S, Comandone A, Vincenzi B, Quagliuolo V, Bertuzzi A, Boglione A, Palassini E, Baldi GG, Blay JY, Ryckewaert T, Toulmonde M, Italiano A, Le Cesne A, Ray-Coquard I, Cruz J, Hernández-León CN, Martínez Trufero J, da Silva Moura D, Hindi Muñiz N, De Pas T. Chemotherapy in patients with localized angiosarcoma of any site. A retrospective European study. *Eur J Cancer* 2022; 171:183-192
457. Schaefer IM, **Gronchi A**. WHO Pathology: Highlights of the 2020 Sarcoma Update. *Surg Oncol Clin N Am.* 2022; 31(3):321-340.
458. Haas R, Stelmes JJ, Zaffaroni F, Sauvé N, Clementel E, Bar-Deroma R, Le Péchoux C, Litière S, Marreaud S, Alyamani N, Andratschke N, Sangalli C, Chung P, Miah A, Hurkmans C, **Gronchi A**, Bovee JVMG, Gelderblom H, Kasper B, Weber DC, Bonvalot S. Critical Impact of Radiotherapy Protocol compliance and Quality in the Treatment of Retroperitoneal sarcomas: Results from the EORTC 62092- 22092 STRASS trial. *Cancer* 2022; 128:2796-2805

459. Blay JY, Hindi N, Bollard J, Aguiar Jr S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, Caro H, Carvajal A, Casavilca-Zambrano S, Castro V, Chacon M, Clara M, Collini P, Correa R, Costa FD, Cuellar M, David B, dei Tos AP, Dominguez H, Donati D, Donato M, Dufresne A, Eriksson M, Farias M, Foltan A, Frezza AM, Frisoni T, Garcia D, Gelderblom H, Goin F, Gómez-Mateo MC, **Gronchi A**, Haro J, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes A, Lopez-Pousa A, Lutter G, Martinez H, Martinez-Tlahuel J, Mello C, Morales JM, Nascimento AG, Ortiz E, Palmerini E, Patel S, Pfluger Y, Provenzano S, Rigui A, Rodriguez A, Santos T, Scotlandi K, Soule T, Stacchiotti S, Valverde C, Waisberg F, Zamora E, Casali PG, Martin-Broto J. SELNET Clinical practice guidelines for soft tissue sarcoma and GIST. *Cancer Treat Rev* 2022; 102:102312
460. Blay JY, Palmerini E, Bollard J, Aguiar S, Angel M, Araya B, Badilla R, Bernabeu D, Campos F, CHS CS, Carvajal Montoya A, Casavilca-Zambrano S, Castro-Oliden 5th, Chacón M, Clara-Altamirano MA, Collini P, Correa Genoroso R, Costa FD, Cuellar M, Dei Tos AP, Dominguez Malagon HR, Donati DM, Dufresne A, Eriksson M, Farias-Loza M, Frezza AM, Frisoni T, Garcia-Ortega DY, Gerderblom H, Gouin F, Gómez-Mateo MC, **Gronchi A**, Haro J, Hindi N, Huanca L, Jimenez N, Karanian M, Kasper B, Lopes A, Lopes David BB, Lopez-Pousa A, Lutter G, Maki RG, Martinez-Said H, Martinez-Tlahuel JL, Mello CA, Morales Pérez JM, Moura DS, Nakagawa SA, Nascimento AG, Ortiz-Cruz EJ, Patel S, Pfluger Y, Provenzano S, Righi A, Rodriguez A, Santos TG, Scotlandi K, Mlg S, Soulé T, Stacchiotti S, Valverde CM, Waisberg F, Zamora Estrada E, Martin-Broto J. SELNET Clinical practice guidelines for bone sarcoma. *Crit. Rev Oncol Heamtol* 2022; 174:103685
461. Stacchiotti S, Van der Graaf WTA, Sanfilippo R, Marreaud SI, van Houdt WJ, Judson I, **Gronchi A**, Gelderblom H, Litiere S, Kasper B. First-line chemotherapy in advanced intrabdominal well-differentiated/dedifferentiated liposarcoma: an EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. *Cancer* 2022; 28(15):2932-2938.
462. Tattersall HL, Baia M, Messina V, Borghi A, Almond M, Desai A, Ford SJ, **Gronchi A**. Overall Survival in abdominal wall sarcoma treated with curative intent surgery: a retrospective study from two European referral centres. *J Surg Oncol* 2022; 126:365–371
463. D'Ambrosio L, van Houdt WJ, Stelmes JJ, **Gronchi A**. First and further-line multidisciplinary treatment of retroperitoneal sarcomas. *Curr Opin Oncol* 2022; 34:328–334
464. Alessandrini I, Percio S, Naghshineh E, Zuco V, Stacchiotti S, **Gronchi A**, Pasquali S, Zaffaroni N, Folini M. Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma. *Cancers* 2022; 14(11):2624
465. Radaelli S; Pasquali S; Colombo C; Callegaro D; Sanfilippo R; Stacchiotti S; Provenzano S; Sangalli C; Morosi C; Barisella M; Miceli R; Fiore M; **Gronchi A**. Treatment strategies and outcome of primary myxofibrosarcoma in a large patients cohort. *Eur J Surg Oncol* 2022; 48:1723-1729
466. Colombo C, Fiore M, Grignani G, Tolomeo F, Merlini A, Palassini E, Collini P, Stacchiotti S, Casali PG, Perrone F, Mariani L and **Gronchi A**. A prospective observational study of Active Surveillance in primary desmoid fibromatosis. *Clin Cancer Res* 2022; 28(18):4027-4032
467. Tseng WW , Swallow CJ , Strauss DC , Bonvalot S, Rutkowski P, Ford SJ, Gonzalez RJ, Gladly RA, Gyorki DE, Fairweather M , Lee KW, Albertsmeier M, van Houdt WJ, Fau M, Nessim C, Grignani G, Cardona K, Quagliuolo V, Grignol V, Farma JM, Pennacchioli E, Fiore M, Hayes A, Tzanis D, Skoczylas J, Almond ML, Mullinax JE, Johnston W, Snow H, Haas RL, Callegaro D, Smith MJ, Bouhadiba T, Desai A, Voss R, Sanfilippo R, Jones RL, Baldini EH, Wagner AJ, Catton CN, Stacchiotti S, Thway K, Roland CL, Raut CP, and **Gronchi A**, on behalf of the Transatlantic Australasian RetroPeritoneal Sarcoma Working Group. Management of Locally Recurrent Retroperitoneal Sarcoma in the Adult. An Updated Consensus Approach from the Transatlantic Australasian RetroPeritoneal Sarcoma Working Group. *Ann Surg Oncol* 2022; 29:7335-7348
468. Bonvalot S, Rutkowski P, Thariat J, Carrère S, Ducassou A, Sunyach MP, Agoston P, Hong AM, Mervoyer A, Rastrelli M, Moreno V, Li RK, Tiangco BJ, Casado Herráez A, **Gronchi A**, Sy-Ortin T, Hohenberger P, de Baère T, Le Cesne A, Helfre S, Saada-Bouazid E, Anghel RM, Kantor G, Montero A, Loong HH, Vergés R, Kacso G, Austen L, Servois VF, Wardelmann E, Dimitriu M, Said P, Lazar AJ, Bovée JVMG, Le Péchoux C, Pápai Z. Final safety and HRQoL results of the phase II/III Act.In.Sarc study with preoperative NBTXR3 plus radiotherapy versus radiotherapy in locally advanced soft-tissue sarcoma. *Int J Radiat Oncol Biol Phys* 2022; 114(3):422-432
469. Kaltenmeier C, Stacchiotti S, **Gronchi A**, Sapisochin G, Ashwat E, Liu H, Geller D, Tohme S, Zureikat A, Molinari M. Treatment Modalities and Long-term Outcomes of Hepatic Hemangioendothelioma in the United States: Analysis of the National Cancer Database. *HPB* 2022; 24:1688-1696
470. Borghi A, Scotto di Uccio A, **Gronchi A**. Primary malignancy of the inferior vena cava, a review of surgical treatments and outcomes. *J Cardiovasc Surg (Torino)* 2022; 63(6):649-663
471. Stacchiotti S, Frezza AM, Demetri GD, Blay JY; Bajpai J, Baldi GG; Baldini EH; Benjamin RS; Bonvalot S; Bovée JVMG; Callegaro D; Casali PG; D'Angelo SP; Davis, EJ; Dei Tos AP; Demicco EG; Desai J; Dileo P; Eriksson M; Gelderblom H; George S; Gladly RA; Gounder M; Gupta AA; Haas R; Hayes A; Hohenberger P; Jones KB; Jones RL; Kasper B; Kawai A; Kirsch DG; Kleinerman ES; Le Cesne A; Maestro R; Martin Broto J; Maki RG; Miah AB, Palmerini E, Patel SR; Raut CP; Razak A; Reed DR; Rutkowski P; Sanfilippo RG; Sbaraglia M; Schaefer IM; Strauss D; Strauss SJ; Tap W; Thomas DM; Trama A; Trent JC; Van der Graaf W; van Houdt WJ; vonMehren M; Wilky BA; Fletcher C; **Gronchi A**; Miceli R; Wagner AJ. Retrospective observational studies in ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments. *Cancer Treat Rev* 2022; 110:102455
472. Angelucci M, Strumia A, **Gronchi A**, Alloni R, Schiavoni L, Improta L, Sgarlato G, Agrò FE, Fairweather M, Valeri S. Traditional risk scores do not properly predict perioperative morbidity and mortality for retroperitoneal sarcoma resection. *J Surg Oncol* 2022; 126(7):1367-1368

473. Heesen P, Studer G, Bode B, Windegger H, Staeheli B, Aliu P, Martin-Broto J, **Gronchi A**, Blay JY, Le Cesne A, Fuchs B. Quality of sarcoma care: Longitudinal real-time-assessment and evidence analytics of quality indicators. *Cancers* 2022; 15(1):47.
474. Callegaro D and **Gronchi A**. Radiotherapy in retroperitoneal liposarcoma: are we looking for an answer in the wrong place? *Ann Surg Oncol* 2023; 30:675–677
475. Stacchiotti S, Dürr HR, Schaefer IM, Woertler K, Haas R, Trama A, Caraceni A, Bajpai J, Baldi GG, Bernthal N, Blay JY, Boye K, Broto JM, Chen Wei-Wu T, Dei Tos AP, Desai J, Emhofer S, Eriksson M, **Gronchi A**, Gelderblom H, Hardses J, Hartmann W, Healey J, Italiano A, Jones RL, Kawai A, Leithner A, Loong H, Mascard E, Morosi C, Otten N, Palmerini E, Patel SR, Reichardt P, Rubin B, Rutkowski P, Sangalli C, Schuster K, Seddon B, Shkodra M, Staals EL, Tap W, van de Rijn M, van Langevelde K, Vanhoenacker FM, Wagner A, Wiltink L, Stern S, Van de Sande M, Bauer S. Best clinical management of tenosynovial giant cell tumour (TGCT): a consensus paper from the community of experts. *Cancer Treat Rev* 2023; 112:102491
476. Frezza AM, Stacchiotti S, Chibon F, Coindre JM, Italiano A, Romagnosa C, Bague S, Dei Tos AP, Braglia L, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Diaz Beveridge R, Lugowska I, Lesluyes T, Maestro R, Merlo FD, Casali PG and **Gronchi A**. CINSARC in high-risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: results from the ISG-STs 1001 study. *Cancer Med* 2023; 12:1350–1357.
477. Fiore M; Ljevar S; Pasquali S; Morelli D; Callegaro D; Sanfilippo R; Barisella M; Sangalli C; Miceli R and **Gronchi A**. Preoperative Neutrophil-to-Lymphocyte ratio and a new inflammatory biomarkers prognostic index for primary retroperitoneal sarcomas. *Clin Cancer Res* 2023; 29:614–20
478. Dei Tos AP, Webster F, Agaimy A, Bovée JVMG, Dickson B, Doyle LA, Dry SM, **Gronchi A**, Hameed M, Hemming C, Liegl-Atzwanger B, Thway K, Wagner AJ, Wang J, Yoshida, Fletcher CDM. Datasets for reporting of the Soft Tissue Sarcoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). *Histopathology* 2023; 82:745–754.
479. Saesen S, Van Hemelrijck M, Bogaerts J, Booth CM, Cornelissen JJ, Dekker A, Eisenhauer EA, Freitas A, **Gronchi A**, Hernán MA, Hulstaert F, Ost P, Szturz P, Verkooijen HM, Weller M, Wilson R, Lacombe D, van der Graaf WT. Defining the role of real-world data in cancer clinical research: the position of the European Organisation for Research and Treatment of Cancer. *Eur J Cancer* 2023; 186:52-61
480. Loong HHF, Gupta A and **Gronchi A**. NIRO or No-go? Positioning a novel systemic treatment option for desmoid tumours. *Ann Surg Oncol* 2023; 30:2570–2573
481. Conti L, Buriro F, Baia M, Pasquali S, Miceli R, De Rosa L, **Gronchi A**, Fiore M. Contemporary role of amputation for patients with extremity soft tissue sarcoma. *Eur J Surg Oncol* 2023; 49(5):934-940
482. Danieli M and **Gronchi A**. Staging systems and Nomograms for Soft Tissue Sarcoma. *Curr Oncol* 2023; 30(4):3648-3671
483. Sanfilippo R, Hindi N, Cruz J, Blay JY, Lopez Pousa A, Italiano A, Alvarez R, Gutierrez A, Rincón I, Sangalli C, Pérez Aguiar JL, Romero J, Morosi C, Sunyach MP, Fabbioni C, Romagosa C, Ranchere-Vince D, Dei Tos AP, Casali PG, Martin Broto J and **Gronchi A**. Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase II Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups. *Jama Oncol* 2023; 9(5):656-663
484. Bonvalot S, Roland CL, Raut CP, Le Pechoux C, Tzanis D, Frezza AM, **Gronchi A**. Histology-tailored multidisciplinary management of primary retroperitoneal sarcomas. *Eur J Surg Oncol* 2023; 49:1061-1067
485. Danieli M, Swallow CJ, **Gronchi A**. How to treat liposarcomas located in retroperitoneum. *Eur J Surg Oncol* 2023; 49:1068-1080
486. Giani C, Radaelli S, Miceli R, Gandola L, Sangalli C, Frezza AM, Provenzano S, Pasquali S, Bertulli R, Fiore M, Callegaro D, Casanova M, Chiaravalli S, Collini P, Dagrada GP, Morosi C, Zaffaroni N, Casali PG, Ferrari A, **Gronchi A**, Stacchiotti S. Long-term survivors with Desmoplastic Small Round Cell Tumour (DSRCT): results form a retrospective single-institution case series analysis. *Cancer Med* 2023; 12: 10694-10703
487. Drohan A and **Gronchi A**. Next Questions in the Management of Retroperitoneal Sarcoma. *Curr Opin Oncol* 2023; 35(4):301-308.
488. Improtà L, Pasquali S, Iadecola S, Barisella M, Fiore M, Radaelli S, Colombo C, Alloni R, Callegaro D, Valeri S, Miceli R, **Gronchi A**. Organ infiltration and patient risk after multivisceral surgery for primary retroperitoneal liposarcomas. *Ann Surg Oncol* 2023; 30(7):4500-4510
489. Borghi A and **Gronchi A**. Desmoid fibromatosis (extra abdominal), a surgeon's nightmare and the current philosophy in its treatment. *Bone Joint J* 2023; 105-B(7):729-734
490. Corn S, Nessim C, Roland RL, **Gronchi A**, Freeman C and Dumitra S. Data Dissemination of the Role of Neoadjuvant Radiation in Retroperitoneal Sarcoma: A CTOS and CSSO Survey. *Curr Oncol* 2023; 30(6):5807-5815
491. Callegaro D, Raut CP; Ajayi T; Strauss DC; Bonvalot S, Ng D, Stoeckle E, Fairweather M, Rutkowski P, van Houdt WJ, Gelderblom H, Sangalli C, Hayes A; Honoré C; Gladly RA; Fau M; Haas R; Tzanis D; Miah AB; Chung P; Baldini EH; Marreaud S; Litiere S; Swallow CJ; **Gronchi A**. Preoperative radiotherapy in patients with primary retroperitoneal sarcoma: EORTC-62092 trial (STRASS) vs off-trial (STREXIT) results. *Ann Surg* 2023; 278(1):127-13
492. Reijers SJM, Davies E, Grünhagen DJ, Fiore M, Honore C, Rastrelli M, Vassos N, Podleska LE, Niethard M, Jakob J, Perhavec A, Duarte C, González F, Deroose JP, Stas M, Boecxstaens V, Schrage Y, Snow H, Algarra SM, Martinez Said H, Garcia Ortega DY, Martin K, Mattsson J, Djafarzian R, Lorenzo GD, Colombo C, **Gronchi A**, Matter M, Verhoef C, Olofsson Bagge R, Hohenberger P, Hayes AJ, van Houdt WJ.

Variations in response rates to isolated limb perfusion in different soft tissue sarcoma subtypes: an international multicenter study. *Eur J Cancer* 2023; 190:112949

493. Noh S, Nessim C, Nguyen L, Keung EZ, Roland CL, Strauss DC, Sivarajah G, Fiore M, Biondi D, Cioffi S, Mehtsun W, Cananzi FCM, Sicoli F, Quagliuolo V, Chen J, Luo C, Gladly R, Swallow CJ, Johnston W, Ford SJ, Evenden C, Tirotta F, Almond ML, Rutkowski P, Krotewicz M, Pennacchioli E, Cardona K, Gamboa A, Hompes D, Kollár A, Ryser CO, Vassos N, Raut CP, Fairweather M, Adamkova Krakorova M, Quilidian SD, Perhavec A, Nizri E, Farma JM, Greco SH, Vincenzi V, González Lopez JA, Solerdecoll MS, Iwata S, Fukushima S, Kim T, Tolomeo F, Snow H, Howlett-Jansen Y, Tzanis D, Nikulin M, Gronchi A, and Sicklick JK on behalf of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. The Natural History of Retroperitoneal-Abdominal-Pelvic Ganglioneuromas: An International Study by the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Surg* 2023; 278(2):267-273
494. Lambdin J, Ryan C, Gregory S, Cardona K, Hernandez JM, van Houdt WJ, **Gronchi A**. A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2). *Ann Surg Oncol* 2023; 30:4573-4575
495. Zagami P, Comandone A, Fiore M, Baldi GG, Grignani G, Vincenzi B, **Gronchi A**, Antonarelli G, Boglione A, Pennacchioli E, Curigliano G, Conforti F and De Pas TM. The rare entity of Gastrointestinal Leiomyosarcomas: An Italian multicenter retrospective study in high-volume referral centers. *Cancer Med* 2023; 12(16):17047-17055
496. Sicklick JK, Swallow CJ, Raut CP, Callegaro D, Fiore M, Strauss DC, and **Gronchi A**. Creation and Implementation of a Monthly International Tumor Board: Experience of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). *Ann Surg Oncol* 2023; 30:6287-6289.
497. Radaelli S, Baia M, Drohan A, Morosi C, Sangalli C, Colombo C, Callegaro D, Fiore M and **Gronchi A**. Six surgical stages in the resection of primary right retroperitoneal liposarcoma: a standardized comprehensive approach. *Ann Surg Oncol* 2023; 30:6896-6897
498. Pastorino U, Leuzzi G, Sabia F, Girotti P, Duranti L, Radaelli S, Fiore M, Stacchiotti S, Patrizia G, Salvioni R, **Gronchi A**. Long term outcome of complex surgical resection and reconstruction for rare thoracic cancers. *Tumori J* 2023; 109(5):450-457
499. Danieli M, Barretta F, Radaelli S, Fiore M, Sangalli C, Barisella M, Palassini E, Miceli R, Frezza AM, Callegaro D, Collini P, Casali PG, Stacchiotti S and **Gronchi A**. Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall. *Cancer* 2023; 129:3417-3429
500. Amani A, Orton M, Emsley R, Vit S, Morland-Kelly C, Strauss DC, Lunn J, Doran S, Lmalem H, Nzokiranteve A, Litiere S, Stanciu I, Bonvalot S, Haas R, **Gronchi A**, Van Gestel D, Ducassou A, Raut CP, Meeus P, Spalek M, Hatton M, Thway K, Fisher C, Jones RL, Huang P, Messiou C. Radiomics in sarcoma of the retroperitoneum (RADSARC-R): A novel externally validated CT-based radiomics model for the prediction of histological subtype and tumor grade. *Lancet Oncol* 2023; 24:1277-86
501. Zucco V, Pasquali S, Tortoreto M, Percio S, Doldi V, Barisella M, Collini P, Dagrada GP, Brich S, Gasparini P, Fiore M, Casanova M, Frezza AM, **Gronchi A**, Stacchiotti S, Ferrari A and Zaffaroni N. Effectiveness of irinotecan plus trabectedin in a patient-derived xenograft of desmoplastic small round cell tumor. *Dis Model Mech* 2023; 16(6):dmm049649
502. D'Ambrosio L, Fumagalli E, De Pas TM, Nannini M, Bertuzzi A, Carpano S, Boglione A, Buonadonna A, Comandini D, Gasperoni S, Vincenzi B, Brunello A, Badalamenti G, Maccaroni E, Baldi GG, Merlini A, Mogavero A, Ligorio F, Pennacchioli E, Conforti F, Manessi G, Aliberti S, Tolomeo F, Fiore M, Sbaraglia M, Dei Tos AP, Stacchiotti S, Pantaleo MA, **Gronchi A**, Grignani G. Guideline-based Follow-up Outcomes in Patients Affected by Gastrointestinal Stromal Tumor with Low Risk of Recurrence: A Report from the Italian Sarcoma Group. *Jama Netw Open* 2023; 6(11):e2341522
503. Stacchiotti S, Baldi GG, Frezza AM, Morosi C, Greco FG, Collini P, Barisella M, Dagrada GP, Zaffaroni N, Pasquali S, **Gronchi A**, Huang P, Ingrosso M, Tinè G, Miceli R, Casali PG. Regorafenib in advanced Solitary Fibrous Tumor: results from an exploratory phase II clinical study. *Eur J Cancer* 2023; 195:113391
504. **Gronchi A**, Palmerini E, Quagliuolo V, Martin Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Tendero O, Diaz Beveridge R, Ferraresi V, Lugowska I, Pizzamiglio S, Verderio P, Fontana V, Donati DM, Palassini E, Sanfilippo R, Bianchi G, Bertuzzi A, Morosi C, Pasquali S, Stacchiotti S, Bague S, Coindre JM, Miceli R, Dei Tos AP, Casali PG. Neoadjuvant chemotherapy in high-grade myxoid liposarcoma: results of the expanded cohort of a randomized trial from Italian (ISG), Spanish (GEIS), French (FSG) and Polish Sarcoma Groups (PSG). *J Clin Oncol* 2024; 42:898-906
505. Borghi A and **Gronchi A**. Extremity and truncal soft tissue sarcoma: risk assessment and multidisciplinary management. *Semin Radiat Oncol* 2024; 34:147-163
506. Callegaro D, Barretta F, Raut CP, Johnston W, Strauss DC, Honoré C, Bonvalot S, Fairweather M, Rutkowski P, van Houdt WJ, Gladly RA, Tirotta F, Tzanis D, Skoczylas J, Haas RL, Miceli R, Swallow CJ, **Gronchi A**. New Sarculator prognostic nomograms for patients with primary retroperitoneal sarcoma: case volume does matter. *Ann Surg* 2024; 279:857-865
507. Palassini E, Baldi GG, Sulfaro S, Barisella M, Bianchi G, Campanacci D, Fiore M, Gambarotti M, Gennaro M, Morosi C, Navarra F, Palmerini E, Sangalli C, Sbaraglia M, Trama A, Asafei S, Badalamenti G, Bertulli R, Bertuzzi A, Biagini R, Buonadonna A, Brunello A, Callegaro D, Cananzi F, Cianchetti M, Collini P, Comandini D, Curcio A, D'Ambrosio L, De Pas M, Dei Tos AP, Ferraresi V, Ferrari A, Franchi A, Frezza AM, Fumagalli E, Ghilli M, Greto D, Grignani G, Guida M, Krengli M, Luksch R, Marrari A, Mastore M, Merlini A, Milano G, Navarra P, Pantaleo MA, Parafioriti A, Pellegrini I, Pennacchioli E, Rastrelli M, Setola E, Tafuto S, Turano S, Valeri S, Vincenzi B, Vitolo V, Ivanescu A,

Paloschi F, Casali PG, **Gronchi A**, Stacchiotti S. Clinical recommendations for treatment of localized angiosarcoma: a consensus paper by the Italian Sarcoma Group. *Cancer Treat Rev* 2024; 126:102722.

508. Palassini E, Baldi GG, Ciniselli CM, Gennaro M, **Gronchi A**, Sangalli C, Conforti F, Collini P, Frezza AM, Pellegrini I, Allajbej A, Fiore M, Morosi C, Pennacchioli E, Barisella M, Casali PG, Verderio P, De Pas T, Stacchiotti S. Outcome improvement with chemotherapy and radiotherapy in primary, localized, radiation-associated angiosarcoma of the breast region: a retrospective case series analysis. *ESMO Open* 2024; 9(6):103474
509. Borghi A and **Gronchi A**. Sarculator: how to improve further prognostication of all sarcomas. *Curr Opin Oncol* 2024; 36(4):253-262
510. Khan M, Baia M, Fiore M, Colombo C, Callegaro D, Pasquali S, **Gronchi A** and Radaelli S. Initial local resection versus early referral for spermatic cord sarcoma: any impact on treatment timelines and oncological outcomes? *Eur J Surg Oncol* 2024; 50(6):108269.
511. Sorrentino L, Colletti G, Belli F, **Gronchi A**. Extraperitoneal lateral pelvic sidewall excision: a novel rectal-sparing approach for lateral locally recurrent rectal cancer. *Updates Surg* 2024; 76(3):1109-1113
512. Pasquali S, Vallacchi V, Lalli L, Collini P, Barisella M, Romagosa C, Bague S, Coindre JM, Dei Tos AP, Palmerini E, Quagliuolo V, Martin-Broto J, Lopez-Pousa A, Grignani G, Blay JY, Diaz Beveridge R, Casiraghi E, Brich S, Renne SL, Bergamaschi L, Vergani B, Sbaraglia M, Casali PG, Rivoltini L, Stacchiotti S, **Gronchi A**. Spatial Distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy. *Ebiomedicine* 2024; 106:105220
513. Madhumeeta C, Iadecola S, Jenks A, Pankova V, Tam YB, Burns J, Amani A, Wilding C, Cheng L, Chudasama P, Callegaro D, Strauss DC, Thway K, **Gronchi A**, Robin JL, Miceli R, Pasquali S, Huang PH. Proteomic profiling improves prognostic risk stratification of the Sarculator nomogram in soft tissue sarcomas of the extremities and trunk wall. *Cancer Med* 2024; 13(14):e70026
514. Fiore M, Sarre-Lazcano C, Smith M, Khan M, Raut CP, Honore C, Sargos P, Cananzi F, Grignani G, Iwata S, **Gronchi A** on behalf of the Transatlantic Australasian RetroPeritoneal Sarcoma Working Group. Primary Pelvic Soft Tissue Sarcoma (PELVISARC): outcome in a series of 401 patients from the Transatlantic Australasian RetroPeritoneal Sarcoma Working Group. *Br J Surg* 2024; 111(5):znae128
515. Kasper B, Baldini E, Bonvalot S, Callegaro D, Cardona K, Colombo C, Corradini N, Crago A, Dei Tos AP, Dileo P, Elnekave E, Erinjeri JP, Fariba N, Farma J, Ferrari A, Fiore M, Gladly R, Gounder M, Haas R, Husson O, Kurtz JE, Lazar A, Orbach D, Penel N, Ratan R, Raut CP, Roland CL, Schut AR, Sparber-Sauer M, Strauss DC, Van der Graaf W, Vitellaro M, Weiss A and **Gronchi A** on behalf of the Desmoid Tumor Working Group. Current Management of Desmoid Tumors: an update from the desmoid tumor working group. *Jama Oncol* 2024; 10(8):1121-1128
516. Chowdhury A, Thway K, Pasquali S, Callegaro D, **Gronchi A**, Jones RL, Huang PH. Opportunities and challenges in soft tissue sarcoma risk stratification in the era of personalised medicine. *Curr Treat Options Oncol* 2024; 25:1124-1135
517. Radaelli S, Merlini A, Khan M and **Gronchi A**. Progress in histology specific treatments in soft tissue sarcoma. *Exp Rev Anticancer Ther* 2024; 24(9):845-868
518. Giani C, Denu RA, Ljevar S, **Gronchi A**, Napolitano A, Rosenbaum E, Salawu A, Bajpai J, Connolly EA, Lee ATJ, Trent J, Kosela-Paterczyk H, Zola Li CC, Ogura K, Palmerini E, Baldi GG, Brunello A, Campos F, Cicala CM, Maki RG, Wagner AJ, Andelkovic V, Loong HH, Wong DD, Jones RL, Tap W, Lazar AJ, Demicco EG, Hong A, Bovee JVMG, Dei Tos AP, Fletcher C, Baumhoer D, Sbaraglia M, Schaefer IM, Miceli R, Stacchiotti S. Low-grade Fibromyxoid Sarcoma and Sclerosing Epithelioid Fibrosarcoma: outcome of advanced disease and systemic therapies from an international retrospective study of ultra-rare sarcoma working group. *ESMO Open* 2024; 9(9):103689
519. Acem I, Steyerberg EW, Spreafico M, Grünhagen DJ, Callegaro D, Spinner RJ, Pendleton C, Coert JH, Miceli R, Abruzzese G, Flucke UE, Slooff WBM, van Dalen T, Been LB, Bonenkamp HJ, Anten MHME, Broen MPG, Bemelmans MHA, Bramer JAM, Schaap GR, Kievit AJ, van der Hage J, van Houdt W, van de Sande MAJ, **Gronchi A**, Verhoef C, Martin E. Survival after Resection of Malignant Peripheral Nerve Sheath Tumors: introducing and validating a novel type-specific prognostic model. *Neurooncol Adv* 2024; 6(1):vdae083
520. Gervais MK, Basile G, Dulude JP, Mottard S, **Gronchi A**. Histology tailored approach to soft tissue sarcoma. *Ann Surg Oncol* 2024; 31(12):7915-7929
521. Angelucci A, Baia M, Garo M, Alloni R, Callegaro D, Pagnoni C, Radaelli S, Colombo C, **Gronchi A**, Valeri S and Fiore M. Surgical Outcome in retroperitoneal sarcoma surgery: accuracy of P-Poosum, ACS-NSQIP and inflammatory biomarkers prognostic index (IBPI) risk-calculators for prediction of severe and overall morbidity. *Ann Surg Oncol* 2024; 31:7957-7966
522. Pantano F, Simonetti S, Iuliani M, Guillen MJ, Cuevas C, Aviles P, Cavaliere S, Napolitano A, Cortellini A, Mazzocca A, Nibid L, Sabarese G, Perrone G, Gambarotti M, Righi A, Palmerini E, Stacchiotti S, Barisella M, **Gronchi A**, Valeri S, Sbaraglia M, Dei Tos AP, Tonini G and Vincenzi B. S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models. *Oncogene* 2024; 43(40):2986-2994
523. Gatto A, Cavalli EM, Stucchi S, Giacomini G, Belingheri M, Radaelli S, **Gronchi A**, Marchesi A. One-Stage Surgical Resection and Functional Reconstruction for Upper Limb Soft Tissue Sarcoma. *Ann Plast Surg*. 2024; 93(5):575-588.
524. Stacchiotti S, Martini S, Pasquali S, Frezza AM, Beretta A, Percio S, Lecchi M, Tortoreto M, Barisella M, Collini P, Dagrada GP, Merlini A, Huang PH, Jenks A, Jones RL, Tap WD, Ingrosso M, Morosi C, Brich S, Giani C, Verderio P, Casali PG, Leonard H, **Gronchi A**, Zuco V, Zaffaroni N. GDF-15 predicts aggressiveness and is down-regulated by sirolimus through ATF4/ATF5 suppression in epithelioid hemangioendothelioma. *Clin Cancer Res* 2024; 30(22):5122-5137

525. Bergamaschi L, Zorza M, Rini F, Perrone F, Rivoltini L, **Gronchi A**, Pasquali S, Zaffaroni N, Vallacchi V and Colombo C. Circulating tumor DNA in Desmoid Fibromatosis during active surveillance. *Ann Surg Oncol* 2024; 31(13):9265-9271
526. Mowery YM, Ballman KV, Hong AM, Schuetze SM, Wagner AJ, Monga V, Heise RS, Attia S, Choy E, Burgess MA, Bae S, Pryor DI, Van Tine BA, Tinoco G, Chmielowski B, Freeman C, **Gronchi A**, Meyer CF, Dickson MA, Hartner L, Davis LE, Powers BC, Moding EJ, Weinhold KJ, Matt van de Rijn M, Brigman BE, Riedel RF, Kirsch DG. Pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity: a randomised, open-label clinical trial. *Lancet* 2024; 404(10467):2053-2064
527. Sigalotti L, Frezza AM, Sbaraglia M, Del Savio E, Baldazzi D, Valenti B, Bellan E, De Benedictis I, Doni M, Gambarotti M, Vincenzi B, Brunello A, Baldi GG, Palmerini E, Pasquali S, Ciuffetti ME, Varano V, Cappello F, Appolloni V, Pastrello C, Jurisica I, **Gronchi A**, Stacchiotti S, Casali PG, Dei Tos AP & Maestro R. Proximal and classic epithelioid sarcomas are distinct molecular entities defined by MYC/GATA3 and SOX17/endothelial markers, respectively. *Modern Pathol* 2024; 38(1):100647
528. Pasquali S, Iadecola S, Vanzulli A, Infante G, Bologna M, Corino V, Greco G, Vigorito R, Morosi C, Beretta A, Percio S, Vallacchi V, Collini P, Sanfilippo R, Fabbri C, Stacchiotti S, Fiore M, Huang P, Benelli M, Mainardi L, Miceli R, **Gronchi A**, Callegaro D. Radiomic features of primary retroperitoneal sarcomas: a prognostic study. *Eur J Cancer* 2024; 213:115120
529. Rausa E, Duroni V, Ferrari D, Signoroni S, Ciniselli CM, Lauricella S, Brignola C, Ricci MT, **Gronchi A**, Verderio P, Vitellaro M. Risk factors and protective measures for desmoid tumours in familial adenomatous polyposis: retrospective cohort study. *BJS Open* 2024; 9(1):zrae148
530. Neemann F, Jansen L, Hermann S, Silcher C, Hettler M, Hohenberger P, Callegaro D, **Gronchi A**, Fiore M, Miceli R, Van Coevorden F, Van Houdt W, Bonvalot S, Rutkowski P, Skoczylas J, Swallow CJ, Gladdy R, Strauss DC, Hayes A, Fairweather M, Raut CP, Jakob J. Comparing epidemiological and clinical data from RPS patients documented in a German cancer registry to a cohort from TARPSWG reference centres. *J Cancer Res Clin Oncol* 2024; 150(12):514
531. Baia M*, Zanframundo C*, Ljevar S, Della Valle S, Misotti A, Rampello NN, Proto P, Callegaro D, Colombo C, Radaelli S, Sanfilippo R, Sangalli C, Morosi C, Pasquali S, Miceli R, **Gronchi A**, Fiore M. Preoperative nutritional support to tackle morbidity in multivisceral resection for retroperitoneal sarcoma. Early outcomes from a novel prehabilitation program in a prospective cohort. *Eur J Surg Oncol* 2024; 50(12):108663
532. Gennaro M, Mariani L, Palassini E, Stacchiotti S, Sangalli C, Listortia C, Vingianie A, Cortinovis U, Collini P, Allajbej A, Fiore M, Casali PG, Folli S, **Gronchi A**. Timeline of surgery in localized angiosarcoma of the breast: Improving outcome following multidisciplinary treatment optimization. *Eur J Surg Oncol* 2024; 50:108699
533. Fuchs B and **Gronchi A**. Establishing the Sarcoma HASM Network- A Hub and Spoke Model Network for Global Integrated and Precision Care. *ESMO Open* 2024; 9(12):103734
534. Tseng WW, Barretta F, Fiore M, Colombo C, Radaelli S, Baia M, Morosi C, Collini P, Sanfilippo R, Fabbri C, Stacchiotti S, Roberts RF, Callegaro D and **Gronchi A**. Extent of Macroscopic Vascular Invasion Predicts Distant Metastasis in Primary Leiomyosarcoma of the Inferior Vena Cava. *J Surg Oncol* 2024; 130(8):1691-1699
535. Giani C, Salawu A, Ljevar S, Denu RA, Napolitano A, Palmerini E, Connolly EA, Ogura K, Wong DD, Scanferla R, Rosenbaum E, Bajpai J, Chia-Chen Li Z, Bae S, D'Ambrosio L, Bialick S, Wagner AJ, Lee ATJ, Kosela-Paterczyk H, Baldi GG, Brunello A, Lee YC, Loong HH, Boikos S, Campos F, Cicala CM, Maki RG, Hindi N, Figura C, Almohsen SS, Patel S, Jones RL, Ibrahim T, Karim R, Kawai A, Carey-Smith R, Boyle R, Taverna SM, Lazar AJ, Demicco EG, Bovee JMVG, Dei Tos AP, Fletcher C, Baumhoer D, Sbaraglia M, Schaefer IM, Miceli R, **Gronchi A**, Stacchiotti S. International multicenter retrospective study from the Ultrarare Sarcoma Working Group on Low-Grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma and Hybrid Forms: outcome of primary localized disease. *Am J Surg Pathol* 2025; 49:27–34
536. Colombo C, Hakkesteegt S, Le Cesne A, Barretta F, Blay JY, Grunhagen DJ, Penel N, Lam L, Fiore M, Palassini E, Grignani G, Tolomeo F, Collini P, Merlini A, Perrone F, Stacchiotti S, Verhoef C, Bonvalot S, **Gronchi A** on behalf of the Italian and French Sarcoma Group and Dutch Grafiti Group. Active surveillance in patients with extra-abdominal desmoid-type fibromatosis: a pooled analysis of three prospective observational studies. *Clin Cancer Res* 2025; 31(3):603–610
537. Van Houdt WJ and **Gronchi A**. Sarcoma: last years practice changing papers. *Ann Surg Oncol* 2025; 32(3):1497-1503
538. Józwiak-Hagymásya J, Széles A, Dócia T, Németha B, Mezeia D, Vargaa H, **Gronchi A**, van Houdt WJ, Tordaid A, Csanádia M. Economic evaluations and health economic models of soft tissue sarcomas: Systematic literature review from a European and North American perspective. *Crit Rev Oncol Hematol* 2025; 209:104661
539. Vanzulli A, Vigorito R, Buonomenna C, Palmerini E, Quagliuolo V, Martín Broto J, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Diaz Beveridge R, Ferraresi V, Lugowska I, Pizzamiglio S, Verderio P, Duroni V, Fontana V, Donati DM, Palassini E, Bianchi G, Bertuzzi A, Buonadonna A, Pasquali S, Dei Tos AP, Casali PG, Morosi C, Stacchiotti S, **Gronchi A**. Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy. Final results of ISG-STs 1001, a randomized clinical trial. *ESMO Open* 2025; 10(3):104299.
540. Baia M, Drohan A, Radaelli S, Callegaro D, Colombo C, Pasquali S, Sanfilippo R, Sangalli C, Morosi C, Fiore M, **Gronchi A**. Surgery for Primary Right Retroperitoneal Leiomyosarcoma of the inferior vena cava: use of cadaveric aortic homograft for IVC reconstruction. *Ann Surg Oncol* 2025; 32(4):2979-2980
541. Fairweather M, Jolissaint JS, Fiore M, Strauss DC, Bonvalot S, Ford SJ, van Houdt W, Swallow CJ, Rutkowski P, **Gronchi A**, Raut CP. Development of a surgical complexity score to predict post-operative morbidity following primary retroperitoneal sarcoma resection: a

collaborative study from the Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG). Br J Surgery 2025; 112(3):znaf029

542. Tirota F, Fiore M, Bonvalot S, Strauss DC, Rutkowski P, Gyorki DE, van Houdt WJ, Callegaro D, Albertsmeier M, Tzanis D, Cananzi F, Sicklick JK, Mullinax J, Wilkinson M, Grignol VP, Cardona K, Bouhadiba T, Novak M, Valeri S, Fairweather M, Ford SJ, Skoczylas J, Snow H, Hayes AJ, Hodson J, Raut CP, **Gronchi A** on behalf of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Defining Benchmark Values for Outcomes of Comprehensive Resection of Primary Retroperitoneal Liposarcoma. EClinicalMedicine 2025;84: 103280
543. Tseng WW, Barretta F, Tucci F, Barisella M, Radaelli S, Colombo C, Callegaro D, Morosi C, Sanfilippo R, Fabbioni C, Stacchiotti S, Sun S, Collini P, Fiore M and Gronchi A. Pleomorphic Liposarcoma of the Extremity and Trunk: Multimodality Therapy For Some But Not All? J Surg Oncol 2025; 131(2):291-297
544. Kruiswijk AA, Vlug LAE, Acem I, Engelhardt EG, **Gronchi A**, Callegaro D, Haas RL, van de Wal RJP, van de Sande MAJ, van Bodegom-Vos L. Risk-prediction models for clinical decision making in sarcoma care: an international survey among soft-tissue sarcoma clinicians. Ann Surg Oncol 2025; 32(4):2958-2970
545. Improta L, Bouhadiba TM, Germanotta M, **Gronchi A**, Tzanis D, Baia M, Pagnoni C, Fiore M, Valeri S. Celiac ganglion resection as an intraoperative factor associated with delayed gastric emptying in retroperitoneal sarcoma surgery: A multicentric prospective cohort study. Eur J Surg Oncol 2025; 51(7):109978
546. Van der Burg SJC, Fiore M, Rutkowski P, Albertsmeier M, Bonvalot S, Grignol VP, Raut CP, Cananzi FCM, Mullinax JE, Gyorki DE, Pennacchioli E, Ford SJ, Nessim C, Cardona K, Callegaro D, Skoczylas J, Lindner LH, **Gronchi A**, Van Houdt WJ, TransAtlantic Australasian Retroperitoneal Sarcoma Working Group. Radiologic and pathologic response evaluation after neoadjuvant chemotherapy for primary retroperitoneal sarcoma: a Transatlantic Australasian Retroperitoneal Sarcoma Working Group (TARPSWG) collaboration. Ann Surg Oncol 2025; 32(7):5359-5366
547. Baldini EH and **Gronchi A**. Local Control in Soft Tissue Sarcoma. Hematol Oncol Clin North Am 2025; 39(4):693-708
548. Benuzzi L, Baia M, Cantù P, Rosa R, Wood M, Baccalini E, Fiore M, Colombo C, Radaelli S, **Gronchi A**, Callegaro D. Laparoscopic Pancreas-Preserving Duodenal Resection for Duodenal GIST. Ann Surg Oncol 2025; 32(7):5358
549. Fiore M, Ljevar S, Raut CP, Personeni G, Rabih M, Gladly R, Mercier K, Sulciner M, Rossi E, Tzanis D, Suraweera H, Colombo C, Coppola M, Bonvalot S, Iadecola S, Sarre-Lazcano C, Figura C, Salvatore D, Miceli R, **Gronchi A**. Impact and safety of pregnancy on desmoid fibromatosis management in the era of active surveillance. An international multicenter retrospective observational study. Eur J Cancer 2025; 222:115474
550. Callegaro D, Tinè G, Oppong FB, Nzokirantevye A, Litiere S, Percio S, Carenzo A, De Cecco L, Chibon F, Brich S, Bertolotti A, Collini P, Frezza AM, Huang P, Haas RL, Bonvalot S, van Houdt WJ, Miceli R, Pasquali S, **Gronchi A**. CINSARC and Sarculator in patients with primary retroperitoneal sarcoma: a combined analysis of single institution data and EORTC – STBSG 62092 trial (STRASS). Clin Cancer Res in press
551. Snow H, Fiore M, Xie J, Strauss DC, Tzanis D, Raut CP, Rutkowski P, Ford S, Wallow CJ, van Houdt W, Albertsmeier M, Cananzi F, Sicklick J, Cardona K, Grignol V, Nessim C, Nizri E, Novak M, Pennacchioli E, Valeri S, Callegaro D, Wilkinson M, Bonvalot S, Fairweather M, Skoczylas J, Tirota F, Shapiro J, Angele MK, **Gronchi A**, Gyorki DE on behalf of the Transatlantic Australasian Retroperitoneal Sarcoma Working Group. Global variations in patterns of care for retroperitoneal sarcoma. Ann Surg in press
552. Baia M, Dossa F, Radaelli S, Callegaro D, Colombo C, Pasquali S, Morosi C, Sangalli C, Sanfilippo R, Fiore M, **Gronchi A**. Six Surgical Stages in the Resection of Primary Left Retroperitoneal Liposarcoma: A Standardized Comprehensive Approach. Ann Surg Oncol in press
553. Kobbeltvedt MR, Lobmaier I, Spreafico M, Callegaro D, Miceli R, Kizilaslan F, Swanson D, Hompland I, Pasquali S, Fiocco M, van de Sande MAJ, **Gronchi A**, Boye K. A comparison of the risk prediction models PERSARC and Sarculator in patients with localized soft tissue sarcoma of the extremities and trunk wall. ESMO Open in press
554. Bogani G, Caruso G, Ray-Coquard I, Ramirez PT, Concin N, Ngoi NYL, Coleman RL, Mariani A, Cliby W, Leitao MM, Rustum NA, Casali PG, **Gronchi A**, Vergote I, Kroep J, Enomoto T, Takehara K, Denys H, Takano M, Provencher D, Wimberger P, Kim SI, Kim JW, Zannoni GF, Tan DSP, Casarin J, Paolini B, Chiappa V, Raspagliesi F, Cuccu I, Di Donato V, O'Malley DM, Mutch D, Brown J, Herrera F, Colombo N, Pignata S, Scambia G, Slomovitz BM and Monk BJ. Uterine Leiomyosarcoma. Int J Gynecol Cancer in press

Elenco delle **pubblicazioni non censite da Medline, in inglese**

1. **Gronchi A**, Casali PG, Olmi P. Sacro-coccygeal chordoma: diagnosis and treatment review. Sem Col Rectal Surg, 2004; 15(1): 26-32.
2. **Gronchi A**, Casali PG The impact of systemic treatment on patient survival of soft tissue sarcoma. Eur Oncol in press
3. Thomas DM, **Gronchi A**, O'Sullivan B. A multidisciplinary approach to retroperitoneal sarcoma. Am Soc Clin Oncol Ed Book 1701-1708, 2009
4. Pennacchioli E, Colombo C, Berselli M and **Gronchi A**. Update on management of GIST and postsurgical use of imatinib. Open Access Surgery 2010; 3: 63-71.
5. Radaelli S, Desai A, Colombo C, Fiore M and **Gronchi A**. Perioperative therapies for localized retroperitoneal soft tissue sarcoma. Oncology and Hematology Review 2012; 8(1): 65-70

Allegato 3

Elenco dei **Capitoli di libri, in inglese**

- **Gronchi A** and Fiore M. Chordoma. In Khatri VP ed: Clinical Scenarios in Surgical Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006: 299-302.
- Santinami M, **Gronchi A**, Maurichi M, Zoras O, Patuzzo R, Pennacchioli E. Limb's perfusion: rationale, techniques and results. In Zoras O ed: Regional Oncotherapies. Athens: Paschalidis Medical Publications Ltd; 2006:193-226.
- **Gronchi A**, Colombo C and Fiore M. Surgery of Primary Tumor. In Blay JY ed: 100 Key Questions on Soft Tissue Sarcoma. Mallorca: Permanyer Publications; 2010: 55-67.
- **Gronchi A**, Fiore M, Palaia R. Surgical Treatment. In de Lutio di Castelguidone E and Messina A eds: GISTs - Gastrointestinal Stromal Tumors. Milan: Springer Verlag Italia; 2011: 107-112.
- Fletcher CDM, Singer S, **Gronchi A**. Tumor of Soft Tissue: Introduction. In Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F eds: WHO Classification of Tumours of Soft Tissue and Bone. Lyon; IARC; 2013: 14-16
- **Gronchi A**. Surgical Management of Soft Tissue Sarcomas. In Blay JY ed. Atlas of data and images on STS. Madrid; Grupo Editorial Entheos. 2013: 177-231
- Raut CP and **Gronchi A**. The management of Soft Tissue Sarcoma. In Cameron JL and Cameron AM eds: Current Surgical Therapy. Philadelphia: Elsevier Saunders; 2014: 706-717
- Comier JN, **Gronchi A** and Pollock RE. Soft Tissue Sarcoma. In Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB, Pollock RE eds: Schwartz's Principles of Surgery. New York: McGraw-Hill Professional; 2014: 1465-1493
- Casali PG, Dei Tos AP and **Gronchi A**. Gastrointestinal Stromal Tumor. In DeVita, Hellman, and Rosenberg eds: Cancer. Principles & Practice of Oncology. Philadelphia Wolters Kluwer Health; 2015: 745-756
- **Gronchi A**, Dei Tos AP, Casali PG. Sarcomas of Soft Tissue and Bone. In Kerr DJ, Haller DG, van de Velde CJH, Baumann M eds: Oxford Textbook of Oncology. Oxford: Oxford University Press; 2016: 844-866
- Fontana A, Callegaro D and **Gronchi A**. Standard of care in early phases. In Blay JY ed: 100 Key Questions on Soft Tissue Sarcoma. Mallorca: Permanyer Publications; 2016: 17-28
- Sandrucci S, Stacchiotti S and **Gronchi A**. Retroperitoneal Sarcoma. In Poston G, Wyld L, Audisio RA eds: Surgical Oncology. Theory and Multidisciplinary Practice. Boca Raton: CRC Press Taylor & Francis Group; 2017: 617-629
- Fiore M, Radaelli S and **Gronchi A**. Retroperitoneal Sarcoma involving the Inferior Vena Cava. In Azoulay D, Lim C, Salloum eds: Surgery of the Inferior Vena Cava: multidisciplinary approach. Cham: Springer International Publishing Switzerland; 2017: 61-74
- Radaelli S, Colombo C, Fiore M and **Gronchi A**. Soft Tissue Tumors of the Groin and Inguinal region. In Delman KA and Master VA eds: Malignancies of the Groin. Springer International Publishing Switzerland; 2017: 123-157
- Quagliuolo V and **Gronchi A**. Eds. Current treatment of Retroperitoneal Sarcoma: a joint effort with the Italian Society of Surgical Oncology. Springer-Verlag Italia; 2018
- Casali PG, Dei Tos AP and **Gronchi A**. Gastrointestinal Stromal Tumor. In DeVita, Hellman, and Rosenberg eds: Cancer. Principles & Practice of Oncology. Philadelphia Wolters Kluwer Health; 2019: 895-906
- Gonzalez RJ, **Gronchi A** and Pollock RE. Soft Tissue Sarcoma. In Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Kao LS, Matthews JB, Pollock RE eds: Schwartz's Principles of Surgery. New York: McGraw-Hill Professional; 2019: 1567-1598
- **Gronchi A**. Principles of Local Therapy of Soft Tissue Neoplasms. In Dei Tos AP ed: Soft Tissue Sarcomas: A Pattern-Based Approach to Diagnosis. Cambridge: Cambridge University Press United Kingdom; 2019: 55-65
- **Gronchi A** and Raut CP. Management of Soft Tissue Sarcoma. In Cameron JL and Cameron AM eds: Current Surgical Therapy. Philadelphia: Elsevier Saunders; 2020: 825-839
- Fletcher CDM, Baldini EH, Blay JY, **Gronchi A**, Lazar AJ, Messiou C, Pollock RE, Singer S. Soft Tissue Tumors: Introduction. In Antonescu CR, Bridge JA, Cunha IW, Dei Tos AP, Fletcher CDM, Folpe AL, Goldblum JR, Hornick JL, Miettinen M, Oda Y eds: WHO Classification of Tumours of Soft Tissue. Lyon; IARC; 2020: 6-12
- Tseng WW, Dei Tos AP, Sanfilippo RG, Wang J and **Gronchi A**. Dedifferentiated Liposarcoma. In Trent JC, Rosenberg AE, Pollock RE and Delaney TF eds: Sarcomas: Evidence-based diagnosis and management. New York: Springer Publishing Company; 2020: 125-136
- Stacchiotti S, Baldi GG, Morosi C, Dei Tos AP and **Gronchi A**. Extraskelatal Myxoid Chondrosarcoma. In Trent JC, Rosenberg AE, Pollock RE and Delaney TF eds: Sarcomas: Evidence-based diagnosis and management. New York: Springer Publishing Company; 2020:289-298
- Sanfilippo RG, Fabbri C, Dei Tos AP and **Gronchi A**. Myxoid Liposarcoma. In Trent JC, Rosenberg AE, Pollock RE and Delaney TF eds: Sarcomas: Evidence-based diagnosis and management. New York: Springer Publishing Company; 2020:329-336
- Spolverato G and **Gronchi A**. Desmoid Tumors. In Leon SP, Nathanson P, Zager JS eds: Cancer Metastasis Through the Lymphovascular System. Cham: Springer Nature; 2022: 619-627.
- Casali PG, Dei Tos AP and **Gronchi A**. Gastrointestinal Stromal Tumor. In DeVita, Hellman, and Rosenberg eds: Cancer. Principles & Practice of Oncology. Philadelphia Wolters Kluwer Health; 2023: 604-617
- Danieli M and **Gronchi A**. Surgical Strategy in Primary, Relapse, and "Whoops" Cases. In Harzem Özger, Franklin H. Sim, Ajay Puri, Levent Eralp eds: Diagnosis and Treatment of Soft Tissue Tumors. Changes, Challenges and Strategies. Cham: Springer Nature; 2025: 175-186

- **Allegato 4**

Elenco dei **Libri, in italiano (o altre lingue nazionali)**

- Azzarelli A, **Gronchi A**, De Pas T, Marsiglia HR. Strategia terapeutica integrata in Sarcomi delle parti molli. In Veronesi U ed. Oncologia Chirurgica. Milano: Masson; 1999: 869-875.
- Casali PG, **Gronchi A**, Olmi P, Rosai J. Basi scientifiche per la definizione di linee guida in ambito clinico per i sarcomi dei tessuti molli dell'adulto. In Silvestrini R ed. Progetto Strategico Oncologia. Milano: CNR-MIUR; 2002.
- Casali PG, **Gronchi A**, Olmi P e Azzarelli A. Sarcomi delle parti molli dell'adulto. In Bonadonna G, Robustelli della Cuna G, Valagussa P, eds Medicina Oncologica. Milano: Masson; 2003: 1261-1274.
- Mussi C and **Gronchi A**. Tumori primitivi della parete addominale. In Croce, Olmi eds Chirurgia della parete addominale. Milano: Masson; 2006: 299-305.
- Mussi C and **Gronchi A**. Tumore desmoide. In Croce, Olmi eds Chirurgia della parete addominale. Milano: Masson; 2006: 307-310.
- **Gronchi A**, Colombo C and Fiore M. Il ruolo della chirurgia. In A. Comandone e S. Barni eds. I sarcomi dei Tessuti Molli. Roma: Il Pensiero Scientifico Editore; 2011: 103-123.
- Casali PG, Comandone A, Ferrari S, **Gronchi A**, Dei Tos AP. Sarcomi. In Cascinu S, Labianca R eds. La medicina Oncologica. Diagnosi, terapia e gestione clinica. Roma: Edra; 2013:
- Hindi Muniz N and **Gronchi A**. Tratamiento quirurgico (principios generales en extremidades y pared del tronco). In Martin-Broto J, Cruz J, Valverde C Y Cubedo R eds. Tratado de Sarcomas de Partes Blandas. Madrid: Nature Publishing Group Iberoamerica; 2015: 83-96
- Spolverato G, Capelli G, Pennacchioli E, Coppola S, **Gronchi A**. Sarcomi, melanoma e carcinoma a cellule di Merkel. In Dionigi Renzo et al. Eds. Dionigi Chirurgia. Milano Edra; 2022; 419-436

Annex 5

Elenco dei Trial Clinici condotti

- Localized High-Risk Soft Tissue Sarcomas of the Extremities and Superficial Trunk in Adults: an Integrated Approach Comprising 3 or 5 Cycles of Adjuvant Chemotherapy. A prospective controlled randomized trial from Italians Sarcoma Group and Spanish Sarcoma Group. **Principal Investigator.** Study accrual closed in 2007 (328 patients recruited). Reported at ASCO as oral presentation in 2010. Published in J Clin Oncol in 2012 and Ann Oncol in 2016
- A Multicenter Phase II Clinical Trial of Neoadjuvant Trabectedin (YONDELIS®) in Patients with Localized Myxoid / Round Cell Liposarcoma. **Principal Investigator.** Study accrual closed in 2009 (30 patients recruited); reported at ESMO as oral presentation in 2009 and at ASCO as poster discussion in 2009. Published in Ann Oncol in 2012.
- Preoperative Chemo-Radiation Therapy in Retroperitoneal Soft Tissue Sarcomas (+ Radiation Boost). A multicentric phase II study from Italian Sarcoma Group. **Principal Investigator.** Study accrual closed in 2010 (86 patients recruited). Preliminary results reported at ASCO as poster discussion and at CTOS as oral presentation in 2011. Final results reported at ASCO in 2013 as poster discussion. Published in Eur J Cancer in 2014 and Ann Surg Oncol in 2017
- A Phase III Randomized Study Evaluating Surgery of Residual Disease in Patients with Metastatic Gastro-Intestinal Stromal Tumor Responding to Imatinib Mesylate. A EORTC study (62063). **Principal Investigator.** Closed in advance for poor accrual in 2011 (12 patients recruited)
- Localized High-Risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults: an Integrating Approach Comprising Standard vs Histotype-Tailored Neoadjuvant Chemotherapy. **Principal Investigator.** Accrual started in 2011. Interim Analysis published in Lancet Oncol 2017; Final analysis presented as oral presentation at ASCO 2019 and published in J Clin Oncol in 2020.
- A phase III randomized study of preoperative radiotherapy plus surgery versus surgery alone for patients with retroperitoneal sarcoma. A EORTC study (62092-22092). **Coinvestigator.** Accrual started in 2012. Final analysis presented at ASCO in 2019 and published in Lancet Oncol in 2020
- Tailored Beta-catenin mutational approach in extra-abdominal sporadic desmoids tumor patients: an observational study. **Principal Investigator.** Accrual started in 2013. Presented at CTOS in 2018 and published in Clin Cancer Res in 2022.
- Phase I-II prospective trial, multicenter, open label, exploring the combination of Trabectedin plus **RA**diotherapy in **Soft Tissue Sarcoma** patients (TRASTS). **Principal Investigator.** Accrual started in 2015. Phase I study published on EClinical Medicine in 2019. Phase II part of the study reported at ASCO 2020 and published on JAMA Oncol in 2023.
- NBTXR3-301 - A multicenter randomized, open-label phase II/III study, to compare the efficacy of NBTXR3, implanted as intratumor injection and activated by radiotherapy, versus radiotherapy alone in patients with locally advanced soft tissue sarcoma of the extremity and trunk wall. **Coinvestigator.** Accrual started in 2016. Final analysis published on Lancet Oncology in 2019
- Sacral Chordoma: a Randomized & Observational study on surgery versus definitive radiation therapy in primary localized disease (SACRO). **Principal Investigator.** Accrual started in 2017
- REtroperitoneal SARcoma Registry (RESAR): prospective collection of primary retroperitoneal sarcoma patient's data, radiological and pathological material for the TransAtlantic Retroperitoneal Sarcoma Working Group. **Principal Investigator.** Accrual started in 2017
- A Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab with Radiotherapy and Adjuvant Pembrolizumab in Patients with High-Risk, Localized Soft Tissue Sarcoma of the Extremity. A SARC study (SU2C-SARC032) **Coinvestigator.** Accrual started in 2019. Final Analysis published on the Lancet in 2024.
- A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High-Risk RetroPeritoneal Sarcoma (STRASS 2). A EORTC Intergroup study 1809. **Principal Investigator.** Accrual started in 2020

Annex 6

Elenco dei Finanziamenti competitivi vinti in qualità di responsabile del progetto

- PRINCIPAL INVESTIGATOR. Tailored beta catenin mutational approach in extra-abdominal desmoid tumor patients: an observational study. Funded by Ricerca Finalizzata RF2009-1511297 (293,600 €). Clinicaltrial.gov NCT02547831 dal 01-01-2013 al 30/11/2015
- PRINCIPAL INVESTIGATOR. Localized High-Risk Soft Tissue Sarcomas of the Extremities and Trunk Wal in Adults: an Integrating Approach Comprising Standard vs Histotype-Tailored Neoadjuvant Chemotherapy. A prospective controlled randomized trial from Italian Sarcoma Group, Spanish Sarcoma Group, French Sarcoma Group, Polish Sarcoma Group. Closed by May 2016. Reported at ESMO as oral presentation (late-breaking abstract) in 2017 and at ASCO as oral presentation in 2019. Preliminary data published in Lancet Oncol in 2017. Funded by a European Union Grant: Eurosarc FP7 278472 (440,966 €). Clinicaltrial.gov NCT01710176 dal 19-05-2011 al 31/5/2018
- PRINCIPAL INVESTIGATOR. T cell immunity in soft tissue sarcoma of the extremities with complex karyotype: a prognostic marker and a therapeutic target. Funded by Ricerca Finalizzata RF 2019-12370923 (449,350 €) dal 15/01/2021 al 30/09/2024
- PRINCIPAL INVESTIGATOR. A pragmatic clinical study on neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with high-risk retroperitoneal sarcoma – STREXIT2. Funded by HORIZON-MISS-2022-CANCER-01-03, n. 101103843 (4,971,875 €) dal 1/6/2023